


06-09-03

DACE


Please type a plus sign (+) inside this box → ☐PTO/SB/21 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i>	Application Number	09/427,447	
	Filing Date	27 Oct 99	
	First Named Inventor	Alexander G. SZYNALSKI	
	Group Art Unit	Office of Petitions	
	Examiner Name	Brian HEARN	
Total Number of Pages in This Submission		Attorney Docket Number	Goen


ENCLOSURES (check all that apply)		
<input checked="" type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers <i>(for an Application)</i>	<input type="checkbox"/> After Allowance Communication to Group
<input checked="" type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group <i>(Appeal Notice, Brief, Reply Brief)</i>
<input type="checkbox"/> After Final	<input checked="" type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) <i>(please identify below):</i>
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	Rule 322(a)(4) Response and Communication
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Pharmaceutical Patent Attorneys, LLC Pohl & Assoc.
Signature	
Date	See below date

RECEIVED
JUN 11 2003
OFFICE OF PETITIONS

CERTIFICATE OF MAILING	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: <input type="text" value="see below date"/>	
Typed or printed name	Jacqueline SENDON
Signature	
Date	06 June 03

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL for FY 2002 <i>Patent fees are subject to annual revision.</i>	Complete if Known	
	Application Number	09/427,447
	Filing Date	27 Oct 99
	First Named Inventor	Alexander G. SZYNALSKI
	Examiner Name	Brian HEARN
	Group Art Unit	Office of Petitions
	Attorney Docket No.	Goen
TOTAL AMOUNT OF PAYMENT	(\$) 130.00	

METHOD OF PAYMENT 1. <input type="checkbox"/> The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to: Deposit Account Number _____ Deposit Account Name _____ <input type="checkbox"/> Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17 <input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27 2. <input checked="" type="checkbox"/> Payment Enclosed: <input type="checkbox"/> Check <input checked="" type="checkbox"/> Credit card <input type="checkbox"/> Money Order <input type="checkbox"/> Other	FEE CALCULATION (continued) 3. ADDITIONAL FEES <table border="1"><thead><tr><th>Large Entity Fee Code (\$)</th><th>Small Entity Fee Code (\$)</th><th>Fee Description</th><th>Fee Paid</th></tr></thead><tbody><tr><td>105 130</td><td>205 65</td><td>Surcharge - late filing fee or oath</td><td>0.00</td></tr><tr><td>127 50</td><td>227 25</td><td>Surcharge - late provisional filing fee or cover sheet</td><td>0.00</td></tr><tr><td>139 130</td><td>139 130</td><td>Non-English specification</td><td>0.00</td></tr><tr><td>147 2,520</td><td>147 2,520</td><td>For filing a request for <i>ex parte</i> reexamination</td><td>0.00</td></tr><tr><td>112 920*</td><td>112 920*</td><td>Requesting publication of SIR prior to Examiner action</td><td>0.00</td></tr><tr><td>113 1,840*</td><td>113 1,840*</td><td>Requesting publication of SIR after Examiner action</td><td>0.00</td></tr><tr><td>115 110</td><td>215 55</td><td>Extension for reply within first month</td><td>0.00</td></tr><tr><td>116 400</td><td>216 200</td><td>Extension for reply within second month</td><td>0.00</td></tr><tr><td>117 920</td><td>217 460</td><td>Extension for reply within third month</td><td>0.00</td></tr><tr><td>118 1,440</td><td>218 720</td><td>Extension for reply within fourth month</td><td>0.00</td></tr><tr><td>128 1,960</td><td>228 980</td><td>Extension for reply within fifth month</td><td>0.00</td></tr><tr><td>119 320</td><td>219 160</td><td>Notice of Appeal</td><td>0.00</td></tr><tr><td>120 320</td><td>220 160</td><td>Filing a brief in support of an appeal</td><td>0.00</td></tr><tr><td>121 280</td><td>221 140</td><td>Request for oral hearing</td><td>0.00</td></tr><tr><td>138 1,510</td><td>138 1,510</td><td>Petition to institute a public use proceeding</td><td>0.00</td></tr><tr><td>140 110</td><td>240 55</td><td>Petition to revive - unavoidable</td><td>0.00</td></tr><tr><td>141 1,280</td><td>241 640</td><td>Petition to revive - unintentional</td><td>0.00</td></tr><tr><td>142 1,280</td><td>242 640</td><td>Utility issue fee (or reissue)</td><td>0.00</td></tr><tr><td>143 460</td><td>243 230</td><td>Design issue fee</td><td>0.00</td></tr><tr><td>144 620</td><td>244 310</td><td>Plant issue fee</td><td>0.00</td></tr><tr><td>122 130</td><td>122 130</td><td>Petitions to the Commissioner</td><td>130.00</td></tr><tr><td>123 50</td><td>123 50</td><td>Processing fee under 37 CFR 1.17(q)</td><td>0.00</td></tr><tr><td>126 180</td><td>126 180</td><td>Submission of Information Disclosure Stmt</td><td>0.00</td></tr><tr><td>581 40</td><td>581 40</td><td>Recording each patent assignment per property (times number of properties)</td><td>0.00</td></tr><tr><td>146 740</td><td>246 370</td><td>Filing a submission after final rejection (37 CFR § 1.129(a))</td><td>0.00</td></tr><tr><td>149 740</td><td>249 370</td><td>For each additional invention to be examined (37 CFR § 1.129(b))</td><td>0.00</td></tr><tr><td>179 740</td><td>279 370</td><td>Request for Continued Examination (RCE)</td><td>0.00</td></tr><tr><td>169 900</td><td>169 900</td><td>Request for expedited examination of a design application</td><td>0.00</td></tr><tr><td colspan="3">Other fee (specify) _____</td><td></td></tr><tr><td colspan="3">Subtotal (3)</td><td>(\$)130.00</td></tr></tbody></table>	Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid	105 130	205 65	Surcharge - late filing fee or oath	0.00	127 50	227 25	Surcharge - late provisional filing fee or cover sheet	0.00	139 130	139 130	Non-English specification	0.00	147 2,520	147 2,520	For filing a request for <i>ex parte</i> reexamination	0.00	112 920*	112 920*	Requesting publication of SIR prior to Examiner action	0.00	113 1,840*	113 1,840*	Requesting publication of SIR after Examiner action	0.00	115 110	215 55	Extension for reply within first month	0.00	116 400	216 200	Extension for reply within second month	0.00	117 920	217 460	Extension for reply within third month	0.00	118 1,440	218 720	Extension for reply within fourth month	0.00	128 1,960	228 980	Extension for reply within fifth month	0.00	119 320	219 160	Notice of Appeal	0.00	120 320	220 160	Filing a brief in support of an appeal	0.00	121 280	221 140	Request for oral hearing	0.00	138 1,510	138 1,510	Petition to institute a public use proceeding	0.00	140 110	240 55	Petition to revive - unavoidable	0.00	141 1,280	241 640	Petition to revive - unintentional	0.00	142 1,280	242 640	Utility issue fee (or reissue)	0.00	143 460	243 230	Design issue fee	0.00	144 620	244 310	Plant issue fee	0.00	122 130	122 130	Petitions to the Commissioner	130.00	123 50	123 50	Processing fee under 37 CFR 1.17(q)	0.00	126 180	126 180	Submission of Information Disclosure Stmt	0.00	581 40	581 40	Recording each patent assignment per property (times number of properties)	0.00	146 740	246 370	Filing a submission after final rejection (37 CFR § 1.129(a))	0.00	149 740	249 370	For each additional invention to be examined (37 CFR § 1.129(b))	0.00	179 740	279 370	Request for Continued Examination (RCE)	0.00	169 900	169 900	Request for expedited examination of a design application	0.00	Other fee (specify) _____				Subtotal (3)			(\$)130.00
Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid																																																																																																																										
105 130	205 65	Surcharge - late filing fee or oath	0.00																																																																																																																										
127 50	227 25	Surcharge - late provisional filing fee or cover sheet	0.00																																																																																																																										
139 130	139 130	Non-English specification	0.00																																																																																																																										
147 2,520	147 2,520	For filing a request for <i>ex parte</i> reexamination	0.00																																																																																																																										
112 920*	112 920*	Requesting publication of SIR prior to Examiner action	0.00																																																																																																																										
113 1,840*	113 1,840*	Requesting publication of SIR after Examiner action	0.00																																																																																																																										
115 110	215 55	Extension for reply within first month	0.00																																																																																																																										
116 400	216 200	Extension for reply within second month	0.00																																																																																																																										
117 920	217 460	Extension for reply within third month	0.00																																																																																																																										
118 1,440	218 720	Extension for reply within fourth month	0.00																																																																																																																										
128 1,960	228 980	Extension for reply within fifth month	0.00																																																																																																																										
119 320	219 160	Notice of Appeal	0.00																																																																																																																										
120 320	220 160	Filing a brief in support of an appeal	0.00																																																																																																																										
121 280	221 140	Request for oral hearing	0.00																																																																																																																										
138 1,510	138 1,510	Petition to institute a public use proceeding	0.00																																																																																																																										
140 110	240 55	Petition to revive - unavoidable	0.00																																																																																																																										
141 1,280	241 640	Petition to revive - unintentional	0.00																																																																																																																										
142 1,280	242 640	Utility issue fee (or reissue)	0.00																																																																																																																										
143 460	243 230	Design issue fee	0.00																																																																																																																										
144 620	244 310	Plant issue fee	0.00																																																																																																																										
122 130	122 130	Petitions to the Commissioner	130.00																																																																																																																										
123 50	123 50	Processing fee under 37 CFR 1.17(q)	0.00																																																																																																																										
126 180	126 180	Submission of Information Disclosure Stmt	0.00																																																																																																																										
581 40	581 40	Recording each patent assignment per property (times number of properties)	0.00																																																																																																																										
146 740	246 370	Filing a submission after final rejection (37 CFR § 1.129(a))	0.00																																																																																																																										
149 740	249 370	For each additional invention to be examined (37 CFR § 1.129(b))	0.00																																																																																																																										
179 740	279 370	Request for Continued Examination (RCE)	0.00																																																																																																																										
169 900	169 900	Request for expedited examination of a design application	0.00																																																																																																																										
Other fee (specify) _____																																																																																																																													
Subtotal (3)			(\$)130.00																																																																																																																										
FEE CALCULATION 1. BASIC FILING FEE <table border="1"><thead><tr><th>Large Entity Fee Code (\$)</th><th>Small Entity Fee Code (\$)</th><th>Fee Description</th><th>Fee Paid</th></tr></thead><tbody><tr><td>101 740</td><td>201 370</td><td>Utility filing fee</td><td>0.00</td></tr><tr><td>106 330</td><td>206 165</td><td>Design filing fee</td><td>0.00</td></tr><tr><td>107 510</td><td>207 255</td><td>Plant filing fee</td><td></td></tr><tr><td>108 740</td><td>208 370</td><td>Reissue filing fee</td><td></td></tr><tr><td>114 160</td><td>214 80</td><td>Provisional filing fee</td><td>0.00</td></tr><tr><td colspan="3">Subtotal (1)</td><td>(\$)0.00</td></tr></tbody></table> 2. EXTRA CLAIM FEES <table border="1"><thead><tr><th>Total Claims</th><th>Extra Claims</th><th>Fee from below</th><th>Fee Paid</th></tr></thead><tbody><tr><td>0</td><td>-20** = 0</td><td>9.00</td><td>0.00</td></tr><tr><td>6</td><td>-3** = 3</td><td>42.00</td><td>0.00</td></tr><tr><td>Multiple Dependent</td><td></td><td></td><td>0.00</td></tr></tbody></table> <table border="1"><thead><tr><th>Large Entity Fee Code (\$)</th><th>Small Entity Fee Code (\$)</th><th>Fee Description</th><th>Fee Paid</th></tr></thead><tbody><tr><td>103 18</td><td>203 9</td><td>Claims in excess of 20</td><td></td></tr><tr><td>102 84</td><td>202 42</td><td>Independent claims in excess of 3</td><td></td></tr><tr><td>104 280</td><td>204 140</td><td>Multiple dependent claim, if not paid</td><td></td></tr><tr><td>109 84</td><td>209 42</td><td>** Reissue independent claims over original patent</td><td></td></tr><tr><td>110 18</td><td>210 9</td><td>** Reissue claims in excess of 20 and over original patent</td><td></td></tr><tr><td colspan="3">Subtotal (2)</td><td>(\$)0.00</td></tr></tbody></table> <small>**or number previously paid, if greater; For Reissues, see above</small>	Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid	101 740	201 370	Utility filing fee	0.00	106 330	206 165	Design filing fee	0.00	107 510	207 255	Plant filing fee		108 740	208 370	Reissue filing fee		114 160	214 80	Provisional filing fee	0.00	Subtotal (1)			(\$)0.00	Total Claims	Extra Claims	Fee from below	Fee Paid	0	-20** = 0	9.00	0.00	6	-3** = 3	42.00	0.00	Multiple Dependent			0.00	Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid	103 18	203 9	Claims in excess of 20		102 84	202 42	Independent claims in excess of 3		104 280	204 140	Multiple dependent claim, if not paid		109 84	209 42	** Reissue independent claims over original patent		110 18	210 9	** Reissue claims in excess of 20 and over original patent		Subtotal (2)			(\$)0.00																																																					
Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid																																																																																																																										
101 740	201 370	Utility filing fee	0.00																																																																																																																										
106 330	206 165	Design filing fee	0.00																																																																																																																										
107 510	207 255	Plant filing fee																																																																																																																											
108 740	208 370	Reissue filing fee																																																																																																																											
114 160	214 80	Provisional filing fee	0.00																																																																																																																										
Subtotal (1)			(\$)0.00																																																																																																																										
Total Claims	Extra Claims	Fee from below	Fee Paid																																																																																																																										
0	-20** = 0	9.00	0.00																																																																																																																										
6	-3** = 3	42.00	0.00																																																																																																																										
Multiple Dependent			0.00																																																																																																																										
Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid																																																																																																																										
103 18	203 9	Claims in excess of 20																																																																																																																											
102 84	202 42	Independent claims in excess of 3																																																																																																																											
104 280	204 140	Multiple dependent claim, if not paid																																																																																																																											
109 84	209 42	** Reissue independent claims over original patent																																																																																																																											
110 18	210 9	** Reissue claims in excess of 20 and over original patent																																																																																																																											
Subtotal (2)			(\$)0.00																																																																																																																										

SUBMITTED BY		Complete (if applicable)	
Name (Print/Type)	Mark POHL	Registration No. (Attorney/Agent)	35,325
Signature		Telephone	(973) 984-0076
		Date	6 June 03

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



IN THE UNITED STATES PATENT OFFICE

Inventor : Alexander G. SZYNALSKI
Serial No. : 09/427,447
Filing Date : 27 Oct. 1999
Title : Stop Smoking Method & Composition
Group Art : Office of Petitions
Examiner : Brian HEARN, Senior Petitions Examiner

5 Commissioner of Patents
Post Office Box 1450
Mail Stop - Petitions
Alexandria, VA 22313-1450
10 BY EXPRESS MAIL


COMMUNICATION

Enclosed find a copy of Applicant's Rule 322(a)(4) RESPONSE and Rule 181 PETITION, together with a Fee Transmittal Form and petition fee.

15 Note that on the evening of June 5th, Applicant filed a Rule 322(a)(4) RESPONSE and Rule 181 PETITION by facsimile. That facsimile was sent in several parts. To assure that the Office reviews a complete and correct copy of the entire document, including all Exhibits, Applicant encloses here a replacement copy of the Rule 322(a)(4) RESPONSE and Rule 181 PETITION.

20 Applicant respectfully requests this complete and correct copy replace the facsimile copy previously transmitted in parts.

Respectfully submitted,


25 
Mark Pohl, Reg. No. 35,325
☎ (973) 984-0076
✉ Mark.Pohl@LicensingLaw.Net
6 June 2003

30 Pharmaceutical Patent Attorneys LLC
55 Madison Avenue, 4th floor
Attn : Mark POHL (P 4014)
Morristown, NJ 07960-7397 USA

RECEIVED

JUN 11 2003

OFFICE OF PETITIONS



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor : Alexander G. SZYNALSKI
Serial No. : 09/427,447
Filing Date : 27 Oct. 1999
Title : Stop Smoking Method & Composition
Group Art : Office of Petitions
Examiner : Brian HEARN, Senior Petitions Examiner

Commissioner of Patents
Post Office Box 1450
Attn: Box DAC / Office of Petitions
Alexandria, VA 22313-1450
Facsimile (703) 308-6916
BY EXPRESS MAIL

RECEIVED

JUN 11 2003

OFFICE OF PETITIONS

Rule 322(a)(4) RESPONSE
and
Rule 181 PETITION

This is a Rule 322(a)(4) RESPONSE to the LETTER RE CERTIFICATE OF CORRECTION mailed 6 May 2003. This is also a Rule 181 PETITION to invoke the supervisory authority of the Commissioner.

Applicant respectfully objects to the proposed Certificate of Correction. Applicant thus petitions for an order staying issue of the requested Certificate.

FACTUAL BACKGROUND

The factual record indicates that the issued claims are intended to read as printed in the issued patent. The prosecution history shows the following:

The original patent application describes a stop-smoking method. Exhibit A (A.G. Szynalski, STOP SMOKING METHOD (27 Oct. 1999)). The claims cover a three part invention. The claims as filed recite:

- (A) an educational program;
- (B) a hypnosis program; and
- (C) lobelia.

5 The patent application describes lobelia, and its efficacy as an anti-smoking drug due to lobelia's antidepressant and anxiolytic activity. Thus, claim element (C), as-filed, covers lobelia literally. Under the doctrine of equivalents, claim element (C) also covered equivalent substances (e.g., substances which perform the same function as lobelia, in the same way, to produce the same result).

10 The Patent Examiner's search revealed no prior art which suggested combining education and hypnosis with lobelia. Further, the search revealed no art suggesting combining education and hypnosis with any lobelia equivalent. Exhibit B (OFFICE ACTION (2 March 01)).

15 Applicant accordingly proposed changing the term "lobelia" to encompass such equivalents literally, rather than under the doctrine of equivalents. This amendment is permissible because knowledge generally available in the art need not be reiterated in the patent application itself; such information may be provided by the art. MANUAL OF PATENT EXAMINING PROCEDURE § 2164.04 (2002), discussing In re Wright, 999 F.2d 1557, 1562 (Fed. Cir. 1993) and In re Marzocchi, 439 F.2d 220 (C.C.P.A. 1971). Accordingly, the "Examiner agreed to consider claims addressed to the use of anti-depressants instead of lobelia, but requested information on efficacy in this usage." Exhibit C (INTERVIEW SUMMARY (19 Sept. 2001)).

20 Applicant accordingly provided this information, showing that antidepressants are known to be effective anti-smoking agents. Exhibit D (AMENDMENT (19 Sept. 2001)). Applicant also requested amending the claim to replace the term "lobelia" with the term "anti-smoking drug." This amendment makes the claim cover lobelia equivalents literally, rather than under the doctrine of equivalents. The AMENDMENT, at page 5, explains:

30 Element C is broadened to encompass equivalents of lobelia literally.

The Specification teaches that lobelia is an antidepressant acetylcholine receptor binder. Specification at 13-15. The Specification teaches other examples of antidepressants, id. at 18 (gotu kola extract; kava kava root).

It is known in the art that antidepressants can be used as stop smoking drugs. For example, bupropion hydrochloride is sold as both an antidepressant (commercially available under the trademark WELLBUTRIN® from Glaxo-Wellcome Inc., Chapel Hill, North Carolina) and a stop-smoking drug (commercially available under the trademark ZYBAN® from Glaxo-Wellcome Inc., Chapel Hill, North Carolina). Physicians' Desk Reference at 1277 *et seq.* (1999). Antidepressants 'produce[] a calming effect within the body, thereby relieving the stress associated with nicotine withdrawal symptoms.' Specification at 18, lines 8-9. This probably explains why individuals quitting smoking feel better when an anti-smoking drug. Id. at 15, lines 12-14.

Accordingly, element (C) is broadened to encompass stop-smoking drugs generally, and dependent claims 21-24 are added to recite lobelia specifically.

Thus, the amendment doesn't necessarily change the outer limits of the claim scope, but changes the legal theory on which lobelia equivalents are covered - covering them literally, rather than under the doctrine of equivalents.

In response, the Examiner acknowledged that, as discussed in the 19 Sept. 2001 INTERVIEW SUMMARY, "[t]he term 'anti-smoking drug is broader in scope than [] lobelia.'" Exhibit E (OFFICE ACTION (4 Dec. 2001)).

The Examiner, however, changed position regarding whether the claim term "lobelia" may be so amended, arguing that evidence regarding knowledge in the art cannot be used to broaden literal claim coverage. Id.

The position taken in the OFFICE ACTION is contrary to law and internal Patent Office procedure. It thus precipitated another interview. The record for the ensuing interview says, "Agreed to Examiner's Amendment to place application in condition for allowance." Exhibit F (INTERVIEW SUMMARY (14 Dec. 2001)).

Regrettably, the INTERVIEW SUMMARY fails to specify exactly what amendment was agreed to.¹

The Office then issued a NOTICE OF ALLOWABILITY. Exhibit G (NOTICE OF ALLOWABILITY (15 Jan. 03)). The NOTICE proposed an Examiner's Amendment.
5 Id. at page 2. This amendment was proposed erroneously, because it was neither agreed to by the Applicant, nor supported by law.

Before Applicant filed an objection to the Examiner's Amendment, the Office corrected its error and withdrew the Examiner's Amendment, replacing the erroneous NOTICE with a CORRECTED NOTICE OF ALLOWABILITY. Exhibit H
10 (CORRECTED NOTICE OF ALLOWABILITY (4 Feb. 03)). The CORRECTED NOTICE corrects the prior NOTICE, omitting the erroneous Examiner's Amendment.

The claims as issued recite "anti-smoking drug," not "lobelia." Exhibit I (U.S. Letters Patent No. 6,431,874 (13 Aug. 02)).

15 LEGAL ANALYSIS

Applicant respectfully believes the request for a Certificate of Correction in this case should not be granted, for several reasons. First, the records of the Patent Office do not clearly and unambiguously show the claims were printed in error; to the contrary, the record shows the Office corrected a potential error in a
20 timely fashion. Second, the error alleged is not correctable under 35 U.S.C. § 254 as a matter of law. Third, the error alleged is not "of consequence" as is required under 35 U.S.C. § 254. We discuss each in turn.

25 The Patent Office Record does not
clearly and unambiguously show error

An issued patent is presumed valid. 35 U.S.C. § 282. This presumption includes a presumption that the Patent Office acted correctly in reviewing and

¹ What was agreed to, was entry of an Examiner's Amendment when and if the Examiner would make of record prior art teaching the three-part combination of (A) education and (B) hypnosis and (C) a non-lobelia anti-smoking drug.

issuing the patent. See Superior Fireplace Co. v. Majestic Prods. Co., 270 F.3d 1358, 1381 (Fed. Cir. 2001). This statutory presumption of validity must be rebutted by clear and convincing evidence. *E.g.*, Ethicon, Inc. v. Quigg, 849 F.2d 1422 (Fed. Cir. 1988).

5 Here, the factual record fails to establish “clear and convincing” evidence of the alleged error. To the contrary, the record shows the claims as issued were correctly issued *vis* both the prior art of record and the papers of record. The proposed Examiner’s Amendment would have violated both law and internal Office procedure, and the Office accordingly rectified this potential error.

10 It may be argued that the Examiner intended to include the Examiner’s Amendment in the CORRECTED NOTICE OF ALLOWABILITY, but the Examiner’s Amendment was omitted inadvertently. This theory fails to establish “clear and convincing” evidence of error, because it is entirely speculative, and relies on speculation regarding the Examiner’s subjective intent. Evidence regarding the
15 Examiner’s intent - speculative or otherwise - cannot be relied on in proving “error.” See Superior Fireplace Co., 270 F.3d at 1369-70 (parol evidence is generally not allowable to prove typographical or clerical error). The file itself, and the MANUAL OF PATENT EXAMINING PROCEDURE pursuant to which the file was processed, both indicate that the claims issued correctly.

20 It may alternatively be argued that the CORRECTED NOTICE OF ALLOWABILITY was intended to replace the original NOTICE not completely, but only partially, leaving some unspecified part of the original NOTICE (the Examiner’s Amendment) in place. Assuming *arguendo* the CORRECTED NOTICE was intended to replace the original NOTICE only partially, it is incumbent on the Office to clearly communicate
25 to the Applicant what part(s) of the NOTICE is intended to be changed, and what part(s) remains unchanged. It is inappropriate to conclude that the Office snuck an Examiner’s Amendment into the claims by misleading the Applicant regarding the amendment status; so doing would divest Applicant of its statutory right to have the Examiner’s decision reviewed by the Board of Patent Appeals.

None of these theories is supported by “clear and convincing” evidence. Here, the Office failed to clearly apprise Applicant of any intent to replace the erroneous NOTICE only in part. No continued intent to change Applicant’s claims was communicated to Applicant, nor even to the Patent Office’s own Publications
5 Branch (who saw no error in the claims), nor to the Patent Office’s own Office of Patent Quality Review (who saw no error in the claims). Having failed to notify Applicant (nor the other branches of the Patent Office) of its intent to enter an unauthorized amendment to Applicant’s patent, the Office cannot now do so.

10 Issuing these claims “by mistake” would require three different PTO departments to each independently make errors
Issuing the claims in error, would require three independent Patent Office departments to have made three independent errors. First, the Patent Examiner
15 would need to erroneously fail to include - nor even mention - the Examiner’s Amendment in the CORRECTED NOTICE OF ALLOWANCE mailed to the Applicant. Second, the Patent Office Printing Branch would need to neglect to read the prosecution file and properly enter the Examiner’s Amendment in the printed patent. Third, the PTO’s own Office of Patent Quality Review would need to
20 overlook the mismatch between the Examiner’s Amendment and the to-be-published claims.

It is not impossible that these three independent departments of the Patent Office would each independently err. It is not impossible that these three independent errors would coincidentally pertain to the same part of the patent -
25 the single most important part of the patent. While it is not impossible, the record fails to show “clear and convincing” evidence proving these three separate errors.

To the contrary, these alleged errors appear contradicted by the file. This is because Office procedure empowers the appropriate PTO Group to investigate the factual basis for a Certificate of Correction, and to prepare a report
30 documenting these findings. MANUAL OF PATENT EXAM. PROC. § 1485 (2002). Here, no such report appears in the file. No report appears to have even been

requested. The Office's own failure to bother to request such a report intimates that the Patent Office believes the report would not provide any evidence to support the errors alleged.

5 The error alleged is not
correctable under 35 U.S.C. 254

The patent statute provides a variety of procedures to correct the alleged error. A Certificate of Correction is not one of them.

10 The claims do not have an
"immediately apparent"
typographical error

The purpose of Section 254 is explained in its legislative history. In introducing the bill to the House of Representatives, Representative Lanham
15 explained,

The purpose of this bill is to save time and money and also promote efficiency in the operation of the Patent Office. The Patent Office is issuing approximately 40,000 patents a year. There are 15 linotype machines at the Government Printing Office engaged in doing
20 nothing but the necessary printing for the Patent Office. Naturally, in the work at the Government Printing Office, and also in the work at the Patent Office itself, in such voluminous printing, certain typographical errors appear and patents are frequently issued under seal with these errors. There has been a custom prevailing in the
25 Patent Office for 30 years, whenever these errors are detected, which are clearly clerical errors, to append a certificate of correction to the patent to show that the error was a typographical error, and the certificate explains this.

30 65 Cong. Rec. 6842-43 (1924) (emphasis added). Section 254 thus allows correction of typographical errors. Clerical or typographical errors are "generally understood to include simple mistakes such as obvious misspellings *that are immediately apparent*. Upon viewing such a misspelling, there is no doubt that a mistake, indeed a clerical or typographical mistake, has occurred." Superior
35 Fireplace Co. v. Majestic Prods. Co., 270 F.3d 1358, 1369-70 (Fed. Cir. 2001) (italics added). An example of an error immediately apparent is an error which

“renders the claim meaningless when read literally.” Sargent-Welch Scientific Co. v. J/B Industries, Inc., 496 F.Supp. 972, 978 (N.D.Ill. 1980).

Here, the mistake alleged is not “immediately apparent” on reading the claims. The claims are not “meaningless when read literally.” There is no allegation that “upon reading the claims, there is no doubt that a mistake, indeed a clerical or typographical mistake, has occurred.” To the contrary, the issued claims read clearly, and are fully supported by law, by the art of record and by the prosecution history. There is no allegation to the contrary.

The alleged error is not subject
to a Certificate of Correction

The REQUEST FOR A CERTIFICATE OF CORRECTION alleges that the patentee has claimed more than it had a right to claim. Procedures to address this kind of alleged error are available under any of 35 U.S.C. § 135 (interferences); 35 U.S.C. § 251 (reissue), 35 U.S.C. § 302 (*ex parte* reexamination); 35 U.S.C. § 311 (*inter partes* reexamination); and 35 U.S.C. § 282(2) (anticipation of claim by prior art).

In contrast, the kind of error alleged is not correctable under 35 U.S.C. § 254. This is because alleged errors which change the scope of an issued claim cannot be corrected by a Certificate of Correction as a matter of law. This is because “Where a proposed correction involves a change in claim scope, the reissue statute is controlling, not the provisions of law governing Certificates of Correction.” In re Arnott, 19 U.S.P.Q.2d 1049, 1054 (Commr. Pat. 1991), *citing Eagle Iron Works v. McLanahan Corp.*, 429 F.2d 1375, 1383 (3rd Cir. 1970); *accord*, In re Shirouchi, 204 U.S.P.Q. 513 (Commr. Pat. 1979) (request to correct claims requires claim amendment beyond the scope of Certificate of Correction; the proper route to amend claims is a reissue proceeding); *see also* Superior Fireplace Co. v. Majestic Prods. Co., 270 F.3d 1358, 1375 (Fed. Cir. 2001) (as a matter of law, an alleged “mistake” that would change the scope of a claim “must thus be viewed as highly important and thus cannot be a mistake of ‘minor character.’”).

5 The Certificate of Correction requestor is well aware of the procedural safeguards mandated in interferences, reissues, *ex parte* reexamination and *inter partes* reexamination. The requestor is well aware such safeguards do not exist in reviewing a Certificate of Correction. See Hallmark Cards, Inc. v. Lehman, 959 F.Supp. 539, 543 (D.D.C. 1997) (“the PTO conducts a thorough and comprehensive review of a patent in reissue and reexamination proceedings” while “Certificates of Correction [] involves a far less intrusive examination of a patent for minor, typographical, and clerical errors”). The requestor attempts to have the Office shortcut required procedural safeguards, by using an inapposite procedure. Granting this request is respectfully believed beyond the Office’s statutory authority.

15 The requestor has not alleged
any “error of consequence”

A Certificate of Correction should only be requested if the error alleged is “of consequence.” MANUAL OF PATENT EXAMINING PROCEDURE § 1480 (2002). Here, it is not.

20 Here, the REQUEST FOR CERTIFICATE OF CORRECTION says the alleged error is “of consequence” because the patent holder is asserting the patent against the requestor. Contrary to the REQUEST FOR CERTIFICATE OF CORRECTION, asserting the patent against the requestor does not make the alleged error “of consequence.” To the contrary, asserting the patent against the requestor moots the Certificate of Correction.

25 This is because a Certificate of Correction has effect only “on the trial of actions for causes thereafter arising,” 35 U.S.C. § 254, *i.e.*, causes arising after the Certificate of Correction issues, Southwest Software, Inc. v. Harlequin Inc., 226 F.3d 1280, 1295 (Fed.Cir. 2000) (Certificate has prospective effect only). Thus, the Certificate should have no effect at all on the already-pending lawsuit. This rule is logical; if the Federal Circuit allowed Certificates of Correction to retroactively change patent claims, then every accused infringer would file a

30

blizzard of requests for correction, making resolution of pending infringement actions impossible.

The requestor has already been sued for infringement. The Certificate of Correction request should have no consequence on this already-pending litigation. Rather, the accused infringer's remedy for allegedly over-broad claims would be to prove in the pending litigation that the issued claims are invalid *vis* the prior art. Because the alleged error is not "of consequence" as a matter of law, the Office should accordingly deny the request. See MANUAL OF PATENT EXAMINING PROCEDURE § 1480 (2002).

POINT TO BE REVIEWED

Whether the Office should issue a Certificate of Correction in this case?


ACTION REQUESTED

Applicant respectfully believes a Certificate of Correction is not legally issuable on the existing factual record. Applicant accordingly requests that the Office deny the third-party REQUEST FOR A CERTIFICATE OF CORRECTION.

ENCLOSURES

The exhibits discussed and a Petition fee are enclosed.

Respectfully submitted,


Mark POHL Esq., Reg.No. 35,325
6 June 2003

Pharmaceutical Patent Attorneys, LLC
55 Madison Avenue, 4th fl. (P 4014)
Morristown, NJ 07960-7397

Direct ☎ (973) 984-0076
Mark.Pohl@LicensingLaw.Net

mbc:mp

RECEIVED

JUN 11 2003

OFFICE OF PETITIONS

A

Stop Smoking Method and Composition

By Alexander Goen Szynalski

A portion of the disclosure of this patent document contains material which is subject to copyright protection. The copyright owner has no objection to the facsimile reproduction by anyone of the patent disclosure, as it appears in the Patent and Trademark Office patent files or records, but otherwise reserves all copyright rights whatsoever.

Background

10 The prior art discloses many stop-smoking products and methods including, for example; (A) education to educate smokers regarding smoking, its physiological dangers and addictive nature, and conscious techniques to stop smoking; (B) hypnosis, to use the unconscious mind to stop smoking; and (C) nutritional supplements, 15 addressing the nutritional challenges with regard to stopping smoking.

Summary

While using each one of these three elements is known in the art, I have found that by combining all of these three 20 elements together, they act on the three areas most important for stopping smoking - the conscious mind, the unconscious mind, and the body - and are synergistically effective in helping people to stop smoking.

This synergy was unexpected. I am a Certified Hypnotist 25 and am a Nutritionist, with over twenty years experience in the fields of hypnosis, seminar presentation and nutrition. I am a member of the American Association of Professional Hypnotherapists, the National Guild of Hypnotists, the

International Association of Counselors and Therapists, and am
certified by the Hypnodyne Foundation. I am listed in Who's Who
in Executives and Professionals, and I was a finalist for the 1999
Ernst & Young *Entrepreneur of the Year* award. I have been a
5 special guest on numerous national television and radio programs,
and was featured on the #1 television fitness show in the country.
I maintain a practice in Cedar Knolls, New Jersey. I have
successfully used hypnosis in many types of situations. I have,
for example, worked with athletes to improve their athletic
10 performance, and have worked with corporations as a sales and
personal-development trainer. I am driven by a sincere passion for
helping people maximize their personal potential and overcome
addictions to smoking and food. I enjoy a reputation for
extremely high success through my seminars.

15 Detailed Description

My invention therefore comprises three elements: (1)
education for the conscious mind regarding smoking, its
physiological dangers and addictive nature, and techniques to stop
smoking; (2) hypnosis for the unconscious mind, which hypnosis
20 addresses the unconscious mind and its way of affecting behavior;
and (3) dietary substances, to address the physiological needs of
a person entailed in stopping smoking.

Education. The first element of my invention is
education regarding smoking. This educational process can include
25 addressing the benefits of a regular exercise program. Thus, the
educational materials or program educates the smoker to engage in
some form of light exercise. Not only will exercise help clear
the body of the toxins acquired through smoking, but exercise will

also help release endorphins which relieve stress as well as making you feel good. Exercise will rapidly reverse the damage done to the body from smoking. If the smoker has not engaged in exercise for a long time, or the smoker has a weight problem or
5 any other health problem, the smoker should consult their physician before starting any regimen of exercise.

In addition to this, I have found that in my preferred embodiment of my invention, the education program also addresses the physiological progression of smoking, its physiological
10 dangers and addictive nature, and some conscious techniques to stop smoking.

Goen Corporation.
© 1999 ^

The physiological progression of smoking entails three discreet steps. Knowing these steps helps the smoker recognize
15 them as they occur, and thus recognize the needs they fill.

Stage 1 - Light a cigarette and inhale. This takes about 7

seconds. The deep breath of the inhale increases the flow of blood and oxygen to the heart and you feel more relaxed (not due to the cigarette, but due to the deep
20 breath).

Stage 2 - Seven seconds to fifteen minutes later, nicotine enters the liver, which in turn releases sugar into the bloodstream. This results in a physical uplift (not from the cigarette, but from the release of sugar into the
25 bloodstream) which then in turn causes the pancreas to release insulin into the bloodstream. This gives you an energy boost. Normally, it is a temporary energy boost because the muscle cells of the body are resistant to

insulin. So what happens is that your energy level goes up and then crashes, all over again. In fifteen minutes, you want to start smoking again due to the tense feelings you experience from your energy level being reduced. What we suggest is for you to sensitize your body to insulin. Before we suggest how you do this, you first should study the two diagrams pictured below. To better understand this phenomenon, we will provide an in-depth clarification of the diagrams.

5
10 Stage 3 - Fifteen to twenty minutes after beginning to smoke, the nicotine interrupts the normal transmission of neurons by competing with acetylcholine at the nerve terminal, producing such effects as an increased heart rate and respiration, along with feelings of tension and of being
15 "wired up." It also increases arousal and a sense of well-being and focused attention. A side benefit to understanding this step is to take proper nutrients so you do not allow this physical and physiological progression of smoking to occur. This will help with
20 maintaining or even reducing weight and increasing lean muscle tissue.

In my preferred embodiment, the smoker is educated on the physiological dangers and addictive nature of smoking. These dangers are now so widely known as to not need to be discussed in
25 detail here.

In my preferred embodiment, the person is educated on the benefits of modifying their daily diet. This addresses

potential weight gain problems, one of the biggest fears of smokers.

Regarding potential weight gain, why do we gain weight when we stop smoking? Muscle cells become more sensitive to

5 insulin. In my preferred embodiment, therefore, I recommend :

- Avoid refined carbohydrates. All carbohydrates start out in their rarest edible form as complex, but we make them refined by processing, preserving, storing, drying, and cooking.

- Increase physical activity, especially five to fifteen minutes
10 after meals.

- Take 100 micrograms of chromium along with the proper cofactors, one half hour before each meal with a full glass of water. The product containing chromium (CHROMIUM CHELAVITE™) that I prefer is TRIMSPA®, available from Vitamerica, Inc., Cedar
15 Knolls, New Jersey.

- Acquire a cigarette cessation product containing the herb lobelia, which aids any withdrawal that some may experience. Lobelia is a natural herb that tricks the body into thinking it is nicotine, but it does not have the side effects. In the preferred
20 embodiment of my invention, I recommend CIGSATION™, available from Vitamerica, Inc., Cedar Knolls, New Jersey.

- Cut back on drinking coffee and other caffeinated beverages. Sometimes the stress or anxiety that quitters experience is due to the physiological effects of caffeine on the nervous system and
25 not due to withdrawal from nicotine. Try drinking decaffeinated tea or some other warm decaffeinated beverage. Drinking a hot tea provides the same psychological effect as drinking hot coffee.

• Eat healthy, nourishing, non-processed foods and take a good vitamin supplement. Remember, the 200+ toxins in cigarette smoke have helped deplete the body of vitamins. Five cigarettes can deplete all the vitamin C in the body! By eating a healthy diet,
5 you will recover your health more quickly.

In my preferred embodiment, the smoker is educated to do this for at least the first week, preferably for the first 21 days, after stopping smoking : $\overset{R}{\wedge}$ • Eat 3 meals a day, including breakfast ✓

- 10 • Have protein and complex carbohydrates with each meal
- Avoid sugar
 - Drink 8 glasses of non-caloric liquids a day - drink water with lemon, seltzer, herbal tea, etc.
 - Keep a pitcher of water on your desk and you'll easily drink 8
15 glasses a day
 - Between meals, drink fruit juices or eat a piece of fruit
 - Eat lots of fruits, vegetables and salads
 - As soon as you finish eating, leave the table and go brush your teeth
- 20 • Use mouthwash whenever possible

In my preferred embodiment, the smoker is admonished :
to not skip any meals (and never miss breakfast); to limit refined- sugar intake (and read packaging labels); to avoid beverages with caffeine (tea, colas, coffee, hot chocolate); and,
25 if you must have them, drink tea or coffee out of a juice glass using a straw; and NO alcohol.

We described above the change in blood sugar levels caused by smoking and the physical and emotional response it has

on the body. If your blood sugar level gets low, you will either crave a cigarette or something sweet. In either case, it will boost your blood sugar level for 10 to 20 minutes and then cause a crash, triggering another urge for a cigarette or a sweet. By eating 3 meals a day, you will tend to have a stable blood sugar level, and this minimizes cigarette and eating urges. Eating protein with carbohydrates at breakfast sets the stage for stable blood sugar levels all through the day. Protein with complex carbohydrates stabilizes the blood sugar.

10 I have also found it useful to teach persons quitting smoking to carry a nonfood item such as a swizzle stick or a low calorie food such as celery or carrot sticks. Use these to gratify any oral habit that has been developed by the conditioned response of putting your hand to your mouth 250 times a day, as if you were
15 a one pack a day smoker.

By providing the smoker with this kind of educational program, the smoker is able to consciously and analytically understand their need to smoke and to approach the decision to smoke, or to not smoke, in an analytical, dispassionate manner.

20 Hypnosis. In addition to the conscious, analytical mind, one can aid the stop-smoking process by using the subconscious mind. In my invention, it is important to use both the conscious mind - via the educational program discussed above - and the unconscious mind, with hypnosis.

25 The subconscious mind dominates your thinking and behaviors. It is programmed using repetition and the subconscious mind basically behaves for two reasons. It tries to take you towards pleasure and it wants you to stay away from pain. For

example, when you have a cup of coffee, you grab a cigarette; you get into a car, you grab a cigarette; you get stuck at a light, you grab a cigarette; you get a break at work, you grab a cigarette; you have a cocktail, you grab a cigarette. If you do not experience these triggers, you may very often go many hours without having a cigarette. It is important that you identify these scenes so we can then break the connection of the cigarettes to the scenes.

With hypnosis, the subconscious mind no longer aids the body to smoke more often, but rather aids the body to stop smoking, during precisely those periods when a smoker is accustomed to having a cigarette. Instead of the subconscious making the body scream for nicotine after a meal, or with coffee or alcohol, the subconscious will help the smoker remain calm and pain free.

When used to stop smoking, I have found that in my preferred embodiment, the hypnosis focuses on interrupting "conditioned responses" generally, and specifically, on interrupting the response to smoke. Conditioned responses are actions (e.g., reaching for a cigarette) motivated not by a consciously-perceived need, but rather by unconscious habit.

Is smoking more of a physical or more of a psychological addiction? For example, how many times have you gone two, three or four hours without even smoking one cigarette and then in another hour you may smoke four, five or six cigarettes? Why is that? It is because certain events, or certain times of the day can trigger you to smoke a cigarette. Therefore, it is necessary

to break these unconscious connections, and such breakage occurs,
I found, most efficiently using unconscious means - hypnosis.

In my preferred embodiment of my invention, the hypnosis
is done in-person and is reinforced later with prerecorded media
5 such as audio-tapes.

Hypnosis techniques are known in the art. In my
preferred embodiment, I prefer the in-person hypnosis to follow a
six-step protocol. The six steps are (1) neuro-linguistic
programming, (2) physical positioning, (3) progressive relaxation,
10 (4) occupying the critical/analytical factor, (5) a process of
suggestion, and (6) changing the language of the subconscious.

(1) Neuro-linguistic programming is a technique known in
the art. It is described in detail in the following works written
since the 1960's.

15 The Structure of Magic, Vol.1 - Richard Bandler/John Grinder

The Structure of Magic, Vol.2 - Grinder/Bandler

Patterns of Hypnotic Techniques of M.H. Erickson, Vol.1 -
Bandler/Grinder

Patterns of Hypnotic Techniques of M.H. Erickson, Vol.2 -
20 Grinder/Bandler

Frogs Into Princes - Bandler/Grinder

Tranceformations - Grinder/Bandler

Using Your Brain for a Change - Richard Bandler

Time for a Change - Richard Bandler

25 Persuasion Engineering - Richard Bandler/John La Valle

The Adventures of Anybody - Richard Bandler

Science and Sanity - Alfred Korzybski

Uncommon Therapy - The Psychiatric Techniques of Erickson - Jay Haley

Training Trances - John Overdurf / Julie Silverthorn

My Voice Will Go With You - Sidney Rosen

5 These are incorporated herein by reference.

(2) Physical positioning is important, to maintain the subject in a state which is both relaxed, yet not sleep-prone.

(3) Physical Positioning and Progressive Relaxation follow the methods known in the art, instructing the subject to
10 progressively relax each part of their body. This can be done with instructions to, for example, physically perform some act, or to mentally visualize some relaxing phenomenon.

(4) Occupying the critical / analytical factor is accomplished in my preferred embodiment by having the subject
15 perform certain tasks which both require some conscious attention, but also are not so difficult or complex as to absorb the subject's entire mental capacity.

(5) The process of suggestion is important to repeat for an effective period of time - usually at least daily for about
20 twenty one days. This time may, however, be less when the subject is relaxed, or is in a highly-emotional state.

(6) The last step is changing the language of the subconscious. This is done by repeating a desired message - e.g., "I am free from smoking" - often enough that the desired message
25 replaces an undesired message in the subconscious mind. For example, one technique is to get friends, coworkers, and family members to help you, by asking them to congratulate you for not smoking. The best way to accomplish this is to stick your hand

out to a friend or family member, asking that person to shake your hand and congratulate you for being a nonsmoker. When that person congratulates you, it is a positive reinforcement. The (former) smoker benefits from this positive feedback, and from knowing that
5 they are doing well in stopping smoking.

In another technique I found successful, smoking is described as like having a best friend. Psychologically, the cigarette is the support that a friend gives you. Imagine having your best friend there for you and then losing him or her. You
10 would not feel very good losing your best friend. However, if you discover that your best friend was abusing your children, most likely you would not feel the same about losing your best friend. You would still have some sort of attachment, but now you would be able to reason your way out of not having this person as a friend.
15 In my preferred embodiment, the educational program teaches smokers to look at smoking in the same way.

In my preferred embodiment of my invention, hypnosis is also administered by listening to a prerecorded audio script which provides stop-smoking messages and positive feedback for not
20 smoking. Such audio tapes are commercially available. In my preferred embodiment, I use an audio tape titled "Smoking Cessation," published by Vitamerica, Inc., Cedar Knolls, New Jersey, www.vitamerica.com, to be listened to once every day for an effective length of time, generally about twenty-one days.

25 Dietary Substances. The third element of my invention is using proper dietary substances. These address the physiological needs of people breaking their physical addiction to

nicotine. Further, one of the biggest fears of smokers is that, in stopping smoking, they will gain excess weight. Thus, in my preferred embodiment, in addition to the dietary substances that support normal form and function while recovering from a smoking addiction, one also uses dietary substances that support normal form and function for those seeking weight-loss or to reduce weight gain. In my preferred embodiment, I recommend CIGSATION™ and TRIM SPECIFICS™, dietary supplements by Vitamerica, Inc., Cedar Knolls, New Jersey, www.vitamerica.com

10 To aid the reader's understanding, I will discuss first the biological basis of the smoking addiction. I will then discuss the dietary substances and the diet modifications I have found effective to combat the physical smoking addiction - the addiction to nicotine. Finally, I will discuss dietary substances
15 to control weight gain.

What causes the addiction to nicotine? The nervous system is divided into two anatomical divisions. The first is the central nervous system, which is composed of the brain and spinal cord. The second is the peripheral nervous system, which includes
20 neurons located outside the brain and spinal cord, which includes any nerves that enter or leave the central nervous system. The peripheral nervous system can be further divided into the efferent division, whose neurons carry signals away from the brain and spinal cord to the peripheral tissues, and the afferent division,
25 whose neurons bring information from the periphery to the central nervous system.

Nerve impulses are transmitted along a path of cells called neurons. The neurons form a knot-like mass called ganglia.

These neurons are connected by a series of bridges. The bridge is called a synapse. In order to cross the bridge, a neurotransmitter is required. Before the nerve impulses reach the relay station or bridge, they are referred to as pre-ganglionic neurons. After crossing the synapse, they are referred to as post-ganglionic neurons. The basic neurotransmitters of the autonomic nervous system are acetylcholine and epinephrine. Acetylcholine mediates the transmission of nerve impulses across autonomic ganglia in both the sympathetic and parasympathetic nervous systems.

Nicotine Receptors. These receptors, in addition to binding acetylcholine, also recognize nicotine. Nicotine initially stimulates and then blocks the receptor. There is a competitive inhibition taking place. In lay terms, the receptor has a greater affinity for nicotine than for acetylcholine. At the same time, nicotine increases the level of the neurotransmitter dopamine in a particular brain pathway which associates a molecular link between nicotine addiction and this pleasure producing pathway. This is why nicotine causes such a strong physiological addiction. Recently, scientists at Yale and at the Pasteur Institute in Paris have found that the beta 2 subunit of a known nicotine receptor in the brain is a critical component in nicotine addiction.

To combat this nicotine addiction, it is useful to use lobelia. *Lobelia inflata* (also known as Indian Tobacco) is a plant. This plant contains three nicotine-like ingredients : 1) lobeline, 2) lobelanidine, and 3) lobelanine. On close inspection of these three ingredients one can notice that all are symmetrical

molecules. In other words, if you cut them each in half, each half is the same. The only exception is with lobeline, which has a slight difference on one side of the molecule. I refer to each of these three compounds, their analogs, and derivatives, as "lobelia." After explaining some basic physiology, you will see why lobelia is important.

Nicotine causes an increase in blood pressure, increases intestinal motility, stimulates the central nervous system, has an anti diuretic effect (ability to retain water), affects heart rate, affects respiration, is highly soluble and crosses the blood-brain barrier, produces some euphoria (feeling of well being), arousal, relaxation, and it improves attention, and crosses the placenta membrane and is secreted in the milk of lactating women.

The chronic effects of Nicotine include nasopharyngeal and bronchial irritation, lung cancer, cardiac irregularities, stimulated salivary secretion, and reduction of gastric acidity.

Let us now consider the structural formulas for the active constituents in lobelia. Because of their basically symmetrical structure, it appears that they have an advantage in competing with nicotine at the effector cell site. It is postulated that these components can attach themselves to the cell site from either side of the molecule and perhaps crowd out the nicotine. Later, after the nicotine is eliminated from the system, lobeline will replace nicotine at the effector cell site. While nicotine is rapidly eliminated from the body within 16-24 hours, the withdrawal symptoms can last for several weeks to several months, depending upon the individual.

Lobelia's action in the body mimics that of nicotine, but does not have the physiological dependence of nicotine. Lobelia exhibits a cross tolerance with nicotine, is one of the most useful systemic relaxants, has a relaxation effect on the central nervous system, has a relaxing action on the autonomic nervous system, has a general relaxing action on neuromuscular action, is a powerful respiratory stimulant, equalizes circulation and relieves vascular tension, provides a truly holistic action with a combination of stimulation and relaxation, and also provides the holistic action of a general relaxant with diffusive stimulation.

Recently, scientists in Japan have discovered an antidepressant component in the leaves of *lobelia inflata*. This probably explains why individuals feel better when taking lobelia.

Given this physiology, the physiologic needs of a smoker can be addressed using lobelia. In addition to lobelia, I have found that other herbal substances are useful as dietary substances. Thus, in my preferred embodiment, lobelia is used along with wood betony, fennel seed and licorice root and several other herbs.

In addition to these vitamin-type nutritional supplements, in my invention one needs lobelia. Lobelia is also known as Indian tobacco or wild tobacco and is native to North America. It includes three components significant here : lobeline, lobelanidine and lobelanine. It is pharmacologically similar to nicotine, but does not have nicotine's physiological dependency.

In my preferred embodiment of my invention, I have found it beneficial to include certain other supplements derived from

plants and herbs. Each the individual ingredients improves the function of lobelia alone, as each provides a specific function to enhance the efficacy of the product.

Wood Betony. Wood betony is used for its sedative and bitter properties. Its anti-hypertensive properties relieve nervous tension and dilate blood vessels, thus producing a calming effect. Wood betony can relieve headaches normally associated with nicotine withdrawal. Its bitter tonic properties also aid in nicotine withdrawal.

Fennel Seed. Fennel seed has been recognized to have carminative and stimulant properties. It has been reported to have a spasmolytic effect on smooth muscles. As a result, it can be used for dyspeptic discomfort, gastrointestinal discomforts and congestion of the upper respiratory tract. Since chain smokers normally have a smoker's cough resulting in congestion of the lungs, fennel seed can aid in treating that congestion. One of the constituents from the volatile oil expressed from fennel is anethol. Anethol has been shown experimentally to reduce secretions of the upper respiratory tract (i.e., lungs).

Licorice Root. The major active ingredient in licorice root is glycyrrhizin. The glycyrrhizin is responsible for a vasopressor response, which is similar to that occurring in nicotine. However, while it mimics that response, it also exhibits anti-inflammatory and an antitussive effects that is comparable to codeine in potency. This is due to the derivative 18 Beta-glycyrrhetinic acid which prevents smoker's cough. In addition, the flavonoids in licorice root have recently been shown to have strong antioxidant and anti-hepatotoxic activities. These

activities will help cleanse the body of the free radicals and other toxic substances generated from smoking. Licorice extracts are often used in anti-smoking preparations as a flavoring agent to mask bitter nauseous or other undesirable tastes from other components of the preparation. Licorice can also be used to treat stomach irritation arising from nicotine usage.

In addition to the foregoing, I have found it useful to use also blue cohosh, black walnut husk, chamomile flower, gotu kola leaf extract, kava kava root, peppermint, sarsaparilla root, slippery elm bark, valerian root, bayberry fruit, myrrh, passion flower, ginger root and eucalyptus oil. Thus, in my preferred embodiment, I use each of these, for the following reasons.

Blue Cohosh. It has demonstrated anti-inflammatory activity in animals. Blue cohosh can be used for nervous disorders.

Black Walnut Husk. Black walnut husk is a blood cleanser and oxidizer. It has been shown to be useful in lung disease and has strong anti-fungal and antibacterial properties. It is a rich dietary source of protein, iodine, chromium, potassium, manganese, vitamin A and the powerful antioxidant vitamin C.

Chamomile Flower. Chamomile flower has essential oils that contain a variety of glycosides, and other important constituents and chemically related compounds. Several of the therapeutic constituents of the volatile oil are chamazulene and alpha bisabolol oxide A. Chamazulene has demonstrated anti-inflammatory activity, pain relieving, wound healing, antispasmodic and anti-microbial properties. Alpha bisabolol has

anti-inflammatory, anti-microbial and anti-peptic activities. Matricin has been found to have a sufficiently stronger anti-inflammatory effect than chamazulene.

Gotu Kola Leaf Extract. The gotu kola leaves contain
5 properties that have been shown to accelerate wound healing, improve memory, relieve fatigue and stress, increase mental acuity and improve behavioral patterns. This produces a calming effect within the body, thereby relieving the stress associated with nicotine withdrawal symptoms.

10 Kava Kava Root. The active ingredients in kava kava root are a group of compounds known as the kavalactones. They are recognized for their biological activity as a sedative, anti-convulsive and tonic. Additional constituents in kava kava root have demonstrated muscle relaxant activity and have been used for
15 their ability to combat nervous anxiety and unrest. Kava kava also has expectorant properties. This allows the heavy smoker to expectorate residual mucus from the lungs.

Peppermint. Peppermint yields a volatile oil that is composed mainly of menthol. Menthol has long been recognized as a
20 cooling agent in topical preparations. Also present are many other ingredients, some of which have been characterized to have biological activity. One such constituent is bisabolene, which has demonstrated to have anti-inflammatory activity. Other constituents in peppermint include flavonoids such as hesperetin
25 and rutin. Also present are tocopherols, carotenoids, choline and azulenes. Azulene isolated from peppermint demonstrated anti-inflammatory and antinuclear effects in experimental animals. Peppermint oil is extensively used as a flavoring agent,

carminative, antiseptic and local anesthetic in cold, cough and other preparations. Peppermint and their oils have been used in traditional medicine as a stomachic, stimulant, antiseptic, local anesthetic and antispasmodic in treating indigestion, sore throat, 5 nausea, diarrhea and colds.

Sarsaparilla Root. The major component of sarsaparilla is a variety of steroids which include sarsasapogenin, smilagenin, sitosterol, stigmasterol and pollinastanol, and their glycosides (saponins) including sarsasaponin (parillin), smilasaponin 10 (smilacin), sarsaparilloside and sitosterol glucoside. Sarsaparilla is reported to have hepatoprotective, diuretic and anti-inflammatory activity.

Slippery Elm Bark. The principal constituent of slippery elm bark is mucilage. The mucilage has demulcent 15 (soothing) and nutritive properties. It can sometimes be used to soothe irritated lungs.

Valerian Root. Valerian root has a variety of constituents but the major one, valerenic acid, produces a nerving or sedative effect. Valerian has CNS depressant activities. As a 20 result, in states of agitation normally witnessed by smokers during withdrawal, this will have a calming effect. It has also been shown that in conditions of fatigue, the herb has demonstrated stimulating properties.

Bayberry Fruit. Bayberry fruit has been recognized to 25 have a tonic effect.

Myrrh. Myrrh is reported to have astringent effects on mucus membranes. It is often used as a flavor component to mask bitter ingredients. It has also been used as a stimulant and

expectorant. The expectorant properties will help the smoker remove mucus and phlegm from the lungs.

Passion Flower. Passion flower contains indole alkaloids, flavonoids and steroids. The indole alkaloids and
5 flavonoids have tranquilizing effects. Anxiolytic and hypotensive activity has also been reported.

Ginger Root. Ginger root is used to combat nausea and vomiting, which may accompany nicotine withdrawal.

Eucalyptus Leaf Oil. The leaves contain .05 to 3.5%
10 oil. The oil consists mostly of eucalyptol (1, 8-cineole). It is used in an anti-smoking formula as an expectorant to help remove mucus from the lungs.

In my preferred embodiment of my invention, these dietary substances are used as found in CIGSATION™ 100% Natural
15 Cigarette Replacement System, commercially available from Vitamerica, Inc., Cedar Knolls, New Jersey 07927, www.vitamerica.com. Each of these dietary substances adds to the benefit obtained from using lobelia alone.

In addition to addressing the physical nicotine
20 addiction, I find it useful to address the smoker's fear of excessive weight gain, by using a "weight control product," a drug or dietary substances useful in controlling unnatural weight gain. Such dietary substances include chromium, choline, inositol, vanadium, gynema sylvestre, lecithin, vitamin B6, ginseng, zinc,
25 mahuang, kola nut extract, spirulina, and methionine. Several of these are known physiological stimulants, which increase thermogenesis in the body and thus promote expending calories. I

will discuss each in turn, and its usefulness in a weight-control product.

Chromium. What is chromium? It's the mineral that no body can afford to be without. Like iron, copper and zinc, chromium is one of the 16 essential trace minerals the body needs to keep healthy and fit. And for people who are overweight and out of shape, chromium may be the most precious mineral of all. In its biologically active form, it helps insulin to metabolize fat, convert protein into muscle, and convert sugar into energy. Chromium-activated insulin actually increases almost twenty times the amount of glucose available for energy production, optimizing energy output so that you feel healthy and alive.

Chromium is the "master" nutrient for controlling blood sugar. It helps overcome sugar cravings, which is a problem with many overweight people. It also plays an important role in controlling blood lipids, lowering harmful LDL cholesterol, and increasing beneficial HDL cholesterol.

Research shows that a chromium deficiency may be a widespread problem. Many people, such as athletes, diabetics, mothers and the elderly, are at especially high risk. A lack of chromium can impair insulin function, thereby inhibiting protein synthesis and energy production. More seriously, it can even lead to type II diabetes and heart disease.

In my preferred embodiment, the chromium is a form of chromium commercially available under the trade name CHROMIUM CHELAVITE™, available from Vitamerica, Inc. of Cedar Knolls, New Jersey.

The most biologically active form of chromium, the true GTF chromium, is the basis for the molecular structure of CHROMIUM CHELAVITE™. Studies on CHROMIUM CHELAVITE™ at a leading Utah university have shown that this form of chromium is clearly superior to both chromium picolinate and chromium polynicotinate in absorb ability. It had an absorption rate that was 53% greater than for chromium picolinate and 91% greater than that observed for chromium polynicotinate.

Choline. Choline is one of the most beneficial nutritional supplements. Technically, it is not a vitamin, even though it is essential for human life. There are three major functions of choline among humans. It is needed for building cell structure, it prevents or minimizes unhealthy fat deposits in the liver, and it acts as a precursor to acetylcholine. Acetylcholine is a neurotransmitter in the brain which is responsible for nerve impulses, memory, learning, mood elevation and depression control.

Choline has a very positive effect on the health of the liver. It is a lipotropic agent (fat eliminator) that can cut away fats in the liver to be used instead of energy. Choline aids in weight loss by facilitating Growth Hormone (GH) releasers, controlling cholesterol, and helping control the appetite. It also helps reduce the "gut transit time", the amount of time it takes food to move through the intestines. In addition to helping speed food through the system, choline also plays an important role in the body's ability to metabolize fat and cholesterol.

Inositol. Inositol is a member of the B complex of vitamins. It provides a calming effect, nourishes brain cells, helps reduce cholesterol, slows artery hardening, prevents eczema,

and is needed for hair growth and metabolism. It is found in high concentrations in the brain, and serves as a brain cell membrane stabilizer. Inositol also helps in lecithin formation, and aids the body in the metabolism of fat and cholesterol.

5 Vanadium. A trace mineral like chromium, vanadium is essential for cellular activity and for the formation of bones and teeth. It also inhibits the synthesis of cholesterol and lowers certain forms of high blood pressure. It works remarkably well as a powerful insulin mimic and has been shown to normalize blood
10 sugar levels, even in diabetics.

 Gynema Sylvestre. This tropical herb is beginning to receive much attention due to impressive results in recent studies. Gynema Sylvestre appears to have a positive effect in lowering blood sugar levels, especially in diabetics. Research
15 also suggests that it can help curb sugar absorption.

 Lecithin. Lecithin is part of every single cell in the body, but has its greatest concentration in the brain. About 17-20% of the brain is made up from lecithin. Lecithin is an emulsifier. It is used in the manufacture of chocolate, because it
20 keeps it liquid and it keeps it moving. Lecithin does the same thing for the fat in the human body; it keeps it moving, right out of the body.

 Lecithin is a natural diuretic and an effective cholesterol reducer. It helps prevent the buildup of cholesterol
25 on arterial walls, thus improving the circulation of the blood. One study that examined 900 men for atherosclerosis (fat deposits in the arteries) showed that those with more than 36% lecithin in

the blood had no atherosclerosis. Those with less than 34% showed evidence of the disease.

Lecithin is also the source of two of the hardest to find B-Complex relatives, choline and inositol. A major function of lecithin is to supply choline in the diet. Choline (see entry) has the function of breaking down fat deposits in the body. Our bodies do not manufacture enough choline. Therefore, we must rely upon our food and supplements such as lecithin to make sure that we get enough.

10 Vitamin B6. Vitamin B6 aids in more bodily functions than any other single nutrient. It facilitates the body's use of carbohydrates, proteins and fats. It promotes mental performance by aiding in the transport of amino acids, which are used by the brain to increase mental energy and memory. It also promotes the
15 transport of choline, and aids in the breakdown of glycogen, the primary fuel for the brain.

Ginseng. For centuries, the Chinese have testified to the beneficial effects of Ginseng on longevity. Ginseng provides stimulation to the entire body, helping to overcome stress and
20 fatigue. Ginseng can regulate and normalize blood pressure and blood sugar levels. It has been called a cure-all and has also been claimed to be a mild sexual stimulant. Over all, Ginseng has a phenomenal effect on the body's energy level.

Zinc. Zinc is another important trace mineral that is
25 used by more than 200 enzymes to keep the body's major metabolic systems going strong. In addition to its role in metabolism, zinc is a potent antioxidant, profoundly important in enhancing the

immune system, stimulating cellular growth, reducing excess levels of damaging free radicals, and improving general health.

Mahuang. Mahuang, also known as ephedra, contains a potent alkaloid, ephedrine. This natural stimulant increases the
5 basal metabolic rate, which helps to burn calories more effectively. It has also been used as a remedy for kidney and bladder problems, as well as for colds, asthma, and hay fever.

Kola Nut Extract. This is a natural stimulant that increases energy and stamina. It has been found to be very useful
10 in preventing fatigue. Kola Nut Extract also acts as a tonic agent for the heart, and it is sometimes useful in relieving pain, neuralgia, and headache.

Spirulina. This famed blue-green algae contains concentrations of nutrients unlike any other single grain, plant
15 or herb. This super nutrient is a naturally digestible food that aids in protecting the immune system, in cholesterol reduction and in mineral absorption. It also helps to cleanse and heal, while also curbing the appetite.

Methionine. Methionine is an amino acid that assists
20 the gall bladder function by helping to synthesize bile salts. It is a lipotropic substance that prevents the deposits of and cohesion of fats in the liver. It is also reported to be a growth hormone releaser.

It serves as an antioxidant in the brain. It helps
25 prevent the buildup of heavy metals and plays an important and essential role in the production of the brain neurotransmitter choline. Methionine is not found in the body. Therefore, it must be gotten via food and supplementation. It is also a good source

of sulfur, and its therapeutic lipotropic effects help to eliminate fatty substances from the body.

Each of these dietary substances can be found in TRIM SPECIFICS™, available from Vitamerica, Cedar Knolls, New Jersey,

5 www.vitamerica.com.

Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The examples I discuss here are included as the preferred embodiment of my
10 invention, and not to further qualify the description.

Claims

I claim:

1. A method for helping a tobacco smoker to stop smoking, said method comprising the steps of:

5 (A) providing to a tobacco smoker an educational program to educate said tobacco smoker's conscious mind, said educational program including education both on the disadvantages of smoking and on conscious techniques to stop smoking,

(B) providing to said tobacco smoker at least one hypnosis
10 program to train said tobacco smoker's subconscious mind to discourage said tobacco smoker from performing smoking behavior, and

(C) providing to said tobacco smoker lobelia in an amount effective to aid in the reduction or cessation of said tobacco
15 smoker's craving to smoke tobacco, such that said tobacco smoker can be helped to stop smoking.

2. The method of claim 1, further comprising the step of:
(D) providing to said tobacco smoker, wood betony.

3. The method of claim 2, further comprising : (E)
20 providing to said tobacco smoker, fennel seed.

4. The method of claim 3, further comprising the step of:
(F) providing to said tobacco smoker, licorice root.

5. The method of claim 4, further comprising the step of:
(G) providing to said tobacco smoker, black walnut husk,
25 chamomile, kava kava root, peppermint, sarsaparilla root, valerian root, bayberry root, passion flower, ginger root, eucalyptus leaf oil, lecithin, vitamin B6, ginseng, zinc, spirulina, and methionine.

6. The method of claim 1, where said hypnosis program comprises prerecorded media useable by said tobacco smoker when alone.

7. The method of claim 1, further comprising the step of:
5 (D) providing to said tobacco smoker, at least one weight-control product.

8. The method of claim 7, where the weight control product includes at least one stimulant.

9. The method of claim 8, where the stimulant is selected
10 from the group consisting of mahuang, kola nut extract, gotu kola leaf extract and myrrh.

10. The method of claim 9, wherein the weight control product comprises chromium.

11. A product to aid a tobacco-smoker in ceasing to smoke
15 tobacco, said product comprising:

(A) means for educating said tobacco smoker's conscious mind, said educational program including education both on the disadvantages of smoking and on conscious techniques to stop smoking,

20 (B) means for hypnosis to train said tobacco smoker's subconscious mind to discourage said tobacco smoker from performing smoking behavior, and

(C) lobelia in an amount effective to aid in the reduction or cessation of said smoker's craving to smoke tobacco.

25 12. The product of claim 11, further comprising: (D) wood betony.

13. The product of claim 12, further comprising: (E) fennel seed.

14. The product of claim 13, further comprising: (F)
licorice root.

15. The product of claim 14, further comprising: (G) black
walnut husk, chamomile, kava kava root, peppermint, sarsaparilla
5 root, valerian root, bayberry root, passion flower, ginger root,
eucalyptus leaf oil, lecithin, vitamin B6, ginseng, zinc,
spirulina, and methionine.

16. The product of claim 11, where said means for hypnosis
comprises prerecorded media useable by said tobacco smoker when
10 alone.

17. The product of claim 11, further comprising: (D) at
least one weight-control product.


18. The product of claim 17, where the weight control
product includes at least one stimulant.

15 19. The method of claim 18, where the stimulant is selected
from the group consisting of mahuang, kola nut extract, gotu kola
leaf extract and myrrh.

20. The method of claim 19, wherein the weight control
product comprises chromium.

Abstract of the Disclosure

The inventor discloses a unique, new and useful process to reduce tobacco smoking, entitled Stop Smoking Method and Composition, consisting of: (1) educating tobacco smokers
5 regarding smoking, its physiological dangers and addictive nature, and techniques to stop smoking; (2) hypnotizing said tobacco smokers, and (3) providing dietary substances to address the nutritional needs of nicotine addiction and the nutritional challenges thereof.





**UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office**

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

54

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
-----------------	-------------	----------------------	---------------------

09/427,447 10/27/99 SZYNALSKI

A

0M32/0302

MARK POHL
55 MADISON AVENUE 4TH FLOOR
MORRISTOWN NJ 07960

EXAMINER

RIMELL, S

ART UNIT

PAPER NUMBER

0712

DATE MAILED:

03/02/00

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

Office Action Summary

Application No.

09/427,447

Applicant(s)

SZYNALSKI, ALEXANDER
GOEN

Examiner

Sam Rimell

Art Unit

3712

- The MAILING DATE of this communication appears on the cover sheet with the correspondence address -

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).

Status

- 1) ☐ Responsive to communication(s) filed on ____.
- 2a) ☐ This action is FINAL. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-20 is/are pending in the application.
- 4a) Of the above claim(s) ____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) ____ is/are allowed.
- 6) ☒ Claim(s) 1-20 is/are rejected.
- 7) ☐ Claim(s) ____ is/are objected to.
- 8) ☐ Claims ____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on ____ is/are objected to by the Examiner.
- 11) ☐ The proposed drawing correction filed on ____ is: a) ☐ approved b) ☐ disapproved.
- 12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. § 119

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).
- a) ☐ All b) ☐ Some * c) ☐ None of the CERTIFIED copies of the priority documents have been:
1. ☐ received.
2. ☐ received in Application No. (Series Code / Serial Number) ____.
3. ☐ received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

- 14) ☐ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. & 119(e).

Attachment(s)

- 14) ☒ Notice of References Cited (PTO-892)
- 15) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 16) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s) ____.
- 17) ☐ Interview Summary (PTO-413) Paper No(s). ____.
- 18) ☐ Notice of Informal Patent Application (PTO-152)
- 19) ☐ Other:

Art Unit: 3712

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1-20 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

Claims 1 and 11 set forth a method in which lobelia is used "in an amount effective to aid in the reduction or cessation of said tobacco smoker's craving to smoke tobacco." However, the disclosure does not reveal what this amount actually is. In fact, the disclosure does not reveal the therapeutically effective dosage amounts for any of the substances disclosed, so the specification is non-enabling for all of claims 1-20. Simply making reference to an OTC product, such as "Cigsation" or "Trim Specifics" is insufficient to meet the disclosure requirement since OTC products do not always label the dosages or contents of the of the substances they contain.

35 U.S.C. 101 reads as follows:

Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.

Claims 1-20 are rejected under 35 U.S.C. 101 because the claimed invention lacks patentable utility.

Claims 1-20 are a claimed method in which he craving to smoke is alleged to be reduced or ceased by the use of education materials, hypnosis, and the ingestion of naturally occurring

Art Unit: 3712

substances, such as lobelia. Additional substances, such as wood betony, licorice root, and peppermint are also alleged as being therapeutically effective. However, there is no evidence that the combined use of educational materials, hypnosis, and the recited natural substances produces a therapeutically effective method for reducing or eliminating a craving for smoking.

There is no clinical evidence that the combined effects will produce the claimed result. In addition, the reference to Schneider et al. (US Pat. 5,414,005) contains a statement in column 3, lines 5-9 that orally ingested lobeline has never been shown to be therapeutically effective in reducing a craving for smoking. Since the other required steps of providing educational materials and providing hypnosis have also never been shown to be therapeutically effective, there is no reason to assume that the combined usage of educational materials, hypnosis and lobeline will be therapeutically effective.

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-20 are rejected under 35 U.S.C. 102(b) as being anticipated by admitted prior art to Vitamerica Inc.

Applicant's disclosure admits (page 5, para 4) that lobeline is utilized in a known prior art ingestible product known as "Cigsation". Applicant's disclosure (page 26, para 2) admits that all the remaining claimed substances are contained in a known prior art ingestible product called "Trim Specifics". Applicant's disclosure further admits (page 11, para 4) that the hypnosis and

Art Unit: 3712

education steps are contained in a known prior art tape program called "Smoking Cessation". All of these products are available from a common source, known as Vitamerica Inc., and are available on the internet at www.vitamerica.com. Since each of these products derives from a common source, it is reasonable to presume that they are intended to be used together in a method for addressing a smoking addiction.

Any inquiry concerning this communication should be directed to Sam Rimell at telephone number (703) 306-5626.



Sam Rimell
Primary Examiner
Art Unit 3712

Notice of References Cited	Application/Control No.		Applicant(s)/Patent Under Reexamination	
	09/427,447		SZYNALSKI, ALEXANDER GOEN	
	Examiner		Art Unit	Page 1 of 1
Sam Rimell		3712		

U.S. PATENT DOCUMENTS

*		DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	DOCUMENT SOURCE **	
							APS	OTHER
<input type="checkbox"/>	A	5414005	May. 1995	Schneider et al.	514	343	<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	B	5780051	Jul. 1998	Eswara et al.	424	449	<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	C	5965567	Oct. 1999	Archer et al.	514	282	<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	D						<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	E						<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	F						<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	G						<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	H						<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	I						<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	J						<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	K						<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	L						<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	M						<input type="checkbox"/>	<input type="checkbox"/>

FOREIGN PATENT DOCUMENTS

*		DOCUMENT NO.	DATE	COUNTRY	NAME	CLASS	SUBCLASS	DOCUMENT SOURCE **	
								APS	OTHER
<input type="checkbox"/>	N							<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	O							<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	P							<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	Q							<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	R							<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	S							<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	T							<input type="checkbox"/>	<input type="checkbox"/>

NON-PATENT DOCUMENTS

*		DOCUMENT (Including Author, Title Date, Source, and Pertinent Pages)	DOCUMENT SOURCE **	
			APS	OTHER
<input type="checkbox"/>	U		<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	V		<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	W		<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	X		<input type="checkbox"/>	<input type="checkbox"/>

*A copy of this reference is not being furnished with this Office action. (See Manual of Patent Examining Procedure, Section 707.05(a).)

**APS encompasses any electronic search i.e. text, image, and Commercial Databases.

U.S. Patent and Trademark Office

PTO 600 (2-99)

Notice of References Cited

Part of Paper No.

C



**UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office**

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
-----------------	-------------	----------------------	---------------------

09/427,447 10/27/99 SZYNALSKI

A

EXAMINER

TM02/0920

MARK POHL
55 MADISON AVENUE, 4TH FLOOR
MORRISTOWN NJ 07960

RIMELL, S

ART UNIT

PAPER NUMBER

2166

DATE MAILED:

09/20/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

Interview Summary	Application No.	Applicant(s)	
	09/427,447	SZYNALSKI, ALEXANDER GOEN	
	Examiner	Art Unit	
	Sam Rimell	2166	

All participants (applicant, applicant's representative, PTO personnel):

(1) Sam Rimell. (3) _____

(2) Mark Pohl. (4) _____

Date of Interview: 19 September 2001.

Type: a) ☒ Telephonic b) ☐ Video Conference
c) ☐ Personal [copy given to: 1) ☐ applicant 2) ☐ applicant's representative]

Exhibit shown or demonstration conducted: d) ☐ Yes e) ☒ No.

If Yes, brief description: _____

Claim(s) discussed: 1 and 11.

Identification of prior art discussed: Cooper et al.

Agreement with respect to the claims f) ☐ was reached. g) ☐ was not reached. h) ☒ N/A.

Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: Examiner suggested modifying claims 1 and 11 to define non-invasive educational techniques, unlike those of Cooper et al. which are invasive to the body. Examiner agreed to consider claims addressed to the use of anti-depressants instead of lobelia, but requested information on efficacy in this usage

(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)

i) ☐ It is not necessary for applicant to provide a separate record of the substance of the interview (if box is checked).

Unless the paragraph above has been checked, THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN ONE MONTH FROM THIS INTERVIEW DATE TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.

Examiner Note: You must sign this form unless it is an Attachment to a signed Office action.



Examiner's signature, if required

Summary of Record of Interview Requirements

Manual of Patent Examining Procedure (MPEP), Section 713.04, Substance of Interview Must be Made of Record

A complete written statement as to the substance of any face-to-face, video conference, or telephone interview with regard to an application must be made of record in the application whether or not an agreement with the examiner was reached at the interview.

Title 37 Code of Federal Regulations (CFR) § 1.133 Interviews

Paragraph (b)

In every instance where reconsideration is requested in view of an interview with an examiner, a complete written statement of the reasons presented at the interview as warranting favorable action must be filed by the applicant. An interview does not remove the necessity for reply to Office action as specified in §§ 1.111, 1.135. (35 U.S.C. 132)

37 CFR §1.2 Business to be transacted in writing.

All business with the Patent or Trademark Office should be transacted in writing. The personal attendance of applicants or their attorneys or agents at the Patent and Trademark Office is unnecessary. The action of the Patent and Trademark Office will be based exclusively on the written record in the Office. No attention will be paid to any alleged oral promise, stipulation, or understanding in relation to which there is disagreement or doubt.

The action of the Patent and Trademark Office cannot be based exclusively on the written record in the Office if that record is itself incomplete through the failure to record the substance of interviews.

It is the responsibility of the applicant or the attorney or agent to make the substance of an interview of record in the application file, unless the examiner indicates he or she will do so. It is the examiner's responsibility to see that such a record is made and to correct material inaccuracies which bear directly on the question of patentability.

Examiners must complete an Interview Summary Form for each interview held where a matter of substance has been discussed during the interview by checking the appropriate boxes and filling in the blanks. Discussions regarding only procedural matters, directed solely to restriction requirements for which interview recordation is otherwise provided for in Section 812.01 of the Manual of Patent Examining Procedure, or pointing out typographical errors or unreadable script in Office actions or the like, are excluded from the interview recordation procedures below. Where the substance of an interview is completely recorded in an Examiners Amendment, no separate Interview Summary Record is required.

The Interview Summary Form shall be given an appropriate Paper No., placed in the right hand portion of the file, and listed on the "Contents" section of the file wrapper. In a personal interview, a duplicate of the Form is given to the applicant (or attorney or agent) at the conclusion of the interview. In the case of a telephone or video-conference interview, the copy is mailed to the applicant's correspondence address either with or prior to the next official communication. If additional correspondence from the examiner is not likely before an allowance or if other circumstances dictate, the Form should be mailed promptly after the interview rather than with the next official communication.

The Form provides for recordation of the following information:

- Application Number (Series Code and Serial Number)
- Name of applicant
- Name of examiner
- Date of interview
- Type of interview (telephonic, video-conference, or personal)
- Name of participant(s) (applicant, attorney or agent, examiner, other PTO personnel, etc.)
- An indication whether or not an exhibit was shown or a demonstration conducted
- An identification of the specific prior art discussed
- An indication whether an agreement was reached and if so, a description of the general nature of the agreement (may be by attachment of a copy of amendments or claims agreed as being allowable). Note: Agreement as to allowability is tentative and does not restrict further action by the examiner to the contrary.
- The signature of the examiner who conducted the interview (if Form is not an attachment to a signed Office action)

It is desirable that the examiner orally remind the applicant of his or her obligation to record the substance of the interview of each case unless both applicant and examiner agree that the examiner will record same. Where the examiner agrees to record the substance of the interview, or when it is adequately recorded on the Form or in an attachment to the Form, the examiner should check the appropriate box at the bottom of the Form which informs the applicant that the submission of a separate record of the substance of the interview as a supplement to the Form is not required.

It should be noted, however, that the Interview Summary Form will not normally be considered a complete and proper recordation of the interview unless it includes, or is supplemented by the applicant or the examiner to include, all of the applicable items required below concerning the substance of the interview.


A complete and proper recordation of the substance of any interview should include at least the following applicable items:

- 1) A brief description of the nature of any exhibit shown or any demonstration conducted,
- 2) an identification of the claims discussed,
- 3) an identification of the specific prior art discussed,
- 4) an identification of the principal proposed amendments of a substantive nature discussed, unless these are already described on the Interview Summary Form completed by the Examiner,
- 5) a brief identification of the general thrust of the principal arguments presented to the examiner,
(The identification of arguments need not be lengthy or elaborate. A verbatim or highly detailed description of the arguments is not required. The identification of the arguments is sufficient if the general nature or thrust of the principal arguments made to the examiner can be understood in the context of the application file. Of course, the applicant may desire to emphasize and fully describe those arguments which he or she feels were or might be persuasive to the examiner.)
- 6) a general indication of any other pertinent matters discussed, and
- 7) if appropriate, the general results or outcome of the interview unless already described in the Interview Summary Form completed by the examiner.

Examiners are expected to carefully review the applicant's record of the substance of an interview. If the record is not complete and accurate, the examiner will give the applicant an extendable one month time period to correct the record.

Examiner to Check for Accuracy

If the claims are allowable for other reasons of record, the examiner should send a letter setting forth the examiner's version of the statement attributed to him or her. If the record is complete and accurate, the examiner should place the indication, "Interview Record OK" on the paper recording the substance of the interview along with the date and the examiner's initials.



Please type a plus sign (+) inside this box → ☐


PTO/SB/21 (08-00)


Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	09/427,447
	Filing Date	27 Oct 1999
	First Named Inventor	Alexander Goen SZYNALSKI
	Group Art Unit	2166
	Examiner Name	Samuel RIMELL, Esq.
Total Number of Pages in This Submission		Attorney Docket Number Nutrimerica

ENCLOSURES (check all that apply)		
<input checked="" type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input checked="" type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input checked="" type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input checked="" type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) <u>one</u>	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Mark POHL, Reg.35,325, Pharma. Patent Attys
Signature	
Date	See below date

CERTIFICATE OF MAILING		
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: <u>see below date</u>		
Typed or printed name	Mark POHL, Reg. No. 35,325	
Signature		Date 19 Sept 01

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB/17 (11-00)
Approved for use through 10/31/2002. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

FEE TRANSMITTAL for FY 2001

Patent fees are subject to annual revision.

TOTAL AMOUNT OF PAYMENT

(\$)27=

Complete if Known

Application Number 09/427,447
Filing Date 27 Oct 1999
First Named Inventor SZYNALSKI
Examiner Name Samuel RIMMEL
Group Art Unit 2166
Attorney Docket No. NutriMerica

METHOD OF PAYMENT

1. ☐ The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to:
- Deposit Account Number
Deposit Account Name
- ☐ Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17
☐ Applicant claims small entity status. See 37 CFR 1.27
2. ☒ Payment Enclosed:
☐ Check ☒ Credit card ☐ Money Order ☐ Other

FEE CALCULATION

1. BASIC FILING FEE

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
101 710	201 355	Utility filing fee	
106 320	206 160	Design filing fee	
107 490	207 245	Plant filing fee	
108 710	208 355	Reissue filing fee	
114 150	214 75	Provisional filing fee	

SUBTOTAL (1) (\$)

2. EXTRA CLAIM FEES

Total Claims -20** = X =
Independent Claims -3** = X =
Multiple Dependent =

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
103 18	203 9	Claims in excess of 20	
102 80	202 40	Independent claims in excess of 3	
104 270	204 135	Multiple dependent claim, if not paid	
109 80	209 40	** Reissue independent claims over original patent	
110 18	210 9	** Reissue claims in excess of 20 and over original patent	

SUBTOTAL (2) (\$)27=

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
105 130	205 65	Surcharge - late filing fee or oath	
127 50	227 25	Surcharge - late provisional filing fee or cover sheet	
139 130	139 130	Non-English specification	
147 2,520	147 2,520	For filing a request for <i>ex parte</i> reexamination	
112 920*	112 920*	Requesting publication of SIR prior to Examiner action	
113 1,840*	113 1,840*	Requesting publication of SIR after Examiner action	
115 110	215 55	Extension for reply within first month	
116 390	216 195	Extension for reply within second month	
117 890	217 445	Extension for reply within third month	
118 1,390	218 695	Extension for reply within fourth month	
128 1,890	228 945	Extension for reply within fifth month	
119 310	219 155	Notice of Appeal	
120 310	220 155	Filing a brief in support of an appeal	
121 270	221 135	Request for oral hearing	
138 1,510	138 1,510	Petition to institute a public use proceeding	
140 110	240 55	Petition to revive - unavoidable	
141 1,240	241 620	Petition to revive - unintentional	
142 1,240	242 620	Utility issue fee (or reissue)	
143 440	243 220	Design issue fee	
144 600	244 300	Plant issue fee	
122 130	122 130	Petitions to the Commissioner	
123 50	123 50	Processing fee under 37 CFR 1.17(q)	
126 180	126 180	Submission of Information Disclosure Stmt	
581 40	581 40	Recording each patent assignment per property (times number of properties)	
146 710	246 355	Filing a submission after final rejection (37 CFR § 1.129(a))	
149 710	249 355	For each additional invention to be examined (37 CFR § 1.129(b))	
179 710	279 355	Request for Continued Examination (RCE)	
169 900	169 900	Request for expedited examination of a design application	

Other fee (specify) _____

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$)

SUBMITTED BY

Name (Print/Type) Mark POHL, Esq.
Signature *Mark Pohl*

Registration No. (Attorney/Agent) 35,325

Complete (if applicable)

Telephone (973) 665-0275
Date 19 Sept 01

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

5

IN THE UNITED STATES PATENT OFFICE

Inventor : Alexander Goen SZYNALSKI
Serial No. : 09/427,447
Filing Date : 27 Oct 1999
Title : Stop Smoking Methods
10 Group Art Unit : 2166
Examiner : Samuel RIMELL, Esq.

15

Assistant Commissioner of Patents
Washington, DC 20231

AMENDMENT

Please amend pending claims 1 and 11 to read:

20 1. A method for helping a tobacco smoker to stop smoking, said method comprising the steps of:

25 (A) providing to a tobacco smoker an non-conditioning, educational program to educate said tobacco smoker's conscious mind, said educational program including education both on the disadvantages of smoking and on conscious techniques to stop smoking,

30 (B) providing to said tobacco smoker at least one hypnosis program to train said tobacco smoker's subconscious mind to discourage said tobacco smoker from performing smoking behavior, and

35 (C) providing to said tobacco smoker lebelia-an anti-smoking drug in an amount effective to aid in the reduction or cessation of said tobacco smoker's craving to smoke tobacco,

40 such that said tobacco smoker can be helped to stop smoking.

45 11. A product to aid a tobacco smoker in ceasing to smoke tobacco, said product comprising:

50 (A) means for educating said tobacco smoker's conscious mind, said educational program including non-conditioning education both on the disadvantages of smoking and on conscious techniques to stop smoking,

(B) means for hypnosis to train said tobacco smoker's subconscious mind to discourage said tobacco smoker from performing smoking behavior, and

(C) ~~lobelia~~ an anti-smoking drug in an amount effective to aid in the reduction or cessation of said tobacco smoker's craving to smoke tobacco.

A clean copy of claims 1 and 11 thus read:

1. A method for helping a tobacco smoker to stop smoking, said method comprising the steps of:

(A) providing to a tobacco smoker a non-conditioning, educational program to educate said tobacco smoker's conscious mind, said educational program including education both on the disadvantages of smoking and on conscious techniques to stop smoking,

(B) providing to said tobacco smoker at least one hypnosis program to train said tobacco smoker's subconscious mind to discourage said tobacco smoker from performing smoking behavior, and

(C) providing to said tobacco smoker an anti-smoking drug in an amount effective to aid in the reduction or cessation of said tobacco smoker's craving to smoke tobacco,

such that said tobacco smoker can be helped to stop smoking.

11. A product to aid a tobacco smoker in ceasing to smoke tobacco, said product comprising:

(A) means for educating said tobacco smoker's conscious mind, said educational program including non-conditioning education both on the disadvantages of smoking and on conscious techniques to stop smoking,

(B) means for hypnosis to train said tobacco smoker's subconscious mind to discourage said tobacco smoker from performing smoking behavior, and

(C) an anti-smoking drug in an amount effective to aid in the reduction or cessation of said tobacco smoker's craving to smoke tobacco.

5 Please withdraw the previous cancellation of claims 7, 8, 17 and 18. Please add new claims 21-24:

21. The method of claim 1, wherein said anti-smoking drug is an antidepressant.

10 22. The method of claim 21, wherein said antidepressant is lobelia.

23. The product of claim 11, wherein said anti-smoking drug is an antidepressant.

15 24. The product of claim 23, wherein said antidepressant is lobelia.

20 REMARKS

Claims 1, 6, 11 and 16 are pending in the application. Claims 1 and 11 stand rejected in light of Cooper et al.

25 Claims 1 and 11

Amendments are made to elements (A) and (C).

Element (A) - "an educational program"

Cooper cannot anticipate claims 1 and 11 because Cooper fails to teach an essential claim element.

30 The claims require three elements: "(A) education...; (B) hypnosis, to use the unconscious mind to stop smoking; and (C) nutritional supplements addressing the nutritional challenges with regard to stopping smoking." Specification at 1. These three elements act on "the conscious mind, the unconscious mind, and the body." Id.

35

The unconscious mind is programmed using repetition of stimuli, to take the subject toward pleasure and away from pain. Id. at 7. The Specification discusses numerous methods for programming the unconscious, id. at 7-10. Methods of programming the unconscious mind are referred to as "hypnosis." In the preferred embodiment, such hypnosis involves, for example, negative conditioning. Id. at 8. ("hypnosis focuses on interrupting 'conditioned responses' generally, and specifically, on interrupting the response to smoke").

Conditioning is "A process of behavior modification by which a subject comes to associate a desired behavior with a previously **unrelated** stimulus." American Heritage Dictionary (2000) (available at www.dictionary.com). Conditioning was discovered by I.P. PAVLOV, who trained dogs to perform an unconscious response (salivation) in response to an unrelated stimulus (a bell). On-Line Medical Dictionary (12 Dec 1998).

Cooper teaches a "negative conditioning" apparatus. Conditioning is a method of programming unconscious response. It is not an educational program for the conscious mind. The claims have been amended to clarify that "conditioning" is a type of hypnosis, not a type of education.

Element (C) - "lobelia"

Element C is broadened to encompass equivalents of lobelia literally.

The Specification teaches that lobelia is an antidepressant acetylcholine receptor binder. Specification at 13-15. The Specification teaches other examples of antidepressants, id. at 18 (gotu kola extract; kava kava root).

It is known in the art that antidepressants can be used as stop-smoking drugs. For example, bupropion hydrochloride is sold as both an antidepressant (commercially available under the trademark WELLBUTRIN® from Glaxo-Wellcome Inc., Chapel Hill, North Carolina) and a stop-smoking drug (commercially available under the trademark ZYBAN® from Glaxo-Wellcome Inc., Chapel Hill, North Carolina). Physicians' Desk Reference at 1277 et seq. (1999). Antidepressants "produce[] a calming effect within the body, thereby relieving the stress associated with nicotine withdrawal symptoms." Specification at 18, lines 8-9. This probably explains why individuals quitting smoking feel better when taking an anti-smoking drug. Id. at 15, lines 12-14.

Accordingly, element (C) is broadened to encompass stop-smoking drugs generally, and dependent claims 21-24 are added to recite lobelia specifically.

Claims 7, 8, 17 and 18

These claims were previously rejected as allegedly non-enabled under Section 112, first paragraph. The claims were then withdrawn based on the understanding that the remaining claims would proceed to prompt allowance. The 24 Oct 2001 Office Action moots the reason to have withdrawn these claims.


These claims comply with 35 USC 112. Claims 7 and 17 recite "at least one weight-control product." Claims 8 and 18 require the weight control product to include a stimulant.

Weight control products ("anorexants"), the use of CNS stimulants as such, and the therapeutically effective amounts, are known nearly universally in the United States. See e.g., The Merck Manual at 2492-93 (1987) ("CNS stimulants are used to ... suppress the appetite. *** The failure of most obese patients to lose weight satisfactorily by attempting to decrease food intake alone has led to widespread use of anorexants. Amphetamine and related compounds ... are most effective for the first 3 to 6 wk."). CNS stimulants which are used as anorexants in include amphetaminil, benzphetamine, chlorphentermine, clortermine, dextroamphetamine sulfate, diethylpropion, n-ethylamphetamine, mazindol, methamphetamine, and others. See The Merck Index (1996). The Specification need not disclose subject matter already common knowledge in the art.

SUMMARY

All pending claims are believed patentable over
the art. Prompt allowance is respectfully requested.

Respectfully Submitted,


Mark POHL, Reg. No. 35,325
19 September 2001

Pharmaceutical Patent Attorneys
55 Madison Avenue, 4th floor (P 4014)
Morristown, NJ 07960-6317 U.S.A.

Direct ☎ +1 (973) 665-0275
Licensinglaw@juno.com

Enclosures:

Physicians' Desk Reference (1999) select pages
Merck Index (1995) select pages
Merck Manual select pages

X:\POHLM\AAOffice\PTO Forms\RESPONSE.DOC

FIFTEENTH EDITION

THE MERCK MANUAL

OF
DIAGNOSIS AND THERAPY

Robert Berkow, M.D., *Editor-in-Chief*
Andrew J. Fletcher, M.B., B.Chir., *Assistant Editor*

Editorial Board

Philip K. Bondy, M.D.
L. Jack Faling, M.D.
Alvan R. Feinstein, M.D.
Eugene P. Frenkel, M.D.
Robert A. Hoekelman, M.D.
Robert G. Petersdorf, M.D.
Fred Plum, M.D.
John Romano, M.D.
G. Victor Rossi, Ph.D.
John H. Talbott, M.D.
Paul H. Tansler, M.D.

Published by

MERCK SHARP & DOHME RESEARCH LABORATORIES

Division of
MERCK & Co., Inc.
Rahway, N.J.

1987

100 mg have been used in severely resistant patients. For maintenance, dosage is reduced to the smallest effective amount. Haloperidol is readily absorbed orally. Peak plasma concentration occurs 2 to 6 h after ingestion and may plateau for as long as 72 h; plasma levels may be detectable for weeks. In acute cases, haloperidol 2 to 5 mg IM may be given.

Haloperidol potentiates the effect of CNS depressants and anticoagulants. It diminishes the effect of L-dopa. It can diminish dyskinesia but aggravates parkinsonism in patients on L-dopa therapy. Since prolonged neuroleptic therapy is associated with development of tardive dyskinesias, haloperidol is not recommended for the treatment of tardive dyskinesias or L-dopa-dyskinesias because it can mask the worsening of neuroleptic-related tardive dyskinesias.

THIOXANTHENES

Of the 4 thioxanthenes marketed in various countries, only chlorprothixene and thiothixene are available in the USA for clinical use. The thioxanthenes resemble the phenothiazines in chemical structure, absorption, metabolism, excretion, and clinical effects. Chlorprothixene and thiothixene have been used in the treatment of schizophrenia and depression. The average oral daily adult dosage is 75 to 200 mg for chlorprothixene and 10 to 30 mg for thiothixene; however, individual patient requirements vary.

Like other neuroleptics, the thioxanthenes interfere with conditioned reflex activity without affecting unconditioned reflex activity. They increase limbic system activity and inhibit proprioceptive arousal reactions. Psychoactive thioxanthenes share some of the properties of tricyclic antidepressants. Thiothixene is comparable to chlorpromazine in therapeutic impact and is particularly effective against affective symptoms. It is especially useful for patients who are socially withdrawn, and is also effective in the management of psychotic depression, tension-agitation, and anxiety.

Fever, fatigue, and drowsiness are the most frequent adverse effects. The sensitivity to sunlight seen with phenothiazines is usually not observed. The relative frequency of adverse effects with thiothixene is lower than with the corresponding phenothiazine analogs. The lower incidence of extrapyramidal effects in long-term maintenance therapy is especially advantageous. Thiothixene has fewer adverse effects on the myocardium than does thioridazine.

OTHER ANTIPSYCHOTIC DRUGS

Loxapine, a tricyclic dibenzoxazine derivative, is chemically distinct from thioxanthenes, butyrophenones, and phenothiazines. Its pharmacologic and toxicologic properties are similar to those of the piperazine group of phenothiazines. Therapeutic efficacy is comparable with that of other neuroleptics in schizophrenia. Side effects include involuntary movements, hypotension, and somnolence. Oral doses range from 60 to 100 mg/day, although some patients may require up to 250 mg/day.

Molindone, a dihydronaloxone derivative, is structurally different from the phenothiazines, butyrophenones, and thioxanthenes, but is also pharmacologically similar to the phenothiazines. The daily oral dose range is 20 to 200 mg.

GENERAL CENTRAL NERVOUS SYSTEM STIMULANTS AND ANOREXICANTS

CNS stimulants are used to increase alertness, inhibit fatigue, suppress the appetite, manage certain children with minimal brain dysfunction or hyperkinesias, and treat narcolepsy. Many of these drugs are related to amphetamine and share the phenethylamine structure. Their activity as psychostimulants is primarily due to an ability to act

indirectly by displacing endogenous catecholamines from storage sites in neural tissues, but may also be partly related to direct catecholamine-like adrenergic receptor activation in the CNS. Their use in clinical medicine continues to decline because of criticism of any use to induce brief mood elevation or to suppress fatigue and a fear that nonchalant prescribing may have contributed to abuse (see also Ch. 139).

The failure of most obese patients to lose weight satisfactorily by attempting to decrease food intake alone has led to widespread use of anorexics. Though these drugs may be of value in beginning a weight reduction program, their long-term utility has been questioned. Amphetamine and related compounds such as diethylpropion, phentermine, and phendimetrazine are most effective for the first 3 to 6 wk. The suggestion that they might be useful intermittently over a long period to aid in weight control has been made. The dosage usually is divided and given before meals, but some agents have a long duration of action and may be given less frequently. Most anorexics may disturb sleep if given late in the day. The use of agents less subject to abuse than amphetamine or phenmetrazine is recommended whenever feasible.

Amphetamine is the prototype CNS stimulant. There are a variety of amphetamine salts and mixtures in various formulations. Amphetamine produces mood elevation with increased wakefulness, alertness, concentration, and physical performance. Sympathetic and diastolic blood pressures are raised, the respiratory center is stimulated, and appetite is suppressed through a central effect. It is rapidly absorbed from the GI tract, reaches high concentrations in the CNS, and is largely metabolized. Its prolonged duration of sympathomimetic action relates to its resistance to metabolic degradation by enzymes that metabolize catecholamines. Amphetamine and related compounds, when taken repeatedly, induce tolerance to some degree, but this is partially dependent on dosage.

Insomnia, dizziness, excessive sweating, tremors, and euphoria may occur; and feelings of depression and fatigue often accompany withdrawal. Anxiety and panic states are seen, particularly at the high dosage levels associated with amphetamine abuse. Lethal overdose is uncommon because of the large difference between an effective and fatal dose and because tolerance has often occurred. For a detailed discussion of amphetamine abuse and its management, see Ch. 138.

Methylphenidate is a CNS stimulant with effects similar to that of amphetamine. It is used to treat hyperkinesia in children (see LEARNING DISORDERS in Ch. 188) and for narcolepsy (see Ch. 122).

Fenfluramine, a newer anorexic, appears to have minimal abuse potential. Although a phenethylamine, it has sedation as its principal side effect and may be given late in the day without disturbing sleep. It should be avoided in patients with a history of mental depression and migraine. Some feel that a low night-time dose of fenfluramine may be combined with a daytime dose of phentermine or diethylpropion for effective and minimally symptom-inducing anorexia.

ANTIEMETICS

Drugs that prevent or relieve nausea and vomiting. Nausea and vomiting may be symptoms of disease processes, eg, metabolic or microbial toxins, or responses to stimuli such as drugs, radiation, or motion. The underlying cause should be sought and corrected if possible, as the etiology suggests which antiemetic is optimal for symptomatic treatment. Nausea and vomiting induced by noncytotoxic drugs such as digitalis, estrogens, and iron preparations should be treated by reducing the dose, changing the route of administration, or switching to another drug.

Stimulation of the vomiting center in the medulla can arise in the chemoreceptor trigger zone (CTZ), cerebral cortex, or vestibular apparatus, or can be relayed directly from peripheral areas (eg, gastric mucosa). Though the mechanism of action of the

THE MERCK INDEX

AN ENCYCLOPEDIA OF
CHEMICALS, DRUGS, AND BIOLOGICALS

TWELFTH EDITION

Susan Budavari, *Editor*
Maryadele J. O'Neil, *Senior Associate Editor*
Ann Smith, *Associate Editor*
Patricia E. Heckelman, *Assistant Editor*
Joanne F. Kinneary, *Assistant Editor*

Published by
Merck Research Laboratories
Division of

MERCK & CO., INC.
Whitehouse Station, NJ

1996

[illegible]**ANESTHETIC (LOCAL)**

Ambucaine, 402
 Amolanone, 610
 Amylocaine Hydrochloride, 656
 Benoxinate, 1076
 Benzocaine, 1116
 Betoxycaïne, 1235
 Biphenamine, 1275
 Bupivacaine, 1520
 Butacaine, 1531
 Butamben, 1538
 Butanilicaine, 1542
 Butethamine, 1552
 Butoxycaïne, 1566
 Cartocaine, 1920
 Chloroprocaine Hydrochloride, 2210
 Cocaethylene, 2516
 Cocaine, 2517
 Cyclomethycaine, 2804
 Dibucaine Hydrochloride, 3081
 Dimethisoquin, 3267
 Dimethocaine, 3270
 Dipiperdon Hydrochloride, 3360
 Dyclonine, 3523
 Ecgonidine, 3540
 Ecgonine, 3541
 Ethyl Chloride, 3829
 Etidocaine, 3907
 β -Eucaine, 3939
 Euprocín, 3950
 Fenalcomine, 3996
 Formocaine, 4259
 Hexylcaine Hydrochloride, 4746
 Hydroxytetracaine, 4894
 Isobutyl *p*-Aminobenzoate, 5148
 Leucinoacaine Mesylate, 5476
 Levoadrol *see* 3352
 Lidocaine, 5505
 Mepivacaine, 5905
 Meprylcaine, 5909

6 (INHALATION)

Ethylamine, 2817
 Ethyl Ether, 2965
 Ethyl Mercaptan, 3024
 Ethyl Nitrate, 3137
 Ethyl Oxide, 2852
 Ethyl Sulfide, 4237
 Ethylamine, 4632
 Ethylamine, 4634
 Ethylamine, 5191
 Ethyl Fluoride, 6072
 Ethyl Propyl Ether, 6192
 Ethyl Oxide, 6751
 Ethylamine, 8621
 Ethylamine, 9265
 Ethyl Oxethylene, 9769
 Ethylamine, 10133
 Ethylamine, 10206

(INTRAVENOUS)

Almidon, Igeniol, 44
 Alkylene Acetate, 233
 Alkylene, 239
 Alkaline Sodium, 1553
 Alkaline, 1993
 Alkaloidal, 4742
 Alkaloidal Sodium, 4868
 Alkali, 308
 Alkali Chloride Sodium, 6061
 Alkali, 6270
 Alkali, 7364
 Alkali, 7986
 Alkali, 8020
 Alkali Oxide, see 4860
 Alkaloidal, 9428
 Alkali, 9437
 Alkaloidal, 9257
 Alkali Sodium, 9487

ANGIOTENSIN CONVERTING ENZYME INHIBITOR *see ACE-Inhibitor*

ANGIOTENSIN II RECEPTOR ANTAGONIST *see also* Antihypertensive

Candesartan, 1788
Eprosartan, 3669

Irbesartan, 5097
Losartan, 5613
Valsartan, 10051

ANOREXIC

- Aminorex, 497
- Amphecloral, 620.
- Amphetamine, 623
- Benzphetamine, 1151
- Chlorphentermine, 2235
- Clobenzorex, 2421
- Cloforex, 2440
- Clortermine, 2472
- Cyclixedrine, 2776
- Dextroamphetamine Sulfate, 2996
- Dihydropiropion, 3175
- Diphenmethoxidine, 3362
- N-Ethylamphetamine, 3809
- Fenbutrazate, 4005
- Fenfluramine, 4015
- Fenproporex, 4036
- Furfurylmethylamphetamine, 4327
- Levophacetoperane, 5493
- Mazindol, 5801
- Mefenorex, 5843
- Metamfepramone, 5984
- Methamphetamine, 6015
- Norpseudoephedrine, 6811
- Pentorex, 7275
- Phendimetrazine, 7365
- Phenmetrazine, 7385
- Phentermine, 7415
- Phenylpropanolamine Hydrochloride, 7461
- Picilorex, 7551
- Sibutramine, 8629

ANTACID

Alexitol Sodium, 232
 Almgate, 307
 Aluminum Hydroxide, 355
 Aluminum Magnesium Silicate,
 362
 Aluminum Phosphate, 371
 Azulene, 956
 Basic Aluminum Carbonate Gel,
 1033
 Bismuth Aluminate, 1298
 Bismuth Phosphate, 1316
 Bismuth Subgallate, 1325
 Bismuth Subnitrate, 1326
 Calcium Carbonate, 1697
 Dihydroxyaluminum Aminoacetate,
 3227
 Dihydroxyaluminum Sodium
 Carbonate, 3228
 Ebinar, 3535
 Magaldrate, 5685
 Magnesium Carbonate Hydroxide,
 5696
 Magnesium Hydroxide, 5706
 Magnesium Oxide, 5713
 Magnesium Peroxide, 5717
 Magnesium Phosphate, Tribasic,
 5720
 Magnesium Silicates, 5727
 Potassium Citrate, 7785
 Sodium Bicarbonate, 8726

ANTHELMINTIC (CESTODES)

Arecoline, 815
 Aspidin, 881
 Aspidinol, 882
 Dichlorophen(e), 3120
 Embelin, 3595
 Kosin, 5333

Bencyclane, 1060
 Benfenone, 3753
 Pantofarone, 3975
 Perhexiline, 7305

CALCIUM-REGULATOR

Calcifediol, 1677
 Calcitonin, 1680
 Calcitriol, 1681
 Dihydrotachysterol, 3223
 Elcatonin, 3578
 Ergthavone, 5090
 Parathyroid Hormone, 7168
 Terparatide Acetate, 9309

CALCIUM SUPPLEMENT *see Replenish-
 ing Supplements*

CANCER CHEMOTHERAPY *see
 Antiplastic*

CARDIARY PROTECTANT *see
 Protectant*

CARBONIC ANHYDRASE INHIBI-
 TOR *see also Antiglaucoma; Diuretic*

Acetazolamide, 50
 Acetazolamide, 1545
 Acetazolphenamide, 3127
 Acetazolamide, 3484
 Acetazolamide, 3801
 Acetazolamide, 4174
 Acetazolamide, 6031

CARDIAC DEPRESSANT (ANTIAR-
 RHYTHMIC) *see Antiarrhythmic*

COTONIC

Acetylcholine, 22
 Acetylcholine, 90
 Amino-4-picoline, 486
 Anitnone, 634
 Benfurodil Hemisuccinate, 1070
 Butylcholine, 1782
 Camphoramide, 1782
 Convalloatoxin, 2575
 Cyarin, 2830
 Cyarin, 2943
 Cyarin, 2967
 Cyarin, 3200
 Cyarin, 3201
 Cyarin, 3206
 Cyarin, 3210
 Cyarin, 3456
 Cyarin, 3457
 Cyarin, 3479
 Cyarin, 3482
 Cyarin, 3627
 Cyarin, 3728
 Cyarin, 3996
 Cyarin, 4437
 Cyarin, 4441
 Cyarin, 4505
 Cyarin, 4691
 Cyarin, 4807
 Cyarin, 4921
 Cyarin, 5368
 Cyarin, 5605
 Cyarin, 6284
 Cyarin, 6559
 Cyarin, 6963

Quabain, 7031
 Oxyfedrine, 7096
 Pimobendan, 7588
 Prenalterol, 7917
 Proscillaridin, 8060
 Resibufogenin, 8315
 Scillaren, 8543
 Scillarenin, 8544
 Strophanthin, 9016
 Sulmazole, 9159
 Theobromine, 9418
 Vesnarinone, 10105
 Xamoterol, 10189

CATHARTIC *see Laxative/Cathartic*

CATION-EXCHANGE RESIN *see Ion-
 exchange Resin*

CCK ANTAGONIST

Loxiglumide, 5618
 Proglumide, 7958

CENTRAL STIMULANT *see CNS Stim-
 ulant*

CEREBRAL VASODILATOR *see Vaso-
 dilator (Cerebral)*

CHELATING AGENT

Deferoxamine, 2914
 Ditiocarb Sodium, 3443
 Edetate Calcium Disodium, 3555
 Edetate Disodium, 3556
 Edetate Sodium, 3557
 Edetate Trisodium, 3558
 Penicillamine, 7214
 Pentetate Calcium Trisodium, 7265
 Pentetic Acid, 7266
 Succimer, 9034
 Trientine, 9796

CHOLECYSTOKININ ANTAGONIST
see CCK Antagonist

CHOLELITHOLYTIC AGENT

Chenodiol, 2096
 Methyl *tert*-Butyl Ether, 6111
 Monocetanol, 6335
 Ursodiol, 10026

CHOLERETIC

Alibendol, 243
 Anethole Trithion, 683
 Azintamide, 945
 Cholic Acid, 2258
 Cicotoic Acid, 2327
 Clonobutin, 2398
 Cyclobutylol, 2784
 Cyclovalone, 2823
 Cynarin(e), 2835
 Dehydrocholic Acid, 2922
 Deoxycholic Acid, 2946
 Dimetric Acid, 3248
 α -Ethylbenzyl Alcohol, 3816
 Exipoben, 3959
 Febuprol, 3985
 Fencibutanol, 4009
 Fenipentol, 4016

Florantyrone, 4143
 Hymecromone, 4903
 Menbutone, 5878
 3-(*o*-Methoxyphenyl)-2-phenyl-
 acrylic Acid, 5880
 Metochalcone, 6225
 Moquizone, 6347
 Osalmid, 7018
 Ox Bile Extract, 7052
 4,4'-Oxydi-2-butanol, 7094
 Piprozolol, 7639
 4-Salicyloylmorpholine, 8485
 Sincalide, 8689
 Taurocholic Acid, 9242
 Tocamphyl, 9630
 Trepibutone, 9718
 Vanitolid, 10071

CHOLINERGIC

Acetylcholine *see* 8266
 Acetylcholine Bromide, 87
 Acetylcholine Chloride, 88
 Aclatonium Napadisilate, 116
 Benzpyriminium Bromide, 1153
 Bethanechol Chloride, 1232
 Carbachol, 1823
 Carpronium Chloride, 1913
 Demecarium Bromide, 2936
 Dexpanthenol, 2988
 Diisopropyl Paraaxon, 3242
 Echothiophate Iodide, 3549
 Edrophonium Chloride, 3562
 Eptastigmine, 3672
 Eseridine, 3740
 Furtrethionium, 4334
 Isoflurophate, 5192
 Methacholine Chloride, 6003
 Muscarine, 6389
 Neostigmine, 6553
 Oxapropanium Iodide, 7056
 Physostigmine, 7540
 Pyridostigmine Bromide, 8161
 Xanomeline, 10190

CHOLINESTERASE INHIBITOR

Amibenonium Chloride, 396
 Distigmine Bromide, 3426
 Eptastigmine, 3672
 Galanthamine, 4357

CHOLINESTERASE REACTIVATOR

Asoxime Chloride, 870
 Obidoxime Chloride, 6835
 Pralidoxime Chloride, 7884

CNS STIMULANT

Amineptine, 429
 Amphetamine, 623
 — Amphetaminil, 624
 Bemegride, 1054
 — Benzphetamine, 1151
 Brucine, 1476
 Caffeine, 1674
 — Chlorphentermine, 2235
 — Clortermine, 2472
 Coca, 2515
 Deanol, 2900
 Demanyl Phosphate, 2935
 Dexoadrol *see* 3352
 — Dextroamphetamine Sulfate, 2996
 — Diethylpropion, 3175
 — *N*-Ethylamphetamine, 3809
 Ethamivan, 3765
 Etifelmin, 3919
 Eryptamine, 3937
 Fencamfamine, 4006

CNS STIMULANT (continued)

Fenethylamine, 4014
 Fenozolone, 4028
 Flurothyl, 4236
 Hexacyclone Sodium, 4717
 Homocamfin, 4768
 Mazindol, 5801
 Mefexamide, 5844
 — Methamphetamine, 6015
 Methylphenidate, 6186
 Modafinil, 6311
 Nikethamide, 6635
 Pemoline, 7206
 Pentylene tetrazole, 7283
 — Phendimetrazine, 7365
 — Phenmetrazine, 7385
 — Phentermine, 7415
 Picrotoxin, 7570
 Pipradrol, 7638
 Prolintane, 7964
 Pyrovalerone, 8194

**COGNITION ACTIVATOR see
Nootropic****CONTRACEPTIVE (INJECTABLE)**

Medroxyprogesterone, 5838
 Norethindrone, 6790

CONTRACEPTIVE (ORAL)

Desogestrel, 2971
 Ethinyl Estradiol, 3780
 Ethynodiol, 3905
 Gestodene, 4421
 Lynestrenol, 5659
 Mestranol, 5976
 Norethindrone, 6790
 Norethynodrel, 6791
 Norgestimate, 6796
 Norgestrel, 6797

**CONTROL OF INTRAOCULAR
PRESSURE see also Antiglaucoma**

Apraclonidine, 791

**CONVERTING ENZYME INHIBITOR
see ACE-Inhibitor****CORONARY VASODILATOR see
Vasodilator (Coronary)****CYTOPROTECTANT (GASTRIC) see
also Antilucerative**

Acetylglutamide Aluminum Complex
 see 25
 Acetoxolone, 76
 Benexate Hydrochloride, 4065
 Carbenoxolone, 1839
 Cetraxate, 2067
 Guaiazulene, 4581
 Irsogladine, 5113
 Plauotol, 7692
 Polaprezinc, 7712
 Rebamipide, 8296
 Sofalcone, 8850
 Spizofurone, 8918
 Sucralfate, 9049
 Teprenone, 9296
 Troxipide, 9921
 Zolimidine, 10320

DEBRIDING AGENT

Collagenase, 2544
 Deoxyribonuclease I, 2953
 Papain, 7148

DECONGESTANT

Amidephrine, 418
 Cafaminol, 1671
 Cyclopentamine, 2808
 Ephedrine, 3645
 Epinephrine, 3656
 Fenoxazoline, 4025
 Indanazoline, 4967
 Metizoline, 6223
 Naphazoline, 6455
 Nordefrin Hydrochloride, 6785
 Octodrine, 6854
 Oxymetazoline, 7100
 Phenylephrine Hydrochloride, 7440
 Phenylpropanolamine Hydro-
 chloride, 7461
 Phenylpropylmethylamine, 7462
 Propylhexedrine, 8045
 Pseudoephedrine see 3641
 Tetrahydrozoline, 9358
 Tramazoline, 9702
 Tuaminoheptane, 9934
 Tymazoline, 9965
 Xylometazoline, 10219

DEPIGMENTOR

Hydroquinine, 4852
 Hydroquinone, 4853
 Monobenzene, 6331

**DERMATITIS HERPETIFORMIS
SUPPRESSANT**

Dapsone, 2885
 Sulfapyridine, 9108

DIAGNOSTIC AID

Alsactide, 322
 Americium, 410
 p-Aminohippuric Acid, 462
 Anazoline Sodium, 669
 Arbutamine, 811
 Arginine, 817
 Bentronide, 1081
 Betazole, 1230
 Ceruletide, 2048
 Colfosceril Palmitate, 2540
 Congo Red, 2562
 Dexamethasone, 2986
 Edrophonium Chloride, 3562
 Evan's Blue, 3952
 Fluorescein, 4194
 Galactose, 4353
 Glycerol, 4493
 Histamine, 4756
 Indocyanine Green, 4992
 Inulin, 5024
 Iodinated Serum Albumin see 8613
 Isosulphan Blue see 9161
 Mannitol, 5788
 Merisoprol Hg 197, 5959
 Methacholine Chloride, 6003
 Metyrapone, 6246
 Oleic Acid, 6965
 Penicilloyl Polylysine, 7233
 3-Pentadecylcatechol, 7244
 Pentagastrin, 7250
 Phenolsulfonphthalein, 7397
 Phenoltetrachlorophthalein, 7398
 Phentolamine, 7417

Piperoxan, 7631
 Porfimer Sodium, 7751
 Rose Bengal, 8421
 Saralasin, 8518
 Sodium Benzoate, 8725
 Sodium Chromate(VI) (K₂Cr₂O₇)
 active, see 8745
 Sodium Iodide, Radioactive
 Sulfobromophthalein Sodium
 Teriparatide Acetate, 9302
 Tolonium Chloride, 9651
 TSH, 9931
 Tuberculin, 9937
 Tubocurarine Chloride, 9937
 Vitamin B₁₂, Radioactive
 Xylose, 10220

**DIAGNOSTIC AID (CONTRAST
AGENT)**


Gadodiamide, 4345
 Gadopentetic Acid, 4347
 Gadoteridol, 4348
 Perflubron, 7299

**DIAGNOSTIC AID (RADIOACTIVE
IMAGING AGENT)**

Butedronic Acid Complex with
^{99m}Tc see 1546
 Disofenin Complex with
^{99m}Tc see 3422
 Exametazine Complex with
^{99m}Tc see 3957
 Fludeoxyglucose F¹⁸, 4665
 Iobenguane, 5027
 Iofetamine, 5066
 Lidofenin Complex with
^{99m}Tc see 5506
 Medronic Acid Complex with
^{99m}Tc see 5837
 Oxidronic Acid Complex with
^{99m}Tc see 7074
 Pamidronic Acid Complex with
^{99m}Tc see 7135
 Pentetate Chelate with
^{99m}Tc see 7267
 Satumomab Pendetide with
^{99m}Tc see 8530
 Sodium Pertechnetate, 8530
 Sodium Phosphate, Radioactive
 8807
 Stannous Pyrophosphate
 with ^{99m}Tc see 8945
 Succimer Complex with
^{99m}Tc see 9034
 Technetium, 9256
 Technetium ^{99m}Tc Bismuth
 Technetium ^{99m}Tc Methylene
 Technetium ^{99m}Tc Sestamibi
 Technetium ^{99m}Tc Tetrofosmin
 9260
 Tetrofosmin Complex with
^{99m}Tc see 9383
¹³³Xenon see 10206

**DIAGNOSTIC AID (RADIOACTIVE
MEDIUM)**

Acetrizoate Sodium, 751
 Barium Sulfate, 1023
 Bunamiodyl Sodium, 751
 Diatrizoate Sodium, 751
 Ethiodized Oil, 3781
 Iobenzamic Acid, 5028
 Iocarmic Acid, 5029
 Iocetamic Acid, 5030
 Iodipamide, 5043
 Iodixanol, 5044



PHYSICIANS' DESK REFERENCE[®]

Medical Consultant

Ronald Arky, MD, Charles S. Davidson Professor of Medicine and Master, Francis Weld Peabody Society, Harvard Medical School

Vice President of Directory Services: Stephen B. Greenberg

Director of Product Management: David P. Reiss

Senior Product Manager: Mark A. Friedman

Associate Product Manager: Bill Shaughnessy

Director of Sales: Dikran N. Barsamian

National Sales Manager: Anthony Sorce

National Account Manager: Don Bruccoleri

Account Managers:

Marion Gray, RPh

Lawrence C. Keary

Jeffrey F. Prohl

Christopher N. Schmidt

Stephen M. Silverberg

Suzanne E. Yarrow, RN

National Sales Manager, Trade Group: Bill Gaffney

Director of Direct Marketing: Michael Bennett

Direct Marketing Manager: Lorraine M. Loening

Promotion Manager: Donna R. Lynn

Director, Professional Support Services: Mukesh Mehta, RPh

Senior Drug Information Specialist: Thomas Fleming, RPh

Drug Information Specialist: Maria Deutsch, MS, RPh, CDE

Editor, Special Projects: David W. Sifton

Vice President of Production: David A. Pitler

Director of Print Purchasing: Majorie A. Duffy

Director of Operations: Carrie Williams

Manager of Production: Kimberly H. Vivas

Senior Production Coordinators: Amy B. Brooks, Dawn McCall

Production Coordinator: Mary Ellen R. Breun

PDR Data Manager: Jeffrey D. Schaefer

Senior Format Editor: Gregory J. Westley

Index Editors: Johanna M. Mazur, Robert N. Woerner

Art Associate: Joan K. Akerlind

Senior Digital Imaging Coordinator: Shawn W. Cahill

Digital Imaging Coordinator: Frank J. McElroy, III

Electronic Publishing Designer: Robert K. Grossman

Fulfillment Managers: Stephanie DeNardi, Kenneth Siebert

Copyright © 1999 and published by Medical Economics Company, Inc. at Montvale, NJ 07645-1742. All rights reserved. None of the content of this publication may be reproduced, stored in a retrieval system, resold, redistributed, or transmitted in any form or by any means (electronic, mechanical, photocopying, recording, or otherwise) without the prior written permission of the publisher. PHYSICIANS' DESK REFERENCE[®], PDR[®], PDR For Nonprescription Drugs[®], PDR For Ophthalmology[®], Pocket PDR[®], and The PDR[®] Family Guide to Prescription Drugs[®] are registered trademarks used herein under license. PDR Companion Guide[™], PDR[®] for Herbal Medicines[™], PDR[®] Medical Dictionary[™], PDR[®] Nurse's Handbook[™], PDR[®] Nurse's Dictionary[™], The PDR[®] Family Guide Encyclopedia of Medical Care[™], PDR[®] Electronic Library[™], and PDR[®] Drug Interactions, Side Effects, Indications, Contraindications System[™] are trademarks used herein under license.

Officers of Medical Economics Company: President and Chief Executive Officer: Curtis B. Allen; Vice President, New Media: L. Suzanne BeDell; Vice President, Corporate Human Resources: Pamela M. Bilash; Vice President and Chief Information Officer: Steven M. Bressler; Senior Vice President, Finance, and Chief Financial Officer: Thomas W. Ehardt; Vice President, Directory Services: Stephen B. Greenberg; Vice President, New Business Planning: Linda G. Hope; Executive Vice President, Healthcare Publishing and Communications: Thomas J. Kelly; Executive Vice President, Magazine Publishing: Lee A. Maniscalco; Vice President, Group Publisher: Terrence W. Meacock; Vice President, Production: David A. Pitler; Vice President, Group Publisher: Thomas C. Pizor; Vice President, Magazine Business Management: Eric Schlett; Senior Vice President, Operations: John R. Ware



Printed on recycled paper

ISSN: 1543-6328

DOSAGE AND ADMINISTRATION

CAUTION— RAPID OR BOLUS INTRAVENOUS AND INTRAMUSCULAR OR SUBCUTANEOUS INJECTION MUST BE AVOIDED. Therapy should be initiated as early as possible following onset of signs and symptoms. For diagnosis—see INDICATIONS.

Dosage: Herpes Simplex Infections: Mucosal and Cutaneous Herpes Simplex (HSV-1 and HSV-2) Infections in Immunocompromised Patients: 5 mg/kg infused at a constant rate over 1 hour, every 8 hours (15 mg/kg/day) for 7 days in adult patients with normal renal function. In pediatric patients under 12 years of age, more accurate dosing can be attained by infusing 250 mg/m² at a constant rate over 1 hour, every 8 hours (750 mg/m²/day) for 7 days.

Severe Initial Clinical Episodes of Herpes Genitalis: The same dose given above—administered for 5 days.

Herpes Simplex Encephalitis: 10 mg/kg infused at a constant rate over at least 1 hour, every 8 hours for 10 days. In pediatric patients between 6 months and 12 years of age, more accurate dosing is achieved by infusing 500 mg/m² at a constant rate over at least 1 hour, every 8 hours for 10 days.

Varicella Zoster Infections: Zoster in Immunocompromised Patients: 10 mg/kg infused at a constant rate over 1 hour, every 8 hours for 7 days in adult patients with normal renal function. In pediatric patients under 12 years of age, equivalent plasma concentrations are attained by infusing 500 mg/m² at a constant rate over at least 1 hour, every 8 hours for 7 days. Obese patients should be dosed at 10 mg/kg (Ideal Body Weight). A maximum dose equivalent to 500 mg/m² every 8 hours should not be exceeded for any patient.

Patients with Acute or Chronic Renal Impairment: Refer to DOSAGE AND ADMINISTRATION section for recommended doses, and adjust the dosing interval as indicated in the table below.

Creatinine Clearance (mL/min/1.73 m ²)	Percent of Recommended Dose	Dosing Interval (hours)
>50	100%	8
25–50	100%	12
10–25	100%	24
0–10	50%	24

Hemodialysis: For patients who require dialysis, the mean plasma half-life of acyclovir during hemodialysis is approximately 5 hours. This results in a 60% decrease in plasma concentrations following a 6-hour dialysis period. Therefore, the patient's dosing schedule should be adjusted so that an additional dose is administered after each dialysis.^{24,25}

Peritoneal Dialysis: No supplemental dose appears to be necessary after adjustment of the dosing interval.^{40,41}

Method of Preparation: Each 10-mL vial contains acyclovir sodium equivalent to 500 mg of acyclovir. Each 20-mL vial contains acyclovir sodium equivalent to 1000 mg of acyclovir. The contents of the vial should be dissolved in Sterile Water for Injection as follows:

Contents of Vial	Amount of Diluent
500 mg	10 mL
1000 mg	20 mL

The resulting solution in each case contains 50 mg acyclovir per mL (pH approximately 11). Shake the vial well to assure complete dissolution before measuring and transferring each individual dose. DO NOT USE BACTERIOSTATIC WATER FOR INJECTION CONTAINING BENZYL ALCOHOL OR PARABENS.

Administration: The calculated dose should then be removed and added to any appropriate intravenous solution at a volume selected for administration during each 1-hour infusion. Infusion concentrations of approximately 7 mg/mL or lower are recommended. In clinical studies, the average 70-kg adult received between 60 and 150 mL of fluid per dose. Higher concentrations (e.g., 10 mg/mL) may produce phlebitis or inflammation at the injection site upon inadvertent extravasation. Standard, commercially available electrolyte and glucose solutions are suitable for intravenous administration; biologic or colloidal fluids (e.g., blood products, protein solutions, etc.) are not recommended.

Once in solution in the vial at a concentration of 50 mg/mL, the drug should be used within 12 hours. Once diluted for administration, each dose should be used within 24 hours. Refrigeration of reconstituted solutions may result in formation of a precipitate which will redissolve at room temperature.

HOW SUPPLIED

20-mL sterile vials, each containing acyclovir sodium equivalent to 1000 mg of acyclovir, tray of 10 (NDC 0173-0952-01).

Store at 15° to 25°C (59° to 77°F).

REFERENCES

- O'Brien JJ, Campoli-Richards DM. Acyclovir—an updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. *Drugs*. 1989;37:233-309.
- Littler E, Zeuthen J, McBride AA, et al. Identification of an Epstein-Barr virus-coded thymidine kinase. *EMBO J*. 1986;5:1959-1966.
- Miller WH, Miller RL. Phosphorylation of acyclovir (acycloguanosine) monophosphate by GMP kinase. *J Biol Chem*. 1980;255:7204-7207.
- Furman PA, St Clair MH, Fyfe JA, et al. Inhibition of herpes simplex virus-induced DNA polymerase activity and viral DNA replication by 9-(2-hydroxyethoxymethyl)guanine and its triphosphate. *J Virol*. 1979;32:72-77.
- Derse D, Cheng YC, Furman PA, et al. Inhibition of purified human and herpes simplex virus-induced DNA polymerases by 9-(2-hydroxyethoxymethyl)guanine triphosphate: effects on primer-template function. *J Biol Chem*. 1981;256:11447-11451.
- McGuirt PV, Shaw JE, Elion GB, et al. Identification of small DNA fragments synthesized in herpes simplex virus-infected cells in the presence of acyclovir. *Antimicrob Agents Chemother*. 1984;25:507-509.
- Barry DW, Blum MR. Antiviral drugs: acyclovir. In: Turner P, Shand DG, eds. *Recent Advances in Clinical Pharmacology*. ed 3. New York: Churchill Livingstone, 1983; chap 4.
- DeClercq E. Comparative efficacy of antiherpes drugs in different cell lines. *Antimicrob Agents Chemother*. 1982;21:661-663.
- McLaren C, Ellis MN, Hunter GA. A colorimetric assay for the measurement of the sensitivity of herpes simplex viruses to antiviral agents. *Antiviral Res*. 1983;3:223-234.
- Barry DW, Nusinoff-Lehrman S. Viral resistance in clinical practice: summary of five years experience with acyclovir. In: Kono R, Nakajima A, eds. *Herpes Viruses and Virus Chemotherapy (Ex Med Int Congr Ser 667)*. New York: Excerpta Medica, 1985;269-270.
- Dekker C, Ellis MN, McLaren C, et al. Virus resistance in clinical practice. *J Antimicrob Chemother*. 1983;12 (suppl B):137-152.
- Sibrack CD, Gutman LT, Wilfert CM, et al. Pathogenicity of acyclovir-resistant herpes simplex virus type 1 from an immunodeficient child. *J Infect Dis*. 1982;146: 673-682.
- Crumpacker CS, Schnipper LE, Marlowe SI, et al. Resistance to antiviral drugs of herpes simplex virus isolated from a patient treated with acyclovir. *N Engl J Med*. 1982;306:343-346.
- Wade JC, Newton B, McLaren C, et al. Intravenous acyclovir to treat mucocutaneous herpes simplex virus infection after marrow transplantation: a double-blind trial. *Ann Intern Med*. 1982;96:265-269.
- Burns WH, Saral R, Santos GW, et al. Isolation and characterization of resistant herpes simplex virus after acyclovir therapy. *Lancet*. 1982;1:421-423.
- Straus SE, Takiff HE, Seidlin M, et al. Suppression of frequently recurring genital herpes: a placebo-controlled double-blind trial of oral acyclovir. *N Engl J Med*. 1984;310:1545-1550.
- Collins P. Viral sensitivity following the introduction of acyclovir. *Am J Med*. 1988;85(suppl 2A):129-134.
- Erlich KS, Mills J, Chatis P, et al. Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome. *N Engl J Med*. 1989;320:293-296.
- Hill EL, Ellis MN, Barry DW. In: *28th Intersci Conf on Antimicrob Agents Chemother*. Los Angeles, 1988, Abstr. No. 0840:260.
- Ellis MN, Keller PM, Fyfe JA, et al. Clinical isolates of herpes simplex virus type 2 that induces a thymidine kinase with altered substrate specificity. *Antimicrob Agents Chemother*. 1987;31:1117-1125.
- Collins P, Larder BA, Oliver NM, et al. Characterization of a DNA polymerase mutant of herpes simplex virus from a severely immunocompromised patient receiving acyclovir. *J Gen Virol*. 1989;70:375-382.
- Field HJ, Darby G, Wildy P. Isolation and characterization of acyclovir-resistant mutants of herpes simplex virus. *J Gen Virol*. 1980;49:115-124.
- Blum MR, Liao SH, deMiranda P. Overview of acyclovir pharmacokinetic disposition in adults and children. *Am J Med*. 1982;73:186-192.
- Laskin OL, Longstreth JA, Whelton A, et al. Effect of renal failure on the pharmacokinetics of acyclovir. *Am J Med*. 1982;73:197-201.

- hemodialysis on acyclovir pharmacokinetics in patients with chronic renal failure. *Am J Med*. 1982;73:202-204.
- Mitchell CD, Bean B, Gentry SR, et al. Acyclovir therapy for mucocutaneous herpes simplex infections in immunocompromised patients. *Lancet*. 1981;1:1389-1392.
- Meyers JD, Wade JC, Mitchell CD, et al. Multicenter collaborative trial of intravenous acyclovir for treatment of mucocutaneous herpes simplex virus infection in the immunocompromised host. *Am J Med*. 1982;73: 229-235.
- Data on file, Glaxo Wellcome Inc.
- Corey L, Fife KH, Benedetti JK, et al. Intravenous acyclovir for the treatment of primary genital herpes. *Ann Intern Med*. 1983;98:914-921.
- Mindel A, Adler MW, Sutherland S, et al. Intravenous acyclovir treatment for primary genital herpes. *Lancet*. 1982;1:697-700.
- Whitley RJ, Alford CA, Hirsch MS, et al. Vidarabine versus acyclovir therapy in herpes simplex encephalitis. *N Engl J Med*. 1986;314:144-149.
- Skoldenberg B, Forsgren M, Alestig K, et al. Acyclovir versus vidarabine in herpes simplex encephalitis: randomized multicenter study in consecutive Swedish patients. *Lancet*. 1984;2:707-711.
- Balfour HH Jr, Bean B, Laskin OL, et al. Acyclovir halts progression of herpes zoster in immunocompromised patients. *N Engl J Med*. 1983;308:1448-1453.
- Shepp DH, Danilker PS, Meyers JD. Treatment of varicella-zoster virus infection in severely immunocompromised patients. *N Engl J Med*. 1986;314:208-212.
- Naib ZM, Nahmias AJ, Josey WE, et al. Relation of cytohistopathology of genital herpesvirus infection to cervical anaplasia. *Cancer Res*. 1973;33:1452-1463.
- Laskin OL, deMiranda P, King DH, et al. Effects of probenecid on the pharmacokinetics and elimination of acyclovir in humans. *Antimicrob Agents Chemother*. 1982;21:804-807.
- Stahlmann R, Klug S, Lewandowski C, et al. Teratogenicity of acyclovir in rats. *Infection*. 1987;15:261-262.
- Lau RJ, Emery MG, Galinsky RE, et al. Unexpected accumulation of acyclovir in breast milk with estimate of infant exposure. *Obstet Gynecol*. 1987;69:468-471.
- Meyer LJ, deMiranda P, Sheth N, et al. Acyclovir in human breast milk. *Am J Obstet Gynecol*. 1988;158:586-588.
- Boelart J, Schurgers M, Daneels R, et al. Multiple dose pharmacokinetics of intravenous acyclovir in patients on continuous ambulatory peritoneal dialysis. *J Antimicrob Chemother*. 1987;20:69-76.
- Shah GM, Winer RL, Krasny HC. Acyclovir pharmacokinetics in a patient on continuous ambulatory peritoneal dialysis. *Am J Kidney Dis*. 1986;7:507-510.

April 1998/RL-543

Shown in Product Identification Guide, page 315

ZYBAN™

[zī'ban]

(bupropion hydrochloride)
Sustained-Release Tablets

DESCRIPTION

ZYBAN (bupropion hydrochloride) Sustained-Release Tablets are a non-nicotine aid to smoking cessation. Initially developed and marketed as an antidepressant (WELLBUTRIN® [bupropion hydrochloride] Tablets and WELLBUTRIN SR [bupropion hydrochloride] Sustained-Release Tablets), ZYBAN is chemically unrelated to tricyclic, tetracyclic, selective serotonin re-uptake inhibitor, or other known antidepressant agents. Its structure closely resembles that of diethylpropion; it is related to phenylethylamines. It is (±)-1-(3-chlorophenyl)-2-(4,1,1-dimethylethyl)amino-1-propanone hydrochloride. The molecular weight is 276.2. The molecular formula is C₁₃H₁₅ClNO·HCl. Bupropion hydrochloride powder is white, crystalline, and highly soluble in water. It has a bitter taste and produces the sensation of local anesthesia on the oral mucosa.

ZYBAN is supplied for oral administration as 150-mg (pu), film-coated, sustained-release tablets. Each tablet contains the labeled amount of bupropion hydrochloride and the inactive ingredients carnauba wax, cysteine hydrochloride, hydroxypropyl methylcellulose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polysorbate

Continued on next page

This product information is based on labeling in effect on Jan 1, 1998. For further information, contact via direct mail, phone or web site Medical Information: Glaxo Wellcome Inc., PO Box 13398, Research Triangle Park, NC 27709. Healthcare Professionals (Medical Information): 800-334-0089 Patient (Customer Response Center): 888-TALK2GW (1-888-825-524). Glaxo Wellcome Corporate Web Site: www.glaxowellcome.co

Table 2: Comparative Trial: Quit Rates by Treatment Group

	Treatment Groups		
	Nicotine Transdermal System (NTS) 21 mg/day (n = 244)	ZYBAN™ 300 mg/day (n = 244)	ZYBAN 300 mg/day NTS 21 mg/day (n = 245)
Abstinence From Week 4 Through Specified Week			
Week 7 (4-week quit)	23% (17-30)	36%* (30-42)	49%*† (43-56)
Week 10	20% (14-26)	32%* (26-37)	51%*† (45-58)

* $P < 0.01$ versus placebo; † $P < 0.01$ versus NTS.‡ $P < 0.06$ versus ZYBAN.

The seizure rate associated with doses of sustained-release bupropion up to 300 mg/day is approximately 0.1% (1/1,000). This incidence was prospectively determined during an 8-week treatment exposure in approximately 3,100 depressed patients. Data for the immediate-release formulation of bupropion revealed a seizure incidence of approximately 0.4% (4/1,000) in depressed patients treated at doses in a range of 300 to 450 mg/day. In addition, the estimated seizure incidence increases almost tenfold between 450 and 600 mg/day.

Patient factors: Predisposing factors that may increase the risk of seizure with bupropion use include history of head trauma or prior seizure, central nervous system (CNS) tumor, and concomitant medications that lower seizure threshold.

Clinical situations: Circumstances associated with an increased seizure risk include, among others, excessive use of alcohol; abrupt withdrawal from alcohol or other sedatives; addition to opiates, cocaine, or stimulants; use of over-the-counter stimulants and anorectics; and diabetes treated with oral hypoglycemics or insulin.

Concomitant medications: Many medications (e.g., antipsychotics, antidepressants, theophylline, systemic antidiabetics, and treatment regimens [e.g., abrupt discontinuation of benzodiazepines]) are known to lower seizure threshold.

Recommendations for Reducing the Risk of Seizure: Retrospective analysis of clinical experience gained during the development of bupropion suggests that the risk of seizure may be minimized if:

• the total daily dose of ZYBAN does not exceed 300 mg (the maximum recommended dose for smoking cessation); and

• the recommended daily dose for most patients (300 mg/day) is administered in divided doses (150 mg twice daily).

No single dose should exceed 150 mg to avoid high peak concentrations of bupropion and/or its metabolites.

ZYBAN should be administered with extreme caution to patients with a history of seizure, head trauma, or other predisposition(s) toward seizure, or patients treated with other agents (e.g., antipsychotics, antidepressants, theophylline, systemic antidiabetics, etc.) or treatment regimens (e.g., abrupt discontinuation of a benzodiazepine) that lower seizure threshold.

Potential for Hepatotoxicity: In rats receiving large doses of bupropion chronically, there was an increase in incidence of hepatic hyperplastic nodules and hepatocellular hypertrophy. In dogs receiving large doses of bupropion chronically, various histologic changes were seen in the liver, and laboratory tests suggesting mild hepatocellular injury were noted.

PRECAUTIONS

General: Allergic Reactions. Anaphylactoid reactions characterized by symptoms such as pruritus, urticaria, angioedema, and dyspnea requiring medical treatment have been reported at a rate of about 1.3 per thousand in clinical trials of ZYBAN. In addition, there have been rare spontaneous postmarketing reports of erythema multiforme, Stevens-Johnson syndrome, and anaphylactic shock associated with bupropion.

Insomnia. In the dose-response smoking cessation trial, 29% of patients treated with 150 mg/day of ZYBAN and 35% of patients treated with 300 mg/day of ZYBAN experienced insomnia, compared to 21% of placebo-treated patients. Symptoms were sufficiently severe to require discontinuation of treatment in 0.6% of patients treated with ZYBAN and none of the patients treated with placebo. In the comparative trial, 40% of the patients treated with 300 mg/day of ZYBAN, 25% of the patients treated with 21 mg/day of NTS, and 45% of the patients treated with the combination of ZYBAN and NTS experienced insomnia compared to 18% of placebo-treated patients. Symptoms were

not severe enough to require discontinuation of treatment in 0.8% of patients treated with ZYBAN and none of the patients in the other three treatment groups.

Insomnia may be minimized by avoiding bedtime doses and, if necessary, reduction in dose.

Psychosis, Confusion, and Other Neuropsychiatric Phenomena. In clinical trials with ZYBAN conducted in non-depressed smokers, the incidence of neuropsychiatric side effects was generally comparable to placebo. Depressed patients treated with bupropion in depression trials have been reported to show a variety of neuropsychiatric signs and symptoms including delusions, hallucinations, psychosis, concentration disturbance, paranoia, and confusion. In some cases, these symptoms abated upon dose reduction and/or withdrawal of treatment.

Activation of Psychosis and/or Mania. Antidepressants can precipitate manic episodes in bipolar disorder patients during the depressed phase of their illness and may activate latent psychosis in other susceptible individuals. The sustained-release formulation of bupropion is expected to pose similar risks. There were no reports of activation of psychosis or mania in clinical trials with ZYBAN conducted in non-depressed smokers.

Use in Patients With Systemic Illness. There is no clinical experience establishing the safety of ZYBAN in patients with a recent history of myocardial infarction or unstable heart disease. Therefore, care should be exercised if it is used in these groups. Bupropion was well tolerated in depressed patients who had previously developed orthostatic hypotension while receiving tricyclic antidepressants, and was generally well tolerated in a group of 36 depressed inpatients with stable CHF. However, bupropion was associated with a rise in supine blood pressure in the study of patients with CHF, resulting in discontinuation of treatment in two patients for exacerbation of baseline hypertension.

In the comparative trial, 6.1% of patients treated with the combination of ZYBAN and NTS had treatment-emergent hypertension compared to 2.5%, 1.6%, and 3.1% of patients treated with ZYBAN, NTS, and placebo, respectively. The majority of these patients had evidence of preexisting hypertension. Three patients (1.2%) treated with the combination of ZYBAN and NTS and one patient (0.4%) treated with NTS had study medication discontinued due to hypertension compared to none of the patients treated with ZYBAN or placebo. Monitoring for treatment-emergent hypertension is recommended in patients receiving the combination of ZYBAN and NTS.

Because bupropion hydrochloride and its metabolites are almost completely excreted through the kidney and metabolites are likely to undergo conjugation in the liver prior to urinary excretion, treatment of patients with renal or hepatic impairment should be initiated at reduced dosage as bupropion and its metabolites may accumulate in such patients to a greater extent than usual. The patient should be closely monitored for possible toxic effects of elevated blood and tissue levels of drug and metabolites.

Information for Patients: See PATIENT INFORMATION at the end of this labeling for the text of the separate leaflet provided for patients. Physicians are advised to review the leaflet with their patients and to emphasize that ZYBAN contains the same active ingredient found in WELLBUTRIN and WELLBUTRIN SR used to treat depression and that ZYBAN should not be used in conjunction with WELLBUTRIN, WELLBUTRIN SR, or any other medications that contain bupropion hydrochloride.

Laboratory Tests: There are no specific laboratory tests recommended.

Drug Interactions: In vitro studies indicate that bupropion is primarily metabolized to hydroxybupropion by the CYP2B6 isoenzyme. Therefore, the potential exists for a drug interaction between ZYBAN and drugs that affect the CYP2B6 isoenzyme metabolism (e.g., orphenadrine and cyclophosphamide). The thiohydrobupropion metabolite of bupropion does not appear to be produced by the cytochrome

P450 isoenzymes. No systemic data have been collected; the metabolism of ZYBAN following concomitant administration with other drugs or, alternatively, the effect of a concomitant administration of ZYBAN on the metabolism of other drugs.

Animal data indicated that bupropion may be an inducer drug-metabolizing enzymes in humans. However, following chronic administration of bupropion, 100 mg t.i.d. to healthy male volunteers for 14 days, there was no evidence of induction of its own metabolism. Because bupropion is extensively metabolized, the administration of other drugs may affect its clinical activity. In particular, certain drugs may induce the metabolism of bupropion (e.g., carbamazepine, phenobarbital, phenytoin) while other drugs may inhibit the metabolism of bupropion (e.g., cimetidine).

Studies in animals demonstrate that the acute toxicity of bupropion is enhanced by the MAO inhibitor phenelzine (see CONTRAINDICATIONS).

Limited clinical data suggest a higher incidence of adverse experiences in patients receiving concurrent administration of bupropion and levodopa. Administration of ZYBAN to patients receiving levodopa concurrently should be undertaken with caution, using small initial doses and gradual dose increases.

Concurrent administration of ZYBAN and agents (e.g., antipsychotics, antidepressants, theophylline, systemic antidiabetics, etc.) or treatment regimens (e.g., abrupt discontinuation of benzodiazepines) that lower seizure threshold should be undertaken only with extreme caution (see WARNINGS).

Physiological changes resulting from smoking cessation itself, with or without treatment with ZYBAN, may alter the pharmacokinetics of some concomitant medications, which may require dosage adjustment.

Carcinogenesis, Mutagenesis, Impairment of Fertility: Life time carcinogenicity studies were performed in rats at doses up to 300 and 450 mg/kg per day, respectively. These doses are approximately ten and twenty times the maximum recommended human dose (MRHD), respectively, on a mg/m² basis. In the rat study, there was an increase in nodular proliferative lesions of the liver at doses of 100, 300, and 450 mg/kg per day (approximately three, ten, and thirty times the MRHD, on a mg/m² basis); lower doses were not tested. The question of whether or not such lesions may be precursors of neoplasms of the liver is currently unresolved. Similar liver lesions were not seen in the mouse study, and no increase in malignant tumors of the liver and other organs was seen in either study.

Bupropion produced a positive response (two to three times control mutation rate) in two of five strains in the Ames bacterial mutagenicity test and an increase in chromosomal aberrations in one of three in vivo rat bone marrow cytogenetic studies.

A fertility study in rats at doses up to 300 mg/kg revealed evidence of impaired fertility. In rabbits, no evidence of impaired fertility was observed at doses up to 150 mg/kg (approximately 14 times the MRHD, on a mg/m² basis), and at doses up to 150 mg/kg in rabbits (approximately 10 times the MRHD, on a mg/m² basis). There is no evidence of impaired fertility or harm to the fetus during bupropion. There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Pregnant smokers should be encouraged to attempt cessation using educational and behavioral interventions before pharmacological approaches are used.

Pregnancy, Teratogenic Effects, Pregnancy Category B: For at least one study, bupropion has been shown to be safe in rats at doses up to 450 mg/kg (approximately 14 times the MRHD, on a mg/m² basis), and at doses up to 150 mg/kg in rabbits (approximately 10 times the MRHD, on a mg/m² basis). There is no evidence of impaired fertility or harm to the fetus during bupropion.

There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. Pregnant smokers should be encouraged to attempt cessation using educational and behavioral interventions before pharmacological approaches are used.

To monitor fetal outcomes of pregnant women exposed to ZYBAN, Glaxo Wellcome Inc. maintains a Bupropion Pregnancy Registry. Health care providers are encouraged to register patients by calling (800) 722-3292, ext. 3944.

Labor and Delivery: The effect of ZYBAN on labor and delivery in humans is unknown.

Nursing Mothers: Bupropion and its metabolites are secreted in human milk. Because of the potential for serious adverse reactions in nursing infants from ZYBAN, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Use: Clinical trials with ZYBAN did not include individuals under the age of 18. Therefore, the safety and efficacy in a pediatric smoking population have not been established. The immediate-release formulation of bupropion

Continued on next page

This product information is based on labeling in effect on June 1, 1998. For further information, contact via direct mail, phone, or web site Medical Information: Glaxo Wellcome Inc., P.O. Box 13358, Research Triangle Park, NC 27709. Healthcare Professionals (Medical Information): 800-334-0089. Patients (Customer Response Center): 888-TALK2GIV (1-888-825-6249). Glaxo Wellcome Corporate Web Site: www.glaxowellcome.com

ban—Cont

study included a group of patients who were treated with bupropion sustained-release tablets (ZYPAN) in a double-blind, placebo-controlled study. The study was conducted in 104 pediatric patients (age range, 6 to 16) in clinical trials of the drug for other indications. Although generally well tolerated, the limited exposure is insufficient to establish the safety of bupropion in pediatric patients.

In the Elderly: In general, older patients are known to be more sensitive to the effects of drugs. A single-dose pharmacokinetic study demonstrated that the disposition of bupropion and metabolites in elderly subjects was similar to that of younger subjects (see CLINICAL PHARMACOLOGY). Of approximately 6,000 patients who participated in clinical trials with bupropion sustained-release tablets (depression and smoking cessation studies), 303 were 60 to 69 years and 48 were 70 years of age or older. The experience in patients 60 years of age or older was similar to that in younger patients.

VERSE REACTIONS

ADVERSE REACTIONS (all events occurring in clinical trials) are listed in Table 3. Information included under ADVERSE REACTIONS is based primarily on data from the dose-response trial and comparative trial that evaluated ZYPAN for smoking cessation (see CLINICAL TRIALS). Information on additional adverse events associated with the sustained-release formulation of bupropion in depression trials, as well as the immediate-release formulation of bupropion, is included in separate sections (see Other Events Observed During the Clinical Development and Postmarketing Experience of Bupropion).

Adverse Events Associated With the Discontinuation of Treatment: Adverse events were sufficiently troublesome to cause discontinuation of treatment in 8% of the 706 patients treated with ZYPAN and 5% of the 313 patients treated with placebo. The more common events leading to discontinuation of treatment with ZYPAN included nervous system disturbances (8.4%), primarily tremors, and skin disorders (2.4%), primarily rashes.

Incidence of Commonly Observed Adverse Events: The most commonly observed adverse events consistently associated with the use of ZYPAN were dry mouth and insomnia. The most commonly observed adverse events were defined as those that consistently occurred at a rate of five percentage points greater than that for placebo across clinical trials.

Dependence of Adverse Events: The incidence of dry mouth and insomnia may be related to the dose of ZYPAN. The occurrence of these adverse events may be limited by reducing the dose of ZYPAN. In addition, insomnia may be minimized by avoiding bedtime doses.

Adverse Events Occurring at an Incidence of 1% or More in Patients Treated With ZYPAN: Table 3 enumerates selected treatment-emergent adverse events from the dose-response trial that occurred at an incidence of 1% or more and were more common in patients treated with ZYPAN compared to those treated with placebo. Table 4 enumerates selected treatment-emergent adverse events in the comparative trial that occurred at an incidence of 1% or more and were more common in patients treated with ZYPAN, or the combination of ZYPAN and NTS compared to those treated with placebo. Reported adverse events were classified using a COSTART-based dictionary.

Table 3: Treatment-Emergent Adverse Event Incidence in the Dose-Response Trial*

Body System/ Adverse Experience	ZYPAN™ 100 to 300 mg/day (n = 461)	Placebo (n = 150)
Body System/ Adverse Experience		
Dry (General)	2	<1
Head pain	2	<1
Allergic reaction	1	<1
Cardiovascular	1	0
Hot flashes	1	<1
Hypertension	1	<1
Digestive	11	5
Dry mouth	11	5
Increased appetite	2	<1
Nausea	1	<1
Musculoskeletal	1	0
Urthralgia	4	3
Gynecomastia	2	1
Syncope	1	0
Insomnia	31	21
Headache	31	21
Depression	2	0
Tremor	2	0
Somnolence	1	0
Flushing	1	0
Respiratory	1	0
Tracheitis	2	0

Skin	3	<1
Pruritus	3	<1
Rash	2	0
Dry skin	3	0
Urticaria	1	0
Special senses	2	<1
Taste perversion	2	<1

*Selected adverse events with an incidence of at least 1% of patients treated with ZYPAN and more frequent than in the placebo group.

(See table 4 at top of next page)

Other Events Observed During the Clinical Development and Postmarketing Experience of Bupropion: In addition to the adverse events noted above, the following events have been reported in clinical trials with the sustained-release formulation of bupropion in depressed patients and in non-depressed smokers, as well as in clinical trials and postmarketing clinical experience with the immediate-release formulation of bupropion.

Adverse events for which frequencies are provided below occurred in clinical trials with bupropion sustained-release. The frequencies represent the proportion of patients who experienced a treatment-emergent adverse event on at least one occasion in placebo-controlled studies for depression (n=987) or smoking cessation (n=1,013), or patients who experienced an adverse event requiring discontinuation of treatment in an open-label surveillance study with bupropion sustained-release tablets (n=3,100). All treatment-emergent adverse events are included except those listed in Tables 3 and 4; those events listed in other safety-related sections of the insert, those adverse events submitted under COSTART terms that are either overly general or excessively specified so as to be uninformative, those events not reasonably associated with the use of the drug, and those events that were not serious and occurred in fewer than two patients.

Events are further categorized by body system and listed in order of decreasing frequency according to the following definitions of frequency: Frequent adverse events are defined as those occurring in at least 1/100 patients. Infrequent adverse events are those occurring in 1/100 to 1/1,000 patients; while rare events are those occurring in less than 1/1,000 patients.

Adverse events for which frequencies are not provided occurred in clinical trials or postmarketing experience with the immediate-release formulation of bupropion. Only those adverse events not previously listed for sustained-release bupropion are included. The extent to which these events may be associated with ZYPAN is unknown.

Body (General): Frequent were asthenia, fever, and headache. Infrequent were back pain, chills, inguinal hernia, musculoskeletal chest pain, pain, and photosensitivity. Rare was malaise.

Cardiovascular: Infrequent were flushing, migraine, postural hypotension, stroke, tachycardia, and vasodilation. Rare was syncope. Also observed were cardiovascular disorder, complete AV block, extrasystoles, hypotension, myocardial infarction, phlebitis, and pulmonary embolism.

Digestive: Frequent were dyspepsia, flatulence, and vomiting. Infrequent were abnormal liver function, bruxism, dysphagia, gastric reflux, gingivitis, glossitis, jaundice, and stomatitis. Rare was edema of tongue. Also observed were colitis, esophagitis, gastrointestinal hemorrhage, gum hemorrhage, hepatitis, increased salivation, intestinal perforation, liver damage, pancreatitis, stomach ulcer, and stool abnormality.

Endocrine: Also observed was syndrome of inappropriate antidiuretic hormone.

Hemic and Lymphatic: Infrequent was ecchymosis. Also observed were anemia, leukocytosis, leukopenia, lymphadenopathy, and pancytopenia.

Metabolic and Nutritional: Infrequent were edema, increased weight, and peripheral edema. Also observed was glycosuria.

Musculoskeletal: Infrequent were leg cramps and twitching. Also observed were arthritis and muscle rigidity/fever/rhabdomyolysis.

Nervous System: Frequent were agitation, depression, and irritability. Infrequent were abnormal coordination, CNS stimulation, confusion, decreased libido, decreased memory, depersonalization, emotional lability, hostility, hyperkinesia, hypertonia, hypesthesia, paresthesia, suicidal ideation, and vertigo. Rare were amnesia, ataxia, derealization, and hypomania. Also observed were abnormal electroencephalogram (EEG); akinesia; aphasia; coma; delirium; delusions; dysarthria; dyskinesia; dystonia; euphoria; extrapyramidal syndrome; hypokinesia; increased libido; manic reaction; neuralgia; neuropathy; paranoid reaction; and unmasking, tardive dyskinesia.

Respiratory: Rare was bronchospasm. Also observed was pneumonia.

Skin: Frequent was sweating. Infrequent was acne and dry skin. Rare was maculopapular rash. Also observed were angioedema, exfoliative dermatitis, and hirsutism.

Special Senses: Frequent was amblyopia. Infrequent were accommodation abnormality and dry eye. Also observed were deafness, diplopia, and mydriasis.

Urogenital: Frequent was urinary frequency. Infrequent were impotence, polyuria, and urinary urgency. Also observed were abnormal ejaculation, cystitis, dyspareunia, dysuria, gynecostasia, menopause, painful erection, prostate disorder, salpingitis, urinary incontinence, urinary retention, urinary tract disorder, and vaginitis.

DRUG ABUSE AND DEPENDENCE

ZYPAN is likely to have a low abuse potential.

Humans: There have been few reported cases of drug dependence and withdrawal symptoms associated with the immediate-release formulation of bupropion. In human studies of abuse liability, individuals experienced with drugs of abuse reported that bupropion produced a feeling of euphoria and desirability. In these subjects, a single dose of 400 mg (1.33 times the recommended daily dose) of bupropion produced mild amphetamine-like effects compared to placebo on the Morphine-Benzodrine Subscale of the Addiction Research Center Inventories (ARCI), which is indicative of euphoric properties and a score intermediate between placebo and amphetamine on the Liking Scale of the ARCI.

Animals: Studies in rodents and primates have shown that bupropion exhibits some pharmacologic actions common to psychostimulants. In rodents, it has been shown to increase locomotor activity, elicit a mild stereotyped behavioral response, and increase rates of responding in several schedule-controlled behavior paradigms. In primate models to assess the positive reinforcing effects of psychoactive drugs, bupropion was self-administered intravenously. In rats, bupropion produced amphetamine- and cocaine-like discriminative stimulus effects in drug discrimination paradigms used to characterize the subjective effects of psychoactive drugs.

The possibility that bupropion may induce dependence should be kept in mind when evaluating the desirability of including the drug in smoking cessation programs of individual patients.

OVERDOSAGE

Human Overdose Experience: There has been very limited experience with overdoses of the sustained-release formulation of bupropion; three such cases were reported during clinical trials in depressed patients. One patient ingested 3,000 mg of bupropion sustained-release tablets and vomited quickly after the overdose; the patient experienced blurred vision and lightheadedness. A second patient ingested a "handful" of bupropion sustained-release tablets and experienced confusion, lethargy, nausea, jitteriness, and seizure. A third patient ingested 3,600 mg of bupropion sustained-release tablets and a bottle of wine; the patient experienced nausea, visual hallucinations, and "grogginess." None of the patients experienced further sequelae.

There has been extensive experience with overdoses of the immediate-release formulation of bupropion. Thirteen overdoses occurred during clinical trials in depressed patients. Twelve patients ingested 850 to 4,200 mg and recovered without significant sequelae. Another patient who ingested 9,000 mg of the immediate-release formulation of bupropion and 300 mg of triazolam experienced a grand mal seizure and recovered without further sequelae.

Since introduction, overdoses of up to 17,500 mg of the immediate-release formulation of bupropion have been reported. Seizure was reported in approximately one-third of all cases. Other serious reactions reported with overdoses of the immediate-release formulation of bupropion alone included hallucinations, loss of consciousness, and sinus tachycardia. Fever, muscle rigidity, rhabdomyolysis, hypotension, stupor, coma, and respiratory failure have been reported when the immediate-release formulation of bupropion was part of multiple drug overdoses.

Although most patients recovered without sequelae, deaths associated with overdoses of the immediate-release formulation of bupropion alone have been reported rarely in patients ingesting massive doses of the drug. Multiple uncontrolled seizures, bradycardia, cardiac failure, and cardiac arrest prior to death were reported in these patients.

Management of Overdose: Following suspected overdose, hospitalization is advised. If the patient is conscious, vomiting should be induced by syrup of ipecac. Activated charcoal also may be administered every 6 hours during the first 12 hours after ingestion. Baseline laboratory values should be obtained. Electrocardiogram and EEG monitoring also are recommended for the next 48 hours. Adequate fluid intake should be provided.

If the patient is stuporous, comatose, or convulsing, airway intubation is recommended prior to undertaking gastric lavage. Although there is little clinical experience with lavage following an overdose of bupropion, it is likely to be of benefit within the first 12 hours after ingestion since absorption of the drug may not yet be complete.

Table 4: Treatment-Emergent Adverse Event Incidence in the Comparative Trial*

Adverse Experience (COSTART Term)	ZYBAN™ 300 mg/day (n = 243) %	Nicotine Transdermal System (NTS), 21 mg/day (n = 243) %	ZYBAN and NTS (n = 244) %	Placebo (n = 159) %
Body				
Abdominal pain	3	4	1	1
Accidental injury	2	2	1	1
Chest pain	<1	1	3	1
Neck pain	2	1	<1	0
Facial edema	<1	0	1	0
Cardiovascular				
Hypertension	1	<1	2	0
Palpitations	2	0	1	0
Digestive				
Nausea	9	7	11	4
Dry mouth	10	4	9	4
Constipation	8	4	9	3
Diarrhea	4	4	3	1
Anorexia	3	1	5	1
Mouth ulcer	2	1	1	1
Thirst	<1	<1	2	0
Musculoskeletal				
Myalgia	4	3	5	3
Arthralgia	5	3	3	2
Nervous system				
Insomnia	40	28	45	18
Dream abnormality	5	18	13	3
Anxiety	8	6	9	6
Disturbed concentration	9	3	9	4
Dizziness	10	2	8	6
Nervousness	4	<1	2	2
Tremor	1	<1	2	0
Dysphoria	<1	1	2	1
Respiratory				
Rhinitis	12	11	9	8
Increased cough	3	5	<1	1
Pharyngitis	3	2	3	0
Sinusitis	2	2	2	1
Dyspnea	1	0	2	1
Epistaxis	2	1	1	0
Skin				
Application site reaction†	11	17	15	7
Rash	4	3	3	2
Pruritus	3	1	5	1
Urticaria	2	0	2	0
Special Senses				
Taste perversion	3	1	3	2
Tinnitus	1	0	<1	0

*Selected adverse events with an incidence of at least 1% of patients treated with either ZYBAN, NTS, or the combination of ZYBAN and NTS and more frequent than in the placebo group.

†Patients randomized to ZYBAN or placebo received placebo patches.

While diuresis, dialysis, or hemoperfusion are sometimes used to treat drug overdosage, there is no experience with their use in the management of overdoses of bupropion. Because diffusion of bupropion and its metabolites from tissue to plasma may be slow, dialysis may be of minimal benefit. Based on studies in animals, it is recommended that seizures be treated with an intravenous benzodiazepine preparation and other supportive measures as appropriate. Further information about the treatment of overdoses may be available from a poison control center.

DOSAGE AND ADMINISTRATION

ZYBAN: Usual Dosage for Adults: The recommended and maximum dose of ZYBAN is 300 mg/day, given as 150 mg twice daily. Dosing should begin at 150 mg/day given every day for the first 3 days, followed by a dose increase for most patients to the recommended usual dose of 300 mg/day. There should be an interval of at least 8 hours between successive doses. Doses above 300 mg/day should not be used (see WARNINGS). Treatment with ZYBAN should be initiated while the patient is still smoking, since approximately 1 week of treatment is required to achieve steady-state blood levels of bupropion. Patients should set a "target quit date" within the first 2 weeks of treatment with ZYBAN, generally in the second week. Treatment with ZYBAN should be continued for 7 to 12 weeks; duration of treatment should be based on the relative benefits and risks for individual patients. If a patient has not made significant progress towards abstinence by the seventh week of therapy with ZYBAN, it is unlikely that he or she will quit during that attempt, and treatment should probably be discontinued. Dose tapering of ZYBAN is not required when discontinuing treatment. It is important that patients continue to receive counseling and support throughout treatment with ZYBAN, and for a period of time thereafter.

Individualization of Therapy: Patients are more likely to quit smoking and remain abstinent if they are seen frequently and receive support from their physicians or other health care professionals. It is important to ensure that patients read the instructions provided to them and have their questions answered. Physicians should review the patient's overall smoking cessation program that includes treatment with ZYBAN. Patients should be advised of the importance of participating in the behavioral interventions, counseling, and/or support services to be used in conjunction with ZYBAN. See information for patients at the end of the package insert.

The goal of therapy with ZYBAN is complete abstinence. If a patient has not made significant progress towards abstinence by the seventh week of therapy with ZYBAN, it is unlikely that he or she will quit during that attempt, and treatment should be discontinued. Patients who fail to quit smoking during an attempt may benefit from interventions to improve their chances for success on subsequent attempts. Patients who are unsuccessful should be evaluated to determine why they failed. A new quit attempt should be encouraged when factors that contributed to failure can be eliminated or reduced, and conditions are more favorable.

Maintenance: Although clinical data are not available regarding the long-term use (>12 weeks) of bupropion for smoking cessation, bupropion has been used for longer periods of time in the treatment of depression. Whether to continue treatment with ZYBAN for periods longer than 12 weeks for smoking cessation must be determined for individual patients.

Combination Treatment With ZYBAN and a Nicotine Transdermal System (NTS): Combination treatment with ZYBAN and NTS may be prescribed for smoking cessation. The prescriber should review the complete prescribing in-

formation for both ZYBAN and NTS before using combination treatment. See also CLINICAL TRIALS for met and dosing used in the ZYBAN and NTS combination. Monitoring for treatment-emergent hypertension in patients treated with the combination of ZYBAN and NTS is recommended.

HOW SUPPLIED

ZYBAN Sustained-Release Tablets, 150 mg of bupropion hydrochloride, are purple, round, biconvex, film-coated tablets printed with "ZYBAN 150" in bottles of 60 (NDC 0173-01-02) tablets and the ZYBAN Advantage Pack™ contains a bottle of 60 (NDC 0173-0556-01) tablets.

Store at controlled room temperature, 20° to 25°C (68° to 77°F) (see USP). Dispense in tight, light-resistant containers as defined in the USP.

PATIENT INFORMATION: The following wording, contained in a separate leaflet provided for patients.

Information for the Patient

ZYBAN™ (bupropion hydrochloride) Sustained-Release Tablets

Please read this information before you start taking ZYBAN. Also read this leaflet each time you renew your prescription, in case anything has changed. This information is not intended to take the place of discussions between you and your doctor. You and your doctor should discuss ZYBAN as part of your plan to stop smoking. Your doctor has prescribed ZYBAN for your use only. Do not let anyone else use your ZYBAN.

IMPORTANT WARNING:

There is a chance that approximately 1 out of every 10 people taking bupropion hydrochloride, the active ingredient in ZYBAN, will have a seizure. The chance of this happening increases if you:

- have a seizure disorder (for example, epilepsy);
- have or have had an eating disorder (for example, bulimia or anorexia nervosa);
- take more than the recommended amount of ZYBAN;
- take other medicines with the same active ingredient as is in ZYBAN, such as WELLBUTRIN® (bupropion hydrochloride) Tablets and WELLBUTRIN® SR (bupropion hydrochloride) Sustained-Release Tablets. (Both of the medicines are used to treat depression.)

You can reduce the chance of experiencing a seizure by following your doctor's directions on how to take ZYBAN. You should also discuss with your doctor whether ZYBAN is right for you.

1. What is ZYBAN?

ZYBAN is a prescription medicine to help people quit smoking. Studies have shown that more than one third of people quit smoking for at least 1 month while taking ZYBAN as participating in a patient support program. For many patients, ZYBAN reduces withdrawal symptoms and the urge to smoke. ZYBAN should be used with a patient support program. It is important to participate in the behavior program, counseling, or other support program your health care professional recommends.

2. Who should not take ZYBAN?

You should not take ZYBAN if you:

- have a seizure disorder (for example, epilepsy).
- are already taking WELLBUTRIN, WELLBUTRIN SR, or any other medicines that contain bupropion hydrochloride.
- have or have had an eating disorder (for example, bulimia or anorexia nervosa).
- are currently taking or have recently taken a monoamine oxidase inhibitor (MAOI).
- are allergic to bupropion.

3. Are there special concerns for women?

ZYBAN is not recommended for women who are pregnant, breast-feeding. Women should notify their doctor if they become pregnant or intend to become pregnant while taking ZYBAN.

4. How should I take ZYBAN?

- You should take ZYBAN as directed by your doctor. The usual recommended dosing is to take one 150-mg tablet the morning for the first 3 days. On the fourth day, begin taking one 150-mg tablet in the morning and one 150-mg tablet in the early evening. Doses should be taken at least 8 hours apart.
- Never take an "extra" dose of ZYBAN. If you forget to take a dose, do not take an extra tablet to "catch up" to the dose you forgot. Wait and take your next tablet at the regular time. Do not take more tablets than your doctor prescribed. This is important so you do not increase your chance of having a seizure.
- It is important to swallow ZYBAN Tablets whole. Do not chew, divide, or crush tablets.

Continued on next page

This product information is based on labeling in effect on July 1, 1998. For further information, contact via direct mail, phone or web site Medical Information: Glaxo Wellcome Inc., PO Box 13398, Research Triangle Park, NC 27709. Healthcare Professionals (Medical Information): 800-334-0089 Patient (Customer Response Center): 888-TALK2GW (1-888-825-524) Glaxo Wellcome Corporate Web Site: www.glaxowellcome.com

zyban—Cont.

How long should I take ZYBAN? You should take ZYBAN for 7 to 12 weeks. Follow your doctor's instructions.

When should I stop smoking?

It takes about 1 week for ZYBAN to reach the right levels in your body to be effective. So, to maximize your chance of quitting, you should not stop smoking until you have been taking ZYBAN for 1 week. You should set a date to stop smoking during the second week you're taking ZYBAN.

Can I smoke while taking ZYBAN?

It is not physically dangerous to smoke and use ZYBAN at the same time. However, continuing to smoke after the date you set to stop smoking will seriously reduce your chance of quitting your smoking habit.

Can ZYBAN be used at the same time as nicotine patches?

ZYBAN and nicotine patches can be used at the same time but should only be used together under the supervision of your doctor. Using ZYBAN and nicotine patches together may raise your blood pressure. Your doctor will probably want to check your blood pressure regularly to make sure it stays within acceptable levels. **DO NOT SMOKE AT ANY TIME** if you are using a nicotine patch or any other nicotine product along with ZYBAN. It is possible to get too much nicotine and have serious side effects.

What are possible side effects of ZYBAN?

Like all medicines, ZYBAN may cause side effects. The most common side effects include dry mouth and difficulty sleeping. These side effects are generally mild and often disappear after a few weeks. If you have difficulty sleeping, avoid taking your medicine too close to bedtime. The most common side effects that caused people to stop taking ZYBAN during clinical studies were shakiness and skin rash.

Contact your doctor or health care professional if you have a rash or other troublesome side effects.

Use caution before driving a car or operating complex, hazardous machinery until you know if ZYBAN affects your ability to perform these tasks.

Can I drink alcohol while I am taking ZYBAN?

It is best not to drink alcohol at all or to drink very little while taking ZYBAN. If you drink a lot of alcohol and suddenly stop, you may increase your chance of having a seizure. Therefore, it is important to discuss your use of alcohol with your doctor before you begin taking ZYBAN.

Will ZYBAN affect other medicines I am taking?

ZYBAN may affect other medicines you're taking. It is important not to take medicines that may increase the chance you have a seizure. Therefore, you should make sure that your doctor knows about all medicines—prescription or over-the-counter—you are taking or plan to take.

Do ZYBAN tablets have a characteristic odor?

ZYBAN tablets may have a characteristic odor. If present, this odor is normal. It is not a sign of a bad or expired tablet.

How should I store ZYBAN?

Store ZYBAN at room temperature, out of direct sunlight. Keep ZYBAN in a tightly closed container.

Keep ZYBAN out of the reach of children.

This summary provides important information about ZYBAN. This summary cannot replace the more detailed information that you need from your doctor. If you have any questions or concerns about either ZYBAN or smoking cessation, talk to your doctor or other health care professional.

ABT600 is a registered trademark of Ciba-Geigy Corporation.

U.S. Patent Nos. 5,427,798 and 5,368,970.

Copyright 1997, Glaxo-Wellcome Inc. All rights reserved.

September 1997/RL-448

Shown in Product Identification Guide, page 315

ZYBAN is a registered trademark of Glaxo-Wellcome Inc.

ZYBAN is a registered trademark of Glaxo-Wellcome Inc.

ZYBAN is a registered trademark of Glaxo-Wellcome Inc.

ZYBAN is a registered trademark of Glaxo-Wellcome Inc.

ZYBAN is a registered trademark of Glaxo-Wellcome Inc.

ZYBAN is a registered trademark of Glaxo-Wellcome Inc.

ZYBAN is a registered trademark of Glaxo-Wellcome Inc.

ZYBAN is a registered trademark of Glaxo-Wellcome Inc.

ZYBAN is a registered trademark of Glaxo-Wellcome Inc.

ZYBAN is a registered trademark of Glaxo-Wellcome Inc.

ZYBAN is a registered trademark of Glaxo-Wellcome Inc.

ZYBAN is a registered trademark of Glaxo-Wellcome Inc.

ZYBAN is a registered trademark of Glaxo-Wellcome Inc.

ZYBAN is a registered trademark of Glaxo-Wellcome Inc.

ZYBAN is a registered trademark of Glaxo-Wellcome Inc.

ZYBAN is a registered trademark of Glaxo-Wellcome Inc.

ZYBAN is a registered trademark of Glaxo-Wellcome Inc.

ZYBAN is a registered trademark of Glaxo-Wellcome Inc.

ZYBAN is a registered trademark of Glaxo-Wellcome Inc.

ZYBAN is a registered trademark of Glaxo-Wellcome Inc.

ZYBAN is a registered trademark of Glaxo-Wellcome Inc.

ZYBAN is a registered trademark of Glaxo-Wellcome Inc.

No. 6 Lake, lactose, magnesium stearate, and povidone. Its solubility in water at 37°C is 80.0 mg/dL and is greater in an alkaline solution.

CLINICAL PHARMACOLOGY

ZYLOPRIM acts on purine metabolism, without disrupting the biosynthesis of purines. It reduces the production of uric acid by inhibiting the biochemical reactions immediately preceding its formation.

ZYLOPRIM is a structural analogue of the natural purine base, hypoxanthine. It is an inhibitor of xanthine oxidase, the enzyme responsible for the conversion of hypoxanthine to xanthine and of xanthine to uric acid, the end product of purine metabolism in man. ZYLOPRIM is metabolized to the corresponding xanthine analogue, oxipurinol (alloxanthine), which also is an inhibitor of xanthine oxidase.

It has been shown that reutilization of both hypoxanthine and xanthine for nucleotide and nucleic acid synthesis is markedly enhanced when their oxidations are inhibited by ZYLOPRIM and oxipurinol. This reutilization does not disrupt normal nucleic acid anabolism, however, because feedback inhibition is an integral part of purine biosynthesis. As a result of xanthine oxidase inhibition, the serum concentration of hypoxanthine plus xanthine in patients receiving ZYLOPRIM for treatment of hyperuricemia is usually in the range of 0.3 to 0.4 mg/dL compared to a normal level of approximately 0.15 mg/dL. A maximum of 0.9 mg/dL of these oxypurines has been reported when the serum urate was lowered to less than 2 mg/dL by high doses of ZYLOPRIM. These values are far below the saturation levels at which point their precipitation would be expected to occur (above 7 mg/dL).

The renal clearance of hypoxanthine and xanthine is at least 10 times greater than that of uric acid. The increased xanthine and hypoxanthine in the urine have not been accompanied by problems of nephrolithiasis. Xanthine crystalluria has been reported in only three patients. Two of the patients had Lesch-Nyhan syndrome, which is characterized by excessive uric acid production combined with a deficiency of the enzyme, hypoxanthine-guanine phosphoribosyltransferase (HGPRTase). This enzyme is required for the conversion of hypoxanthine, xanthine, and guanine to their respective nucleotides. The third patient had lymphosarcoma and produced an extremely large amount of uric acid because of rapid cell lysis during chemotherapy.

ZYLOPRIM is approximately 90% absorbed from the gastrointestinal tract. Peak plasma levels generally occur at 1.5 hours and 4.5 hours for ZYLOPRIM and oxipurinol respectively, and after a single oral dose of 300 mg ZYLOPRIM, maximum plasma levels of about 3 mg/mL of ZYLOPRIM and 6.5 mg/mL of oxipurinol are produced. Approximately 20% of the ingested ZYLOPRIM is excreted in the feces. Because of its rapid oxidation to oxipurinol and a renal clearance rate approximately that of glomerular filtration rate, ZYLOPRIM has a plasma half-life of about 1 to 2 hours. Oxipurinol, however, has a longer plasma half-life (approximately 15 hours) and therefore effective xanthine oxidase inhibition is maintained over a 24-hour period with single daily doses of ZYLOPRIM. Whereas ZYLOPRIM is cleared essentially by glomerular filtration, oxipurinol is reabsorbed in the kidney tubules in a manner similar to the reabsorption of uric acid.

The clearance of oxipurinol is increased by uricosuric drugs, and as a consequence, the addition of a uricosuric agent reduces to some degree the inhibition of xanthine oxidase by oxipurinol and increases to some degree the urinary excretion of uric acid. In practice, the net effect of such combined therapy may be useful in some patients in achieving minimum serum uric acid levels provided the total urinary uric acid load does not exceed the competence of the patient's renal function.

Hyperuricemia may be primary, as in gout, or secondary to diseases such as acute and chronic leukemia, polycythemia vera, multiple myeloma, and psoriasis. It may occur with the use of diuretic agents, during renal dialysis, in the presence of renal damage, during starvation or reducing diets, and in the treatment of neoplastic disease where rapid resolution of tissue masses may occur. Asymptomatic hyperuricemia is not an indication for treatment with ZYLOPRIM (see INDICATIONS AND USAGE).

Gout is a metabolic disorder which is characterized by hyperuricemia and resultant deposition of monosodium urate in the tissues, particularly the joints and kidneys. The etiology of this hyperuricemia is the overproduction of uric acid in relation to the patient's ability to excrete it. If progressive deposition of urate is to be arrested or reversed, it is necessary to reduce the serum uric acid level below the saturation point to suppress urate precipitations. Administration of ZYLOPRIM generally results in a fall in both serum and urinary uric acid within 2 to 3 days. The degree of this decrease can be manipulated almost at will since it is dose-dependent. A week or more of treatment with ZYLOPRIM may be required before its full effects are manifested; likewise, uric acid may return to pretreatment levels slowly (usually after a period of 7 to 10 days following cessation of therapy). This reflects primarily the accumulation

and slow clearance of oxipurinol. In some patients a dramatic fall in urinary uric acid excretion may not occur, particularly in those with severe tophaceous gout. It has been postulated that this may be due to the mobilization of urate from tissue deposits as the serum uric acid level begins to fall.

The action of ZYLOPRIM differs from that of uricosuric agents, which lower the serum uric acid level by increasing urinary excretion of uric acid. ZYLOPRIM reduces both the serum and urinary uric acid levels by inhibiting the formation of uric acid. The use of ZYLOPRIM to block the formation of urates avoids the hazard of increased renal excretion of uric acid posed by uricosuric drugs. ZYLOPRIM can substantially reduce serum and urinary uric acid levels in previously refractory patients even in the presence of renal damage serious enough to render uricosuric drugs virtually ineffective. Salicylates may be given concurrently for their antirheumatic effect without compromising the action of ZYLOPRIM. This is in contrast to the nullifying effect of salicylates on uricosuric drugs. ZYLOPRIM also inhibits the enzymatic oxidation of mercaptopurine, the sulfur-containing analogue of hypoxanthine, to 6-thioguanine. This oxidation, which is catalyzed by xanthine oxidase, inactivates mercaptopurine. Hence, the inhibition of such oxidation by ZYLOPRIM may result in as much as a 75% reduction in the therapeutic dose requirement of mercaptopurine when the two compounds are given together.

INDICATIONS AND USAGE

THIS IS NOT AN INNOCUOUS DRUG. IT IS NOT RECOMMENDED FOR THE TREATMENT OF ASYMPTOMATIC HYPERURICEMIA.

ZYLOPRIM reduces serum and urinary uric acid concentrations. Its use should be individualized for each patient and requires an understanding of its mode of action and pharmacokinetics (see CLINICAL PHARMACOLOGY, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS). ZYLOPRIM is indicated in:

- (1) the management of patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis and/or nephropathy);
- (2) the management of patients with leukemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. Treatment with ZYLOPRIM should be discontinued when the potential for overproduction of uric acid is no longer present;
- (3) the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients. Therapy in such patients should be carefully assessed initially and reassessed periodically to determine in each case that treatment is beneficial and that the benefits outweigh the risks.

CONTRAINDICATIONS

Patients who have developed a severe reaction to ZYLOPRIM should not be restarted on the drug.

WARNINGS

ZYLOPRIM SHOULD BE DISCONTINUED AT THE FIRST APPEARANCE OF SKIN RASH OR OTHER SIGNS WHICH MAY INDICATE AN ALLERGIC REACTION. In some instances a skin rash may be followed by more severe hypersensitivity reactions such as exfoliative, urticarial, and purpuric lesions as well as Stevens-Johnson syndrome (erythema multiforme exudativum), and/or generalized vasculitis, irreversible hepatotoxicity, and on rare occasions death. In patients receiving PURINETHOL (mercaptopurine), or IMURAN (azathioprine), the concomitant administration of 300 to 600 mg of ZYLOPRIM per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine. Subsequent adjustment of doses of mercaptopurine or azathioprine should be made on the basis of therapeutic response and the appearance of toxic effects (see CLINICAL PHARMACOLOGY).

A few cases of reversible clinical hepatotoxicity have been noted in patients taking ZYLOPRIM, and in some patients, asymptomatic rises in serum alkaline phosphatase or serum transaminase have been observed. If abnormal weight loss or pruritus develop in patients on ZYLOPRIM, evaluation of liver function should be part of their diagnostic workup. In patients with preexisting liver disease, periodic liver function tests are recommended during the early stages of therapy.

Due to the occasional occurrence of drowsiness, patients should be alerted to the need for due precaution when engaging in activities where alertness is mandatory. The occurrence of hypersensitivity reactions to ZYLOPRIM may be increased in patients with decreased renal function receiving thiadiazides and ZYLOPRIM concurrently. For this reason, in this clinical setting, such combinations should be administered with caution and patients should be observed closely.

PRECAUTIONS General: An increase in acute attacks of gout has been reported during the early stages of administration of

E



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/427,447	10/27/1999	ALEXANDER GOEN SZYNALSKI		3197

7590

12/04/2001

MARK POHL
55 MADISON AVENUE, 4TH FLOOR
MORRISTOWN, NJ 07960

EXAMINER

RIMELL, SAMUEL G

ART UNIT

PAPER NUMBER

2166

DATE MAILED: 12/04/2001

Please find below and/or attached an Office communication concerning this application or proceeding.

176

Office Action Summary	Application No.	Applicant(s)	
	09/427,447	SZYNALSKI, ALEXANDER GOEN	
	Examiner	Art Unit	
	Sam Rimell	2166	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☐ Responsive to communication(s) filed on ____.
- 2a) ☒ This action is FINAL. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1, 11 and 21-24 is/are pending in the application.
- 4a) Of the above claim(s) ____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) ____ is/are allowed.
- 6) ☒ Claim(s) 1, 11 and 21-24 is/are rejected.
- 7) ☐ Claim(s) ____ is/are objected to.
- 8) ☐ Claim(s) ____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on ____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on ____ is: a) ☐ approved b) ☐ disapproved by the Examiner.
If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120.

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. ____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
* See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

SAM RIMELL
PLURITY EXAMINER
2166

Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892) 4) ☐ Interview Summary (PTO-413) Paper No(s). ____
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948) 5) ☐ Notice of Informal Patent Application (PTO-152)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s) ____ 6) ☐ Other:

Art Unit: 2166

Claims 1, 11 and 21-24 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

Claims 1 and 11 have been amended to recite the usage of an "anti-smoking drug" instead of the originally recited "Lobelia".

The term "anti-smoking drug" broader in scope than the recitations of Lobelia found in the disclosure. Since the term "anti-smoking drug" can encompass prescription pharmaceuticals, it is far broader in scope than the recitation of Lobelia found in the disclosure.

Claims 1 and 11 can be corrected by deploying the term "Lobelia". This may be accomplished by Examiner's Amendment, with applicant's authorization.

Claim 1, 11 and 21-24 would be allowable if rewritten or amended to overcome the rejection under 35 U.S.C. 112, first paragraph, set forth in this Office action.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire **THREE MONTHS** from the mailing date of this action. In the event a first reply is filed within **TWO MONTHS** of the mailing date of this final action and the advisory action is not mailed until after the end of the **THREE-MONTH** shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event,

Art Unit: 2166

however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication should be directed to Sam Rimell at telephone number (703) 306-5626.

A handwritten signature in black ink, appearing to read 'S. Rimell', is positioned above the printed name and title.

Sam Rimell
Primary Examiner
Art Unit 2166

F

Interview Summary	Application No. 09/427,447	Applicant(s) SZYNALSKI, ALEXANDER GOEN	
	Examiner Sam Rimell	Art Unit 2166	

All participants (applicant, applicant's representative, PTO personnel):

- (1) Sam Rimell. (3) _____
 (2) Mark Pohl. (4) _____

Date of Interview: 14 December 2001 .

Type: a) ☒ Telephonic b) ☐ Video Conference
 c) ☐ Personal [copy given to: 1) ☐ applicant 2) ☐ applicant's representative]

Exhibit shown or demonstration conducted: d) ☐ Yes e) ☐ No.
 If Yes, brief description: _____ .

Claim(s) discussed: _____ .

Identification of prior art discussed: _____ .

Agreement with respect to the claims f) ☒ was reached. g) ☐ was not reached. h) ☐ N/A.


Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: Agreed to Examiner's Amendment to place application in condition for allowance .

(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)

i) ☐ It is not necessary for applicant to provide a separate record of the substance of the interview(if box is checked).

Unless the paragraph above has been checked, THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN ONE MONTH FROM THIS INTERVIEW DATE TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.

Examiner Note: You must sign this form unless it is an Attachment to a signed Office action.



 Examiner's signature, if required

Summary of Record of Interview Requirements

Manual of Patent Examining Procedure (MPEP), Section 713.04, Substance of Interview Must be Made of Record

A complete written statement as to the substance of any face-to-face, video conference, or telephone interview with regard to an application must be made of record in the application whether or not an agreement with the examiner was reached at the interview.

Title 37 Code of Federal Regulations (CFR) § 1.133 Interviews

Paragraph (b)

In every instance where reconsideration is requested in view of an interview with an examiner, a complete written statement of the reasons presented at the interview as warranting favorable action must be filed by the applicant. An interview does not remove the necessity for reply to Office action as specified in §§ 1.111, 1.135. (35 U.S.C. 132)

37 CFR §1.2 Business to be transacted in writing.

All business with the Patent or Trademark Office should be transacted in writing. The personal attendance of applicants or their attorneys or agents at the Patent and Trademark Office is unnecessary. The action of the Patent and Trademark Office will be based exclusively on the written record in the Office. No attention will be paid to any alleged oral promise, stipulation, or understanding in relation to which there is disagreement or doubt.

The action of the Patent and Trademark Office cannot be based exclusively on the written record in the Office if that record is itself incomplete through the failure to record the substance of interviews.

It is the responsibility of the applicant or the attorney or agent to make the substance of an interview of record in the application file, unless the examiner indicates he or she will do so. It is the examiner's responsibility to see that such a record is made and to correct material inaccuracies which bear directly on the question of patentability.

Examiners must complete an Interview Summary Form for each interview held where a matter of substance has been discussed during the interview by checking the appropriate boxes and filling in the blanks. Discussions regarding only procedural matters, directed solely to restriction requirements for which interview recordation is otherwise provided for in Section 812.01 of the Manual of Patent Examining Procedure, or pointing out typographical errors or unreadable script in Office actions or the like, are excluded from the interview recordation procedures below. Where the substance of an interview is completely recorded in an Examiners Amendment, no separate Interview Summary Record is required.

The Interview Summary Form shall be given an appropriate Paper No., placed in the right hand portion of the file, and listed on the "Contents" section of the file wrapper. In a personal interview, a duplicate of the Form is given to the applicant (or attorney or agent) at the conclusion of the interview. In the case of a telephone or video-conference interview, the copy is mailed to the applicant's correspondence address either with or prior to the next official communication. If additional correspondence from the examiner is not likely before an allowance or if other circumstances dictate, the Form should be mailed promptly after the interview rather than with the next official communication.

The Form provides for recordation of the following information:

- Application Number (Series Code and Serial Number)
- Name of applicant
- Name of examiner
- Date of interview
- Type of interview (telephonic, video-conference, or personal)
- Name of participant(s) (applicant, attorney or agent, examiner, other PTO personnel, etc.)
- An indication whether or not an exhibit was shown or a demonstration conducted
- An identification of the specific prior art discussed
- An indication whether an agreement was reached and if so, a description of the general nature of the agreement (may be by attachment of a copy of amendments or claims agreed as being allowable). Note: Agreement as to allowability is tentative and does not restrict further action by the examiner to the contrary.
- The signature of the examiner who conducted the interview (if Form is not an attachment to a signed Office action)

It is desirable that the examiner orally remind the applicant of his or her obligation to record the substance of the interview of each case unless both applicant and examiner agree that the examiner will record same. Where the examiner agrees to record the substance of the interview, or when it is adequately recorded on the Form or in an attachment to the Form, the examiner should check the appropriate box at the bottom of the Form which informs the applicant that the submission of a separate record of the substance of the interview as a supplement to the Form is not required.

It should be noted, however, that the Interview Summary Form will not normally be considered a complete and proper recordation of the interview unless it includes, or is supplemented by the applicant or the examiner to include, all of the applicable items required below concerning the substance of the interview.

A complete and proper recordation of the substance of any interview should include at least the following applicable items:

- 1) A brief description of the nature of any exhibit shown or any demonstration conducted,
- 2) an identification of the claims discussed,
- 3) an identification of the specific prior art discussed,
- 4) an identification of the principal proposed amendments of a substantive nature discussed, unless these are already described on the Interview Summary Form completed by the Examiner,
- 5) a brief identification of the general thrust of the principal arguments presented to the examiner,
(The identification of arguments need not be lengthy or elaborate. A verbatim or highly detailed description of the arguments is not required. The identification of the arguments is sufficient if the general nature or thrust of the principal arguments made to the examiner can be understood in the context of the application file. Of course, the applicant may desire to emphasize and fully describe those arguments which he or she feels were or might be persuasive to the examiner.)
- 6) a general indication of any other pertinent matters discussed, and
- 7) if appropriate, the general results or outcome of the interview unless already described in the Interview Summary Form completed by the examiner.

Examiners are expected to carefully review the applicant's record of the substance of an interview. If the record is not complete and accurate, the examiner will give the applicant an extendable one month time period to correct the record.

Examiner to Check for Accuracy

If the claims are allowable for other reasons of record, the examiner should send a letter setting forth the examiner's version of the statement attributed to him or her. If the record is complete and accurate, the examiner should place the indication, "Interview Record OK" on the paper recording the substance of the interview along with the date and the examiner's initials.

G

Notice of Allowability

Application No.

09/427,447

Examiner

Sam Rimell

Applicant(s)

SZYNALSKI, ALEXANDER GOEN

Art Unit

2166

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to Interview of 12/14/01.
2. ☒ The allowed claim(s) is/are 1 and 11.
3. ☐ The drawings filed on _____ are accepted by the Examiner.
4. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) ☐ All b) ☐ Some* c) ☐ None of the:
 1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).
- * Certified copies not received: _____.
5. ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application):
 - (a) ☐ The translation of the foreign language provisional application has been received.
6. ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. **THIS THREE-MONTH PERIOD IS NOT EXTENDABLE**

7. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
8. ☐ CORRECTED DRAWINGS must be submitted.
 - (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
 - 1) ☐ hereto or 2) ☐ to Paper No. _____.
 - (b) ☐ including changes required by the proposed drawing correction filed _____, which has been approved by the Examiner.
 - (c) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No. _____.

Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the top margin (not the back) of each sheet. The drawings should be filed as a separate paper with a transmittal letter addressed to the Official Draftsperson.

9. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

- | | |
|--|---|
| 1 <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 2 <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3 <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 4 <input checked="" type="checkbox"/> Interview Summary (PTO-413), Paper No. _____ |
| 5 <input type="checkbox"/> Information Disclosure Statements (PTO-1449), Paper No. _____ | 6 <input checked="" type="checkbox"/> Examiner's Amendment/Comment |
| 7 <input type="checkbox"/> Examiner's Comment Regarding Requirement for Deposit of Biological Material | 8 <input checked="" type="checkbox"/> Examiner's Statement of Reasons for Allowance |
| | 9 <input type="checkbox"/> Other |

SAM RIMELL
PRIMARY EXAM
AU 2166

Art Unit: 2166

Examiner's Amendment

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Mark Pohl on 12/14/01.

In claim 1: In part C, change "an anti-smoking drug" to --lobelia--.

In claim 11: In part C, change "an anti-smoking drug" to --lobelia--.

Claims 21-24: These claims are cancelled.

Terminal Disclaimer

The present application includes a terminal disclaimer which appears to have been misdirected to this application. The terminal disclaimer has been refused entry for the present application and will be transferred to a continuation application of the present case. No terminal disclaimer has been required for this application.

Reasons for Allowance

The present application includes two independent claims, 1 and 11. The closest prior art are the US Patents 5,414,005 to Schneider et al. and 5,055,478 to Cooper et al.

Art Unit: 2166

Schneider et al. differs from both claims 1 and 11 in that it does not disclose the usage of an educational program in combination with the usage of lobelia. Schneider et al. is primarily addressed to a sublingual form of lobelia with certain specified advantages.

Copper et al. differs from both claims 1 and 11 in that it does not disclose the combination of a non-conditioning educational program, a hypnosis program and lobelia administration.

Any inquiry concerning this communication should be directed to Sam Rimell at telephone number (703) 306-5626.



Sam Rimell
Primary Examiner
Art Unit 2166

Notice of References Cited	Application/Control No. 09/427,447	Applicant(s)/Patent Under Reexamination SZYNALSKI, ALEXANDER GOEN	
	Examiner Sam Rimell	Art Unit 2166	Page 1 of 1

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification	
	A	US-5055478	10-1991	Cooper et al.	514	343
	B	US-				
	C	US-				
	D	US-				
	E	US-				
	F	US-				
	G	US-				
	H	US-				
	I	US-				
	J	US-				
	K	US-				
	L	US-				
	M	US-				


FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification	
	N						
	O						
	P						
	Q						
	R						
	S						
	T						

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	
	V	
	W	
	X	

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.





UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/427,447	10/27/1999	ALEXANDER GOEN SZYNALSKI		3197

7590

02/04/2002

MARK POHL
55 MADISON AVENUE, 4TH FLOOR
MORRISTOWN, NJ 07960

EXAMINER-

RIMELL, SAMUEL G

ART UNIT

PAPER NUMBER

2166

DATE MAILED: 02/04/2002

Please find below and/or attached an Office communication concerning this application or proceeding.

collected
Notice of Allowability

Application No.

09/427,447

Examiner

Sam Rimell

Applicant(s)

SZYNALSKI, ALEXANDER GOEN

Art Unit

2166

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☐ This communication is responsive to ____.
2. ☒ The allowed claim(s) is/are 1, 6, 11, 16.
3. ☐ The drawings filed on ____ are accepted by the Examiner.
4. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) ☐ All b) ☐ Some* c) ☐ None of the:
 1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. ____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).
- * Certified copies not received: ____.
5. ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
 - (a) ☐ The translation of the foreign language provisional application has been received.
6. ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. **THIS THREE-MONTH PERIOD IS NOT EXTENDABLE**


7. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
8. ☐ CORRECTED DRAWINGS must be submitted.
 - (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
 - 1) ☐ hereto or 2) ☐ to Paper No. ____.
 - (b) ☐ including changes required by the proposed drawing correction filed ____, which has been approved by the Examiner.
 - (c) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No. ____.

Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the top margin (not the back) of each sheet. The drawings should be filed as a separate paper with a transmittal letter addressed to the Official Draftsperson.

9. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

- | | |
|--|--|
| <input type="checkbox"/> Notice of References Cited (PTO-892) | <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | <input type="checkbox"/> Interview Summary (PTO-413), Paper No. ____ |
| <input type="checkbox"/> Information Disclosure Statements (PTO-1449), Paper No. ____ | <input type="checkbox"/> Examiner's Amendment/Comment |
| <input type="checkbox"/> Examiner's Comment Regarding Requirement for Deposit of Biological Material | <input type="checkbox"/> Examiner's Statement of Reasons for Allowance |
| | <input type="checkbox"/> Other |


Sam Rimell
Primary Examiner
Art Unit: 2166

I

(12) **United States Patent**
Szynalski

(10) **Patent No.:** **US 6,431,874 B1**
(45) **Date of Patent:** **Aug. 13, 2002**

(54) **STOP SMOKING METHOD AND COMPOSITION**

5,414,005 A * 5/1995 Schneider et al. 514/343
5,780,051 A * 7/1998 Eswara et al. 424/449
5,965,567 A * 10/1999 Archer et al. 514/282

(75) **Inventor:** **Alexander Goen Szynalski, Randolph, NJ (US)**

(73) **Assignee:** **Goen Corporation, Cedar Knolls, NJ (US)**

(*) **Notice:** Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) **Appl. No.:** **09/427,447**

(22) **Filed:** **Oct. 27, 1999**

(51) **Int. Cl.⁷** **G09B 23/28**

(52) **U.S. Cl.** **434/262**

(58) **Field of Search** 514/282, 343;
424/449; 434/262

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,055,478 A * 10/1991 Cooper et al. 514/343

FOREIGN PATENT DOCUMENTS

GB 1017032 1/1966

* cited by examiner

Primary Examiner—Sam Rimell

(74) *Attorney, Agent, or Firm*—Pharmaceutical Patent Law, LLC; Mark Pohl

(57) **ABSTRACT**

The inventor discloses a unique, new and useful process to reduce tobacco smoking, entitled Stop Smoking Method and Composition, consisting of: (1) educating tobacco smokers regarding smoking, its physiological dangers and addictive nature, and techniques to stop smoking; (2) hypnotizing said tobacco smokers, and (3) providing dietary substances to address the nutritional needs of nicotine addiction and the nutritional challenges thereof.

8 Claims, No Drawings

STOP SMOKING METHOD AND COMPOSITION

A portion of the disclosure of this patent document contains material which is subject to copyright protection. The copyright owner has no objection to the facsimile reproduction by anyone of the patent disclosure, as it appears in the Patent and Trademark Office patent files or records, but otherwise reserves all copyright rights whatsoever.

BACKGROUND

The prior art discloses many stop-smoking products and methods including, for example; (A) education to educate smokers regarding smoking, its physiological dangers and addictive nature, and conscious techniques to stop smoking; (B) hypnosis, to use the unconscious mind to stop smoking; and (C) nutritional supplements, addressing the nutritional challenges with regard to stopping smoking.

SUMMARY

While using each one of these three elements is known in the art, I have found that by combining all of these three elements together, they act on the three areas most important for stopping smoking—the conscious mind, the unconscious mind, and the body—and are synergistically effective in helping people to stop smoking.

This synergy was unexpected. I am a Certified Hypnotist and am a Nutritionist, with over twenty years experience in the fields of hypnosis, seminar presentation and nutrition. I am a member of the American Association of Professional Hypnotherapists, the National Guild of Hypnotists, the International Association of Counselors and Therapists, and am certified by the Hypnodyne Foundation. I am listed in *Who's Who in Executives and Professionals*, and I was a finalist for the 1999 Ernst & Young Entrepreneur of the Year award. I have been a special guest on numerous national television and radio programs, and was featured on the #1 television fitness show in the country. I maintain a practice in Cedar Knolls, N.J. I have successfully used hypnosis in many types of situations. I have, for example, worked with athletes to improve their athletic performance, and have worked with corporations as a sales and personal-development trainer. I am driven by a sincere passion for helping people maximize their personal potential and overcome addictions to smoking and food. I enjoy a reputation for extremely high success through my seminars.

DETAILED DESCRIPTION

My invention therefore comprises three elements: (1) education for the conscious mind regarding smoking, its physiological dangers and addictive nature, and techniques to stop smoking; (2) hypnosis for the unconscious mind, which hypnosis addresses the unconscious mind and its way of affecting behavior; and (3) dietary substances, to address the physiological needs of a person entailed in stopping smoking.

Education. The first element of my invention is education regarding smoking. This educational process can include addressing the benefits of a regular exercise program. Thus, the educational materials or program educates the smoker to engage in some form of light exercise. Not only will exercise help clear the body of the toxins acquired through smoking, but exercise will also help release endorphins which relieve stress as well as making you feel good. Exercise will rapidly

reverse the damage done to the body from smoking. If the smoker has not engaged in exercise for a long time, or the smoker has a weight problem or any other health problem, the smoker should consult their physician before starting any regimen of exercise.

In addition to this, I have found that in my preferred embodiment of my invention, the education program also addresses the physiological progression of smoking, its physiological dangers and addictive nature, and some conscious techniques to stop smoking. ©1999

The physiological progression of smoking entails three discreet steps. Knowing these steps helps the smoker recognize them as they occur, and thus recognize the needs they fill.

Stage 1—Light a cigarette and inhale. This takes about 7 seconds. The deep breath of the inhale increases the flow of blood and oxygen to the heart and you feel more relaxed (not due to the cigarette, but due to the deep breath).

Stage 2—Seven seconds to fifteen minutes later, nicotine enters the liver, which in turn releases sugar into the bloodstream. This results in a physical uplift (not from the cigarette, but from the release of sugar into the bloodstream) which then in turn causes the pancreas to release insulin into the bloodstream. This gives you an energy boost. Normally, it is a temporary energy boost because the muscle cells of the body are resistant to insulin. So what happens is that your energy level goes up and then crashes, all over again. In fifteen minutes, you want to start smoking again due to the tense feelings you experience from your energy level being reduced. What we suggest is for you to sensitize your body to insulin. Before we suggest how you do this, you first should study the two diagrams pictured below. To better understand this phenomenon, we will provide an in-depth clarification of the diagrams.

Stage 3—Fifteen to twenty minutes after beginning to smoke, the nicotine interrupts the normal transmission of neurons by competing with acetylcholine at the nerve terminal, producing such effects as an increased heart rate and respiration, along with feelings of tension and of being “wired up.” It also increases arousal and a sense of well-being and focused attention. A side benefit to understanding this step is to take proper nutrients so you do not allow this physical and physiological progression of smoking to occur. This will help with maintaining or even reducing weight and increasing lean muscle tissue.

In my preferred embodiment, the smoker is educated on the physiological dangers and addictive nature of smoking. These dangers are now so widely known as to not need to be discussed in detail here.

In my preferred embodiment, the person is educated on the benefits of modifying their daily diet. This addresses potential weight gain problems, one of the biggest fears of smokers.

Regarding potential weight gain, why do we gain weight when we stop smoking? Muscle cells become more sensitive to insulin. In my preferred embodiment, therefore, I recommend:

Avoid refined carbohydrates. All carbohydrates start out in their rarest edible form as complex, but we make them refined by processing, preserving, storing, drying, and cooking.

Increase physical activity, especially five to fifteen minutes after meals.

Take 100 micrograms of chromium along with the proper cofactors, one half hour before each meal with a full glass of water. The product containing chromium (CHROMIUM CHELAVITE™) that I prefer is TRIMSPA®, available from Vitamerica, Inc., Cedar Knolls, N.J.

Acquire a cigarette cessation product containing the herb lobelia, which aids any withdrawal that some may experience. Lobelia is a natural herb that tricks the body into thinking it is nicotine, but it does not have the side effects. In the preferred embodiment of my invention, I recommend CIGSATION™, available from Vitamerica, Inc., Cedar Knolls, N.J.

Cut back on drinking coffee and other caffeinated beverages. Sometimes the stress or anxiety that quitters experience is due to the physiological effects of caffeine on the nervous system and not due to withdrawal from nicotine. Try drinking decaffeinated tea or some other warm decaffeinated beverage. Drinking a hot tea provides the same psychological effect as drinking hot coffee.

Eat healthy, nourishing, non-processed foods and take a good vitamin supplement. Remember, the 200+ toxins in cigarette smoke have helped deplete the body of vitamins. Five cigarettes can deplete all the vitamin C in the body! By eating a healthy diet, you will recover your health more quickly.

In my preferred embodiment, the smoker is educated to do this for at least the first week, preferably for the first 21 days, after stopping smoking:

Eat 3 meals a day, including breakfast

Have protein and complex carbohydrates with each meal

Avoid sugar

Drink 8 glasses of non-caloric liquids a day—drink water with lemon, seltzer, herbal tea, etc.

Keep a pitcher of water on your desk and you'll easily drink 8 glasses a day

Between meals, drink fruit juices or eat a piece of fruit

Eat lots of fruits, vegetables and salads

As soon as you finish eating, leave the table and go brush your teeth

Use mouthwash whenever possible

In my preferred embodiment, the smoker is admonished: to not skip any meals (and never miss breakfast); to limit refined-sugar intake (and read packaging labels); to avoid beverages with caffeine (tea, colas, coffee, hot chocolate); and, if you must have them, drink tea or coffee out of a juice glass using a straw; and NO alcohol.

We described above the change in blood sugar levels caused by smoking and the physical and emotional response it has on the body. If your blood sugar level gets low, you will either crave a cigarette or something sweet. In either case, it will boost your blood sugar level for 10 to 20 minutes and then cause a crash, triggering another urge for a cigarette or a sweet. By eating 3 meals a day, you will tend to have a stable blood sugar level, and this minimizes cigarette and eating urges. Eating protein with carbohydrates at breakfast sets the stage for stable blood sugar levels all through the day. Protein with complex carbohydrates stabilizes the blood sugar.

I have also found it useful to teach persons quitting smoking to carry a nonfood item such as a swizzle stick or a low calorie food such as celery or carrot sticks. Use these to gratify any oral habit that has been developed by the conditioned response of putting your hand to your mouth 250 times a day, as if you were a one pack a day smoker.

By providing the smoker with this kind of educational program, the smoker is able to consciously and analytically understand their need to smoke and to approach the decision to smoke, or to not smoke, in an analytical, dispassionate manner.

Hypnosis. In addition to the conscious, analytical mind, one can aid the stop-smoking process by using the subconscious mind. In my invention, it is important to use both the conscious mind—via the educational program discussed above—and the unconscious mind, with hypnosis.

The subconscious mind dominates your thinking and behaviors. It is programmed using repetition and the subconscious mind basically behaves for two reasons. It tries to take you towards pleasure and it wants you to stay away from pain. For example, when you have a cup of coffee, you grab a cigarette; you get into a car, you grab a cigarette; you get stuck at a light, you grab a cigarette; you get a break at work, you grab a cigarette; you have a cocktail, you grab a cigarette. If you do not experience these triggers, you may very often go many hours without having a cigarette. It is important that you identify these scenes so we can then break the connection of the cigarettes to the scenes.

With hypnosis, the subconscious mind no longer aids the body to smoke more often, but rather aids the body to stop smoking, during precisely those periods when a smoker is accustomed to having a cigarette. Instead of the subconscious making the body scream for nicotine after a meal, or with coffee or alcohol, the subconscious will help the smoker remain calm and pain free.

When used to stop smoking, I have found that in my preferred embodiment, the hypnosis focuses on interrupting "conditioned responses" generally, and specifically, on interrupting the response to smoke. Conditioned responses are actions (e.g., reaching for a cigarette) motivated not by a consciously-perceived need, but rather by unconscious habit.

Is smoking more of a physical or more of a psychological addiction? For example, how many times have you gone two, three or four hours without even smoking one cigarette and then in another hour you may smoke four, five or six cigarettes? Why is that? It is because certain events, or certain times of the day can trigger you to smoke a cigarette. Therefore, it is necessary to break these unconscious connections, and such breakage occurs, I found, most efficiently using unconscious means—hypnosis.

In my preferred embodiment of my invention, the hypnosis is done in-person and is reinforced later with pre-recorded media such as audio-tapes.

Hypnosis techniques are known in the art. In my preferred embodiment, I prefer the in-person hypnosis to follow a six-step protocol. The six steps are (1) neuro-linguistic programming, (2) physical positioning, (3) progressive relaxation, (4) occupying the critical/analytical factor, (5) a process of suggestion, and (6) changing the language of the subconscious.

(1) Neuro-linguistic programming is a technique known in the art. It is described in detail in the following works written since the 1960's.

The Structure of Magic, Vol.1—Richard Bandler/John Grinder

The Structure of Magic, Vol.2—Grinder/Bandler

Patterns of Hypnotic Techniques of M. H. Erickson, Vol.1 Bandler/Grinder

Patterns of Hypnotic Techniques of M. H. Erickson, Vol.2 Grinder/Bandler

Frogs Into Princes—Bandler/Grinder

Tranceformations—Grinder/Bandler

Using Your Brain for a Change—Richard Bandler

Time for a Change—Richard Bandler

Persuasion Engineering—Richard Bandler/John La Valle

The Adventures of Anybody—Richard Bandler

Science and Sanity—Alfred Korzybski

Uncommon Therapy—The Psychiatric Techniques of Erickson—Jay Haley

Training Trances—John Overdurf/Julie Silverthorn

My Voice Will Go With You—Sidney Rosen These are incorporated herein by reference.

(2) Physical positioning is important, to maintain the subject in a state which is both relaxed, yet not sleep-prone.

(3) Physical Positioning and Progressive Relaxation follow the methods known in the art, instructing the subject to progressively relax each part of their body. This can be done with instructions to, for example, physically perform some act, or to mentally visualize some relaxing phenomenon.

(4) Occupying the critical/analytical factor is accomplished in my preferred embodiment by having the subject perform certain tasks which both require some conscious attention, but also are not so difficult or complex as to absorb the subject's entire mental capacity.

(5) The process of suggestion is important to repeat for an effective period of time—usually at least daily for about twenty one days. This time may, however, be less when the subject is relaxed, or is in a highly-emotional state.

(6) The last step is changing the language of the subconscious. This is done by repeating a desired message—e.g., “I am free from smoking”—often enough that the desired message replaces an undesired message in the subconscious mind. For example, one technique is to get friends, coworkers, and family members to help you, by asking them to congratulate you for not smoking. The best way to accomplish this is to stick your hand out to a friend or family member, asking that person to shake your hand and congratulate you for being a nonsmoker. When that person congratulates you, it is a positive reinforcement. The (former) smoker benefits from this positive feedback, and from knowing that they are doing well in stopping smoking.

In another technique I found successful, smoking is described as like having a best friend. Psychologically, the cigarette is the support that a friend gives you. Imagine having your best friend there for you and then losing him or her. You would not feel very good losing your best friend. However, if you discover that your best friend was abusing your children, most likely you would not feel the same about losing your best friend. You would still have some sort of attachment, but now you would be able to reason your way out of not having this person as a friend. In my preferred embodiment, the educational program teaches smokers to look at smoking in the same way.

In my preferred embodiment of my invention, hypnosis is also administered by listening to a prerecorded audio script which provides stop-smoking messages and positive feedback for not smoking. Such audio tapes are commercially available. In my preferred embodiment, I use an audio tape titled “Smoking Cessation,” published by Vitamerica, Inc. Cedar Knolls, N.J., www.vitamerica.com, to be listened to once every day for an effective length of time, generally about twenty-one days.

Dietary Substances. The third element of my invention is using proper dietary substances. These address the physiological needs of people breaking their physical addiction to nicotine. Further, one of the biggest fears of smokers is that, in stopping smoking, they will gain excess weight. Thus, in my preferred embodiment, in addition to the dietary substances that support normal form and function while recov-

ering from a smoking addiction, one also uses dietary substances that support normal form and function for those seeking weight-loss or to reduce weight gain. In my preferred embodiment, I recommend CIGSATION™ and TRIM SPECIFICS™, dietary supplements by Vitamerica, Inc., Cedar Knolls, N.J., www.vitamerica.com.

To aid the reader's understanding, I will discuss first the biological basis of the smoking addiction. I will then discuss the dietary substances and the diet modifications I have found effective to combat the physical smoking addiction—the addiction to nicotine. Finally, I will discuss dietary substances to control weight gain.

What causes the addiction to nicotine? The nervous system is divided into two anatomical divisions. The first is the central nervous system, which is composed of the brain and spinal cord. The second is the peripheral nervous system, which includes neurons located outside the brain and spinal cord, which includes any nerves that enter or leave the central nervous system. The peripheral nervous system can be further divided into the efferent division, whose neurons carry signals away from the brain and spinal cord to the peripheral tissues, and the afferent division, whose neurons bring information from the periphery to the central nervous system.

Nerve impulses are transmitted along a path of cells called neurons. The neurons form a knot-like mass called ganglia. These neurons are connected by a series of bridges. The bridge is called a synapse. In order to cross the bridge, a neurotransmitter is required. Before the nerve impulses reach the relay station or bridge, they are referred to as pre-ganglionic neurons. After crossing the synapse, they are referred to as post-ganglionic neurons. The basic neurotransmitters of the autonomic nervous system are acetylcholine and epinephrine. Acetylcholine mediates the transmission of nerve impulses across autonomic ganglia in both the sympathetic and parasympathetic nervous systems.

Nicotine Receptors. These receptors, in addition to binding acetylcholine, also recognize nicotine. Nicotine initially stimulates and then blocks the receptor. There is a competitive inhibition taking place. In lay terms, the receptor has a greater affinity for nicotine than for acetylcholine. At the same time, nicotine increases the level of the neurotransmitter dopamine in a particular brain pathway which associates a molecular link between nicotine addiction and this pleasure producing pathway. This is why nicotine causes such as strong physiological addiction. Recently, scientists at Yale and at the Pasteur Institute in Paris have found that the beta 2 sub unit of a known nicotine receptor in the brain is a critical component in nicotine addiction.

To combat this nicotine addiction, it is useful to use lobelia. *Lobelia inflata* (also known as Indian Tobacco) is a plant. This plant contains three nicotine-like ingredients: 1) lobeline, 2) lobelanidine, and 3) lobelanine. On close inspection of these three ingredients one can notice that all are symmetrical molecules. In other words, if you cut them each in half, each half is the same. The only exception is with lobeline, which has a slight difference on one side of the molecule. I refer to each of these three compounds, their analogs, and derivatives, as “lobelia.” After explaining some basic physiology, you will see why lobelia is important.

Nicotine causes an increase in blood pressure, increases intestinal motility, stimulates the central nervous system, has an anti diuretic effect (ability to retain water), affects heart rate, affects respiration, is highly soluble and crosses the blood-brain barrier, produces some euphoria (feeling of well being), arousal, relaxation, and it improves attention, and crosses the placenta membrane and is secreted in the milk of

lactating women. The chronic effects of Nicotine include nasopharyngeal and bronchial irritation, lung cancer, cardiac irregularities, stimulated salivary secretion, and reduction of gastric acidity.

Let us now consider the structural formulas for the active constituents in lobelia. Because of their basically symmetrical structure, it appears that they have an advantage in competing with nicotine at the effector cell site. It is postulated that these components can attach themselves to the cell site from either side of the molecule and perhaps crowd out the nicotine. Later, after the nicotine is eliminated from the system, lobeline will replace nicotine at the effector cell site. While nicotine is rapidly eliminated from the body within 16-24 hours, the withdrawal symptoms can last for several weeks to several months, depending upon the individual.

Lobelia's action in the body mimics that of nicotine, but does not have the physiological dependence of nicotine. Lobelia exhibits a cross tolerance with nicotine, is one of the most useful systemic relaxants, has a relaxation effect on the central nervous system, has a relaxing action on the autonomic nervous system, has a general relaxing action on neuromuscular action, is a powerful respiratory stimulant, equalizes circulation and relieves vascular tension, provides a truly holistic action with a combination of stimulation and relaxation, and also provides the holistic action of a general relaxant with diffusive stimulation.

Recently, scientists in Japan have discovered an antidepressant component in the leaves of *lobelia inflata*. This probably explains why individuals feel better when taking lobelia.

Given this physiology, the physiologic needs of a smoker can be addressed using lobelia. In addition to lobelia, I have found that other herbal substances are useful as dietary substances. Thus, in my preferred embodiment, lobelia is used along with wood betony, fennel seed and licorice root and several other herbs. In addition to these vitamin-type nutritional supplements, in my invention one needs lobelia. Lobelia is also known as Indian tobacco or wild tobacco and is native to North America. It includes three components significant here: lobeline, lobelanidine and lobelanine. It is pharmacologically similar to nicotine, but does not have nicotine's physiological dependency.

In my preferred embodiment of my invention, I have found it beneficial to include certain other supplements derived from plants and herbs. Each the individual ingredients improves the function of lobelia alone, as each provides a specific function to enhance the efficacy of the product.

Wood Betony. Wood betony is used for its sedative and bitter properties. Its anti-hypertensive properties relieve nervous tension and dilate blood vessels, thus producing a calming effect. Wood betony can relieve headaches normally associated with nicotine withdrawal. Its bitter tonic properties also aid in nicotine withdrawal.

Fennel Seed. Fennel seed has been recognized to have carminative and stimulant properties. It has been reported to have a spasmolytic effect on smooth muscles. As a result, it can be used for dyspeptic discomfort, gastrointestinal discomforts and congestion of the upper respiratory tract. Since chain smokers normally have a smoker's cough resulting in congestion of the lungs, fennel seed can aid in treating that congestion. One of the constituents from the volatile oil expressed from fennel is anethol. Anethol has been shown experimentally to reduce secretions of the upper respiratory tract (i.e., lungs).

Licorice Root. The major active ingredient in licorice root is glycyrrhizin. The glycyrrhizin is responsible for a vaso-

pressor response, which is similar to that occurring in nicotine. However, while it mimics that response, it also exhibits anti-inflammatory and an antitussive effects that is comparable to codeine in potency. This is due to the derivative 18 Beta-glycyrrhetic acid which prevents smoker's cough. In addition, the flavonoids in licorice root have recently been shown to have strong antioxidant and anti-hepatotoxic activities. These activities will help cleanse the body of the free radicals and other toxic substances generated from smoking. Licorice extracts are often used in anti-smoking preparations as a flavoring agent to mask bitter nauseous or other undesirable tastes from other components of the preparation. Licorice can also be used to treat stomach irritation arising from nicotine usage.

In addition to the foregoing, I have found it useful to use also blue cohosh, black walnut husk, chamomile flower, gotu kola leaf extract, kava kava root, peppermint, sarsaparilla root, slippery elm bark, valerian root, bayberry fruit, myrrh, passion flower, ginger root and eucalyptus oil. Thus, in my preferred embodiment, I use each of these, for the following reasons.

Blue Cohosh. It has demonstrated anti-inflammatory activity in animals. Blue cohosh can be used for nervous disorders.

Black Walnut Husk. Black walnut husk is a blood cleanser and oxidizer. It has been shown to be useful in lung disease and has strong anti-fungal and antibacterial properties. It is a rich dietary source of protein, iodine, chromium, potassium, manganese, vitamin A and the powerful antioxidant vitamin C.

Chamomile Flower. Chamomile flower has essential oils that contain a variety of glycosides, and other important constituents and chemically related compounds. Several of the therapeutic constituents of the volatile oil are chamazulene and alpha bisabolol oxide A. Chamazulene has demonstrated anti-inflammatory activity, pain relieving, wound healing, antispasmodic and anti-microbial properties. Alpha bisabolol has anti-inflammatory, anti-microbial and antipeptic activities. Matricin has been found to have a sufficiently stronger anti-inflammatory effect than chamazulene.

Gotu Kola Leaf Extract. The gotu kola leaves contain properties that have been shown to accelerate wound healing, improve memory, relieve fatigue and stress, increase mental acuity and improve behavioral patterns. This produces a calming effect within the body, thereby relieving the stress associated with nicotine withdrawal symptoms.

Kava Kava Root. The active ingredients in kava kava root are a group of compounds known as the kavalactones. They are recognized for their biological activity as a sedative, anti-convulsive and tonic. Additional constituents in kava kava root have demonstrated muscle relaxant activity and have been used for their ability to combat nervous anxiety and unrest. Kava kava also has expectorant properties. This allows the heavy smoker to expectorate residual mucus from the lungs.

Peppermint. Peppermint yields a volatile oil that is composed mainly of menthol. Menthol has long been recognized as a cooling agent in topical preparations. Also present are many other ingredients, some of which have been characterized to have biological activity. One such constituent is bisabolene, which has demonstrated to have anti-inflammatory activity. Other constituents in peppermint include flavonoids such as hesperetin and rutin. Also present are tocopherols, carotenoids, choline and azulenes. Azulene isolated from peppermint demonstrated anti-inflammatory and antinuclear effects in experimental animals. Peppermint

oil is extensively used as a flavoring agent, carminative, antiseptic and local anesthetic in cold, cough and other preparations. Peppermint and their oils have been used in traditional medicine as a stomachic, stimulant, antiseptic, local anesthetic and antispasmodic in treating indigestion, sore throat, nausea, diarrhea and colds.

Sarsaparilla Root. The major component of sarsaparilla is a variety of steroids which include sarsasapogenin, smilagenin, sitosterol, stigmasterol and pollinastanol, and their glycosides (saponins) including sarsasaponin (parillin), smilasaponin (smilacin), sarsaparilloside and sitosterol glucoside. Sarsaparilla is reported to have hepatoprotective, diuretic and anti-inflammatory activity.

Slippery Elm Bark. The principal constituent of slippery elm bark is mucilage. The mucilage has demulcent (soothing) and nutritive properties. It can sometimes be used to soothe irritated lungs.

Valerian Root. Valerian root has a variety of constituents but the major one, valerenic acid, produces a nerving or sedative effect. Valerian has CNS depressant activities. As a result, in states of agitation normally witnessed by smokers during withdrawal, this will have a calming effect. It has also been shown that in conditions of fatigue, the herb has demonstrated stimulating properties.

Bayberry Fruit. Bayberry fruit has been recognized to have a tonic effect.

Myrrh. Myrrh is reported to have astringent effects on mucus membranes. It is often used as a flavor component to mask bitter ingredients. It has also been used as a stimulant and expectorant. The expectorant properties will help the smoker remove mucus and phlegm from the lungs.

Passion Flower. Passion flower contains indole alkaloids, flavonoids and steroids. The indole alkaloids and flavonoids have tranquilizing effects. Anxiolytic and hypotensive activity has also been reported.

Ginger Root. Ginger root is used to combat nausea and vomiting, which may accompany nicotine withdrawal.

Eucalyptus Leaf Oil. The leaves contain 0.05 to 3.5% oil. The oil consists mostly of eucalyptol (1, 8-cineole). It is used in an anti-smoking formula as an expectorant to help remove mucus from the lungs.

In my preferred embodiment of my invention, these dietary substances are used as found in CIGSATION™ 100% Natural Cigarette Replacement System, commercially available from Vitamerica, Inc., Cedar Knolls, N.J. 07927, www.vitamerica.com. Each of these dietary substances adds to the benefit obtained from using lobelia alone.

In addition to addressing the physical nicotine addiction, I find it useful to address the smoker's fear of excessive weight gain, by using a "weight control product," a drug or dietary substances useful in controlling unnatural weight gain. Such dietary substances include chromium, choline, inositol, vanadium, gynema sylvestre, lecithin, vitamin B6, ginseng, zinc, mahuang, kola nut extract, spirulina, and methionine. Several of these are known physiological stimulants, which increase thermogenesis in the body and thus promote expending calories. I will discuss each in turn, and its usefulness in a weight-control product.

Chromium. What is chromium? It's the mineral that no body can afford to be without. Like iron, copper and zinc, chromium is one of the 16 essential trace minerals the body needs to keep healthy and fit. And for people who are overweight and out of shape, chromium may be the most precious mineral of all. In its biologically active form, it helps insulin to metabolize fat, convert protein into muscle, and convert sugar into energy. Chromium-activated insulin actually increases almost twenty times the amount of glu-

cose available for energy production, optimizing energy output so that you feel healthy and alive.

Chromium is the "master" nutrient for controlling blood sugar. It helps overcome sugar cravings, which is a problem with many overweight people. It also plays an important role in controlling blood lipids, lowering harmful LDL cholesterol, and increasing beneficial HDL cholesterol.

Research shows that a chromium deficiency may be a widespread problem. Many people, such as athletes, diabetics, mothers and the elderly, are at especially high risk. A lack of chromium can impair insulin function, thereby inhibiting protein synthesis and energy production. More seriously, it can even lead to type II diabetes and heart disease.

In my preferred embodiment, the chromium is a form of chromium commercially available under the trade name CHROMIUM CHELAVITE™, available from Vitamerica, Inc. of Cedar Knolls, N.J.

The most biologically active form of chromium, the true GTF chromium, is the basis for the molecular structure of CHROMIUM CHELAVITE™. Studies on CHROMIUM CHELAVITE™ at a leading Utah university have shown that this form of chromium is clearly superior to both chromium picolinate and chromium polynicotinate in absorbability. It had an absorption rate that was 53% greater than for chromium picolinate and 91% greater than that observed for chromium polynicotinate.

Choline. Choline is one of the most beneficial nutritional supplements. Technically, it is not a vitamin, even though it is essential for human life. There are three major functions of choline among humans. It is needed for building cell structure, it prevents or minimizes unhealthy fat deposits in the liver, and it acts as a precursor to acetylcholine. Acetylcholine is a neurotransmitter in the brain which is responsible for nerve impulses, memory, learning, mood elevation and depression control.

Choline has a very positive effect on the health of the liver. It is a lipotropic agent (fat eliminator) that can cut away fats in the liver to be used instead of energy. Choline aids in weight loss by facilitating Growth Hormone (GH) releasers, controlling cholesterol, and helping control the appetite. It also helps reduce the "gut transit time", the amount of time it takes food to move through the intestines. In addition to helping speed food through the system, choline also plays an important role in the body's ability to metabolize fat and cholesterol.

Inositol. Inositol is a member of the B complex of vitamins. It provides a calming effect, nourishes brain cells, helps reduce cholesterol, slows artery hardening, prevents eczema, and is needed for hair growth and metabolism. It is found in high concentrations in the brain, and serves as a brain cell membrane stabilizer. Inositol also helps in lecithin formation, and aids the body in the metabolism of fat and cholesterol.

Vanadium. A trace mineral like chromium, vanadium is essential for cellular activity and for the formation of bones and teeth. It also inhibits the synthesis of cholesterol and lowers certain forms of high blood pressure. It works remarkably well as a powerful insulin mimic and has been shown to normalize blood sugar levels, even in diabetics.

Gynema Sylvestre. This tropical herb is beginning to receive much attention due to impressive results in recent studies. Gynema Sylvestre appears to have a positive effect in lowering blood sugar levels, especially in diabetics. Research also suggests that it can help curb sugar absorption.

Lecithin. Lecithin is part of every single cell in the body, but has its greatest concentration in the brain. About 17-20%

of the brain is made up from lecithin. Lecithin is an emulsifier. It is used in the manufacture of chocolate, because it keeps it liquid and it keeps it moving. Lecithin does the same thing for the fat in the human body; it keeps it moving, right out of the body.

Lecithin is a natural diuretic and an effective cholesterol reducer. It helps prevent the buildup of cholesterol on arterial walls, thus improving the circulation of the blood. One study that examined 900 men for atherosclerosis (fat deposits in the arteries) showed that those with more than 36% lecithin in the blood had no atherosclerosis. Those with less than 34% showed evidence of the disease.

Lecithin is also the source of two of the hardest to find B-Complex relatives, choline and inositol. A major function of lecithin is to supply choline in the diet. Choline (see entry) has the function of breaking down fat deposits in the body. Our bodies do not manufacture enough choline. Therefore, we must rely upon our food and supplements such as lecithin to make sure that we get enough.

Vitamin B6. Vitamin B6 aids in more bodily functions than any other single nutrient. It facilitates the body's use of carbohydrates, proteins and fats. It promotes mental performance by aiding in the transport of amino acids, which are used by the brain to increase mental energy and memory. It also promotes the transport of choline, and aids in the breakdown of glycogen, the primary fuel for the brain.

Ginseng. For centuries, the Chinese have testified to the beneficial effects of Ginseng on longevity. Ginseng provides stimulation to the entire body, helping to overcome stress and fatigue. Ginseng can regulate and normalize blood pressure and blood sugar levels. It has been called a cure-all and has also been claimed to be a mild sexual stimulant. Over all, Ginseng has a phenomenal effect on the body's energy level.

Zinc. Zinc is another important trace mineral that is used by more than 200 enzymes to keep the body's major metabolic systems going strong. In addition to its role in metabolism, zinc is a potent antioxidant, profoundly important in enhancing the immune system, stimulating cellular growth, reducing excess levels of damaging free radicals, and improving general health.

Mahuang. Mahuang, also known as ephedra, contains a potent alkaloid, ephedrine. This natural stimulant increases the basal metabolic rate, which helps to burn calories more effectively. It has also been used as a remedy for kidney and bladder problems, as well as for colds, asthma, and hay fever.

Kola Nut Extract. This is a natural stimulant that increases energy and stamina. It has been found to be very useful in preventing fatigue. Kola Nut Extract also acts as a tonic agent for the heart, and it is sometimes useful in relieving pain, neuralgia, and headache.

Spirulina. This famed blue-green algae contains concentrations of nutrients unlike any other single grain, plant or herb. This super nutrient is a naturally digestible food that aids in protecting the immune system, in cholesterol reduction and in mineral absorption. It also helps to cleanse and heal, while also curbing the appetite.

Methionine. Methionine is an amino acid that assists the gall bladder function by helping to synthesize bile salts. It is a lipotropic substance that prevents the deposits of and cohesion of fats in the liver. It is also reported to be a growth hormone releaser.

It serves as an antioxidant in the brain. It helps prevent the buildup of heavy metals and plays an important and essential

role in the production of the brain neurotransmitter choline. Methionine is not found in the body. Therefore, it must be gotten via food and supplementation. It is also a good source of sulfur, and its therapeutic lipotropic effects help to eliminate fatty substances from the body.

Each of these dietary substances can be found in TRIM SPECIFICS™, available from Vitamerica, Cedar Knolls, N.J., www.vitamerica.com.

Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The examples I discuss here are included as the preferred embodiment of my invention, and not to further qualify the description.

I claim:

1. A method for helping a tobacco smoker to stop smoking, said method comprising the steps of:

(A) providing to a tobacco smoker a non-conditioning, educational program to educate said tobacco smoker's conscious mind, said educational program including education both on the disadvantages of smoking and on conscious techniques to stop smoking,

(B) providing to said tobacco smoker at least one hypnosis program to train said tobacco smoker's subconscious mind to discourage said tobacco smoker from performing smoking behavior, and

(C) providing to said tobacco smoker an anti-smoking drug in an amount effective to aid in the reduction or cessation of said tobacco smoker's craving to smoke tobacco,

such that said tobacco smoker can be helped to stop smoking.

2. The method of claim 1, where said hypnosis program comprises prerecorded media useable by said tobacco smoker when alone.

3. A product to aid a tobacco smoker in ceasing to smoke tobacco, said product comprising:

(A) means for educating said tobacco smoker's conscious mind, said educational program including non-conditioning education both on the disadvantages of smoking and on conscious techniques to stop smoking,

(B) means for hypnosis to train said tobacco smoker's subconscious mind to discourage said tobacco smoker from performing smoking behavior, and

(C) an anti-smoking drug in an amount effective to aid in the reduction or cessation of said tobacco smoker's craving to smoke tobacco.

4. The product of claim 3, where said means for hypnosis comprises prerecorded media useable by said tobacco smoker when alone.

5. The method of claim 1, further comprising the step of: (D) providing to said tobacco smoker, at least one weight-control product, in an amount effective to aid in weight control.

6. The method of claim 5, where the weight control product includes at least one stimulant in an amount effective to aid in weight control.

7. The product of claim 3, further comprising: (D) at least one weight-control product in an amount effective to aid in weight control.

8. The product of claim 7, where the weight control product includes at least one stimulant in an amount effective to aid weight control.